22q11.2 Deletion Syndrome

Genetic MONDO:0018923 Pathograph 22 Show in embeddings browser Chromosomal microdeletion syndrome

22q11.2 deletion syndrome is a variably expressive chromosomal disorder caused by a heterozygous, usually recurrent deletion that removes multiple dosage-sensitive genes at chromosome 22q11.2. Major manifestations include congenital heart disease, palatal abnormalities, characteristic facial features, immune deficiency, hypocalcemia related to parathyroid dysfunction, hearing loss, and learning or psychiatric disorders, but no single feature is universal. TBX1 is an important developmental contributor rather than a sufficient explanation for the full contiguous-gene syndrome. DiGeorge syndrome, velocardiofacial syndrome, and CATCH22 are historical labels; DiGeorge syndrome can also refer to phenocopies caused by other defects of thymic and pharyngeal development.

Ask OpenScientist

Ask a research question about 22q11.2 Deletion Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

2
Mappings
1
Inheritance
6
Pathophys.
14
Phenotypes
2
Gaps
22
Pathograph
2
Genes
9
Medical Actions
2
Subtypes
4
Differentials
6
Datasets
1
Trials
21
References
4
Deep Research
🏷

Classifications

IUIS Category
combined immunodeficiency with syndromic features
🔗

Mappings

MONDO
MONDO:0008564 DiGeorge syndrome Not Yet Curated
skos:narrowMatch MONDO
MONDO:0008564 (OMIM:188400, RO:0004003 HGNC:11592 TBX1) is_a the MONDO:0018923 anchor of this entry. DiGeorge syndrome is the historical label for the thymic/parathyroid/conotruncal presentation of the same 22q11.2 deletion this entry curates, and the entry already models the immunodeficiency and cardiac arms. narrowMatch because MONDO models DiGeorge as a child of the deletion syndrome rather than as an equivalent term - the same treatment already applied here to velocardiofacial syndrome.
MONDO:0008644 velocardiofacial syndrome Not Yet Curated
skos:narrowMatch MONDO
MONDO:0008644 (velocardiofacial syndrome) is a subclass of MONDO:0018923 (22q11.2 deletion syndrome) and carries "22q11 deletion syndrome" and "deletion 22q11.2 syndrome" as exact synonyms; it is the Shprintzen/VCF historical label already listed in this entry's synonyms. narrowMatch because MONDO models VCF as a child of the deletion syndrome rather than an equivalent class.
👪

Inheritance

1
Autosomal dominant contiguous-gene deletion HP:0000006
Parental testing is important because inheritance depends on deletion class. An affected individual has a 50% chance of transmitting the deletion in each pregnancy, but severity cannot be predicted from an affected parent.
Autosomal dominant inheritance Expressivity: VARIABLE De novo rate: More than 90% of typical 3.0 (2.54)-Mb deletions are de novo, whereas nested deletions are inherited much more often.
Show evidence (3 references)
PMID:20301696 SUPPORT Human Clinical
"22q11.2DS is an autosomal dominant contiguous gene deletion syndrome."
GeneReviews establishes the inheritance mode.
PMID:20301696 SUPPORT Human Clinical
"In 22q11.2DS caused by a 3.0 (2.54)-Mb deletion, the deletion is de novo in more than 90% of individuals and inherited from a heterozygous parent in about 10% of individuals."
This gives the deletion-class-specific de novo rate for the typical deletion.
PMID:20301696 SUPPORT Human Clinical
"Sixty percent of individuals with 22q11.2DS caused by a nested 22q11.2 deletion inherited the deletion from an affected parent. Offspring of affected individuals have a 50% chance of inheriting the 22q11.2 deletion."
This supports the higher inherited fraction for nested deletions and the 50% transmission risk.
◆

Subtypes

2
DiGeorge syndrome MONDO:0008564
TBX1 hgnc:11592 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in TBX1 (hgnc:11592). hgnc:11592 is a gene from the HUGO Gene Nomenclature Committee.
The historical label for the thymic, parathyroid and conotruncal presentation of the 22q11.2 deletion. It is carried here as a named clinical presentation rather than a separate mechanism: the lesion is the same contiguous-gene deletion this entry curates, and the entry already models the immunodeficiency and cardiac arms as pathophysiology nodes. This row exists so that the MONDO concept, and the gene MONDO attaches to it, are addressable in the same place as the presentation they describe.
Show evidence (1 reference)
PMID:14585638 SUPPORT Human Clinical
"We identified three mutations of TBX1 in two unrelated patients without the 22q11.2 deletion-one with sporadic conotruncal anomaly face syndrome/velocardiofacial syndrome and one with sporadic DiGeorge's syndrome-and in three patients from a family with conotruncal anomaly face..."
Identifies a patient with sporadic DiGeorge syndrome carrying a TBX1 point mutation and no 22q11.2 deletion, which is the human evidence that TBX1 alone can produce this presentation and so the basis for binding the gene on this row.
Velocardiofacial (Shprintzen) syndrome MONDO:0008644
TBX1 hgnc:11592 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in TBX1 (hgnc:11592). hgnc:11592 is a gene from the HUGO Gene Nomenclature Committee.
The historical Shprintzen label, emphasising the velopharyngeal, cardiac and facial features. As with DiGeorge syndrome it names a presentation of the same deletion rather than a distinct lesion, and the entry models its mechanistic substrate as the "Velopharyngeal structural and myogenic insufficiency" node. This entry's own description records both, along with CATCH22, as historical labels for the same deletion, which is why the entry is anchored on the deletion and carries them as subtypes rather than splitting into separate disease files.
Show evidence (1 reference)
PMID:14585638 SUPPORT Human Clinical
"We identified three mutations of TBX1 in two unrelated patients without the 22q11.2 deletion-one with sporadic conotruncal anomaly face syndrome/velocardiofacial syndrome and one with sporadic DiGeorge's syndrome-and in three patients from a family with conotruncal anomaly face..."
Reports TBX1 point mutations without a 22q11.2 deletion in a sporadic case and in a three-member family with conotruncal anomaly face/velocardiofacial syndrome, which is the basis for binding the gene on this row.
?

Discussions and Knowledge Gaps

2
Which deleted genes, remaining-allele variants, deletion boundaries, and genome-wide modifiers causally determine the major cardiac, immune, neurodevelopmental, and psychiatric phenotypes of 22q11.2 deletion syndrome?
KNOWLEDGE GAP OPEN gap_22q11_multigene_genotype_phenotype_prediction
Attached to
pathophysiology#Recurrent LCR22-mediated multigene deletion pathophysiology#TBX1-associated pharyngeal developmental vulnerability pathophysiology#DGCR8-associated miRNA-processing disruption
TBX1 is a major developmental contributor but does not explain the full contiguous-gene syndrome. A large cohort now links deletion size and background variation to lesion-specific cardiac outcomes, while overall genotype-phenotype prediction remains weak. Resolving gene- and tissue-specific contributions is necessary to avoid both singular-TBX1 attribution and untestable multigene narratives.
Proposed experiments
Deletion-resolved longitudinal genotype-phenotype modifier cohort
exp_22q11_multicenter_genotype_phenotype_modifier_cohort
Combine precisely mapped deletion intervals, long-read or whole-genome remaining-allele data, longitudinal cardiac/immune/neuropsychiatric phenotypes, and ancestry-aware analyses across multiple centers to test reproducible gene- and background-modifier effects.
Show evidence (1 reference)
PMID:41891037 SUPPORT Human Clinical
"These lesion-specific findings suggest the hypothesis that deletion interval and broader genetic background may contribute to CHD variability in 22q11.2DS, pending future replication."
The large human cohort identifies deletion interval and background variation as testable contributors while calling for replication.
Which mechanisms observed after homozygous Tbx1 or Ranbp1 loss remain valid in human cells carrying a heterozygous multigene 22q11.2 deletion?
HUMAN MODEL MISMATCH OPEN gap_22q11_human_model_dosage_mismatch
Attached to
pathophysiology#TBX1-associated pharyngeal developmental vulnerability pathophysiology#Candidate cortical and neurotransmitter mechanisms
Homozygous mouse knockouts reproduce striking developmental phenotypes but differ in gene dosage, deleted interval, species, and sometimes viability from affected humans. The COMT/proline observation is also a small, phenotype-specific association. Human isogenic models are needed before these findings are promoted to syndrome-wide causal pathways.
Proposed experiments
Isogenic human 22q11.2 dosage-series comparison
exp_22q11_isogenic_human_dosage_series
Compare human induced pluripotent stem cell-derived pharyngeal, cardiac, thymic, and cortical lineages carrying the recurrent heterozygous deletion, individual-gene heterozygous edits, homozygous knockouts, and corrected controls to separate dosage and interval effects.
⚙

Pathophysiology

6
Recurrent LCR22-mediated multigene deletion
Low-copy repeats at 22q11.2 predispose to non-allelic homologous recombination and recurrent deletions. The common A-D interval removes more than 40 coding genes, so the syndrome reflects combined dosage effects and background modifiers rather than a single-gene lesion.
TBX1 hgnc:11592 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves TBX1 (hgnc:11592). hgnc:11592 is a gene from the HUGO Gene Nomenclature Committee. DGCR8 hgnc:2847 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves DGCR8 (hgnc:2847). hgnc:2847 is a gene from the HUGO Gene Nomenclature Committee.
Downstream
TBX1-associated pharyngeal developmental vulnerability The recurrent proximal deletion makes TBX1 hemizygous.
DGCR8-associated miRNA-processing disruption The recurrent proximal deletion makes DGCR8 hemizygous.
Thymic developmental impairment Combined deleted-region dosage effects can impair thymic development, but individual-gene attribution and modifiers remain incompletely resolved.
Candidate cortical and neurotransmitter mechanisms Deleted-region dosage creates several candidate neurodevelopmental mechanisms whose human causal contributions remain uncertain.
Show evidence (3 references)
PMID:36648576 SUPPORT Other
"These LCRs mediate meiotic non- allelic homologous recombination and are susceptible to either deletion or duplication of these intervals."
This supports the recurrent LCR-mediated deletion mechanism.
PMID:41891037 SUPPORT Human Clinical
"The typical 3 Mb LCR22 A-D deletion was present in 2,788 individuals (92.4%), with smaller A-B (n=172, 5.7%) and A-C (n=56, 1.9%) deletions comprising the remaining cohort."
A large contemporary cohort documents the dominant recurrent deletion and smaller proximal classes.
DOI:10.3390/genes15030321 SUPPORT Other
"The review of the literature confirms the hypothesis that the 22q11.2DS phenotype results from a network of interactions between deleted protein-coding genes and altered epigenetic regulation."
This supports a multigene and regulatory-network model rather than singular TBX1 causation.
TBX1-associated pharyngeal developmental vulnerability
TBX1 dosage is an important contributor to pharyngeal-apparatus and cardiac outflow development. Heterozygous Tbx1 mice model aortic/outflow anomalies, whereas the broader phenotype occurs mainly after homozygous loss; those dosage differences limit extrapolation to the human multigene deletion.
TBX1 hgnc:11592 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves TBX1 (hgnc:11592). hgnc:11592 is a gene from the HUGO Gene Nomenclature Committee.
pharyngeal system development GO:0060037 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves pharyngeal system development (GO:0060037). GO:0060037 is a biological process from the Gene Ontology.
pharyngeal arch UBERON:0002539 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in pharyngeal arch (UBERON:0002539). UBERON:0002539 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Velopharyngeal structural and myogenic insufficiency The same pharyngeal-apparatus vulnerability that underlies the outflow lesion also underlies the velopharyngeal and palatal phenotype. The mouse evidence is homozygous-null and so is dosage-mismatched to the human heterozygous deletion; it supports developmental plausibility rather than a direct human causal claim.
Conotruncal heart defect TBX1 dosage contributes to conotruncal and aortic-arch susceptibility, but other deleted genes and genome-wide modifiers also shape the human lesion.
Show evidence (1 reference)
PMID:11242110 SUPPORT Model Organism
"Tbx1-/- mice displayed a wide range of developmental anomalies encompassing almost all of the common DGS/VCFS features, including hypoplasia of the thymus and parathyroid glands, cardiac outflow tract abnormalities, abnormal facial structures, abnormal vertebrae and cleft palate"
Homozygous knockout supports developmental plausibility, but it is not dosage-equivalent to a heterozygous human multigene deletion.
Velopharyngeal structural and myogenic insufficiency
The velopharyngeal port fails to close during speech because of combined structural and muscular factors - a deep pharynx, palatal anomalies that are often submucous rather than overt, and hypodynamic pharyngeal musculature. This is the mechanistic substrate of the historical velocardiofacial presentation, and it is the proposed explanation for resonance persisting after a purely palatal repair - proposed rather than established, since the supporting surgical comparison is a 14-patient series.
palate development GO:0060021 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves palate development, annotated with roof of mouth development (GO:0060021). GO:0060021 is a biological process from the Gene Ontology.
soft palate UBERON:0001733 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in soft palate (UBERON:0001733). UBERON:0001733 is an anatomical location from the Uberon multi-species anatomy ontology. pharynx UBERON:0001042 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in pharynx, annotated with chordate pharynx (UBERON:0001042). UBERON:0001042 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Velopharyngeal insufficiency Incomplete closure of the velopharyngeal port is the direct functional expression of this combined structural and myogenic deficit.
Hypernasal speech Air escape through the incompletely closed port produces hypernasal resonance, which resists palatoplasty in this syndrome because the pharyngeal and myogenic components are not addressed by palatal repair.
Show evidence (1 reference)
PMID:39056299 SUPPORT Human Clinical
"Patients who underwent palatoplasty achieved an increase in velar length, but this did not lead to resolution of hypernasality, suggesting that underlying anatomical differences such as increased pharyngeal depth and hypodynamic muscles may make palatoplasty less effective at resolving..."
Names both components of this node - pharyngeal depth (structural) and hypodynamic muscles (myogenic) - and shows they persist after velar lengthening, which is why the node is not reducible to palatal anatomy.
DGCR8-associated miRNA-processing disruption
DGCR8 hemizygosity can perturb microRNA biogenesis and downstream gene regulation. This is a candidate contributor to variable expression, not a proven explanation for any single clinical feature.
DGCR8 hgnc:2847 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves DGCR8 (hgnc:2847). hgnc:2847 is a gene from the HUGO Gene Nomenclature Committee.
miRNA processing GO:0035196 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves miRNA processing (GO:0035196). GO:0035196 is a biological process from the Gene Ontology.
Show evidence (1 reference)
DOI:10.3390/genes15030321 SUPPORT Other
"Typical miRNA expression patterns have been identified in 22q11.2DS, due to an alteration in miRNA biogenesis, affecting the expression of several target genes."
The review supports altered miRNA biogenesis while leaving phenotype-level causality unresolved.
Thymic developmental impairment
Reduced thymic tissue can lower thymic T-cell output. Most immune phenotypes are milder T-cell lymphopenia rather than congenital athymia, and clinical appearance alone does not reliably identify the immune severity.
cortical thymic epithelial cell CL:0002364 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cortical thymic epithelial cell (CL:0002364). CL:0002364 is a cell type from the Cell Ontology. T cell CL:0000084 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves T cell (CL:0000084). CL:0000084 is a cell type from the Cell Ontology.
thymus development GO:0048538 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves thymus development (GO:0048538). GO:0048538 is a biological process from the Gene Ontology.
thymus UBERON:0002370 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in thymus (UBERON:0002370). UBERON:0002370 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Cellular immunodeficiency Reduced thymic tissue lowers T-cell output.
Congenital athymia Complete absence of thymic function is the rare severe end of the developmental defect.
Show evidence (1 reference)
PMID:36648576 SUPPORT Other
"An estimated 67–80% of individuals affected with 22q11.2del have some degree of T cell lymphopenia (TCL)."
This establishes T-cell lymphopenia as the common immune presentation.
Candidate cortical and neurotransmitter mechanisms
RANBP1-null mice show impaired upper-layer cortical neuron generation, and a small human study found a COMT-genotype-by-proline association with selected neurophysiologic measures. These observations are candidate mechanisms; they do not establish a causal path from an individual interval gene to human learning difficulties or schizophrenia.
neural progenitor cell CL:0011020 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neural progenitor cell (CL:0011020). CL:0011020 is a cell type from the Cell Ontology.
RANBP1 hgnc:9847 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves RANBP1 (hgnc:9847). hgnc:9847 is a gene from the HUGO Gene Nomenclature Committee. COMT hgnc:2228 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves COMT (hgnc:2228). hgnc:2228 is a gene from the HUGO Gene Nomenclature Committee. PRODH hgnc:9453 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves PRODH (hgnc:9453). hgnc:9453 is a gene from the HUGO Gene Nomenclature Committee.
neurogenesis GO:0022008 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves neurogenesis (GO:0022008). GO:0022008 is a biological process from the Gene Ontology.
cerebral cortex UBERON:0000956 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in cerebral cortex (UBERON:0000956). UBERON:0000956 is an anatomical location from the Uberon multi-species anatomy ontology.
Show evidence (2 references)
PMID:25452572 SUPPORT Model Organism
"Ranbp1(-/-)-dependent proliferative deficits substantially diminish the frequency of layer 2/3, but not layer 5/6 cortical projection neurons."
Homozygous mouse knockout supports a candidate cortical mechanism but is not equivalent to human hemizygosity.
PMID:18769474 SUPPORT Human Clinical
"With regard to the SPEM performance, there was a significant interaction between the COMT158 genotype and proline level with significantly decreased SPEM performance in children with high plasma proline levels and the low activity COMTmet allele."
The small human study supports a limited genotype-by-metabolite association, not a general mechanism for psychosis.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for 22q11.2 Deletion Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

14
Cardiovascular 2
Conotruncal heart defect FREQUENT Conotruncal defect HP:0001710 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Conotruncal defect (HP:0001710). HP:0001710 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:41891037 SUPPORT Human Clinical
"The most frequent class of defects in 22q11.2DS are CTDs; they occurred in 40% of this cohort."
The 40% conotruncal-defect estimate supports the FREQUENT band.
PMID:20301696 SUPPORT Human Clinical
"congenital heart disease, particularly conotruncal malformations (ventricular septal defect, tetralogy of Fallot, interrupted aortic arch, and truncus arteriosus)"
GeneReviews documents the characteristic lesion spectrum.
Congenital athymia VERY_RARE Aplasia of the thymus HP:0005359 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Aplasia of the thymus (HP:0005359). HP:0005359 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36648576 SUPPORT Other
"Stud- ies suggest that approximately 0.5% of those diagnosed with 22q11.2del have a severe immune deficiency with very few T cells due to the absence of a thymus at birth, termed congenital athymia [14, 15]."
The approximately 0.5% estimate maps to the VERY_RARE band.
Ear 1
Hearing impairment HP:0000365 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hearing impairment (HP:0000365). HP:0000365 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301696 SUPPORT Human Clinical
"Hearing loss can be sensorineural and/or conductive."
GeneReviews directly supports both major hearing-loss mechanisms.
Genitourinary 1
Genitourinary anomaly Abnormality of the genitourinary system HP:0000119 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormality of the genitourinary system (HP:0000119). HP:0000119 is a phenotype from the Human Phenotype Ontology.
Coarse binding: source unspecified
Show evidence (1 reference)
PMID:20301696 SUPPORT Human Clinical
"Laryngotracheoesophageal, gastrointestinal, ophthalmologic, central nervous system, skeletal, and genitourinary anomalies also occur."
GeneReviews includes genitourinary anomalies in the clinical spectrum.
Head and Neck 3
Palatal abnormality Abnormal palate morphology HP:0000174 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal palate morphology (HP:0000174). HP:0000174 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301696 SUPPORT Human Clinical
"palatal abnormalities (velopharyngeal incompetence, submucosal cleft palate, bifid uvula, and cleft palate)"
GeneReviews directly describes the human palatal spectrum.
Velopharyngeal insufficiency FREQUENT HP:0000220 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Velopharyngeal insufficiency (HP:0000220). HP:0000220 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:36695155 SUPPORT Human Clinical
"Patients with 22q11.2 deletion syndrome (22q11DelS) often present with velopharyngeal dysfunction (VPD). VPD in patients with 22q11DelS is multifactorial beyond velopharyngeal insufficiency (VPI) alone, and differences in surgical outcomes are poorly understood."
States both that velopharyngeal dysfunction is a common presenting feature of the deletion syndrome and that it is multifactorial rather than reducible to velopharyngeal insufficiency alone.
PMID:41800660 SUPPORT Human Clinical
"22q11.2DS presents a uniquely high burden of ENT disease across the lifespan, including chronic otitis media, elevated cholesteatoma risk, persistent velopharyngeal dysfunction, multilevel airway anomalies, sleep-disordered breathing, dysphagia, and perioperative vulnerability due to vascular,..."
A 2026 otolaryngology state-of-the-art review lists persistent velopharyngeal dysfunction among the lifelong ENT burden of the syndrome.
PMID:39056299 SUPPORT DIRECT Human Clinical
"While not all people with 22q have a palatal abnormality, up to 80% of people with 22q present with VPI."
Supports the FREQUENT band (30-79%). The figure is an upper bound, so it is not read as VERY_FREQUENT; the deep-research report's own phenotype table independently gives ~65-70% for the palatal group. Note this sentence is the paper's introductory summary of the literature rather than a result of its own 14-patient series.
Characteristic facial features Abnormal facial shape HP:0001999 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal facial shape (HP:0001999). HP:0001999 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301696 SUPPORT Human Clinical
"characteristic facial features"
GeneReviews directly identifies characteristic facial features without providing a frequency estimate in this passage.
Immune 2
Cellular immunodeficiency FREQUENT HP:0005374 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cellular immunodeficiency (HP:0005374). HP:0005374 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36648576 SUPPORT Other
"An estimated 67–80% of individuals affected with 22q11.2del have some degree of T cell lymphopenia (TCL)."
The 67-80% estimate maps to the FREQUENT band.
Autoimmunity HP:0002960 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Autoimmunity (HP:0002960). HP:0002960 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301696 SUPPORT Human Clinical
"Psychiatric illness and autoimmune disorders are more common in individuals with 22q11.2DS."
GeneReviews directly supports increased autoimmune disease burden.
Metabolism 1
Hypocalcemia HP:0002901 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypocalcemia (HP:0002901). HP:0002901 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:20664180 SUPPORT Human Clinical
"The spectrum of parathyroid gland dysfunction ranges from severe neonatal hypocalcemia to subclinical hypoparathyroidism."
This directly establishes the hypocalcemia-to-subclinical-hypoparathyroidism spectrum in 22q11.2 deletion syndrome.
PMID:20301696 SUPPORT Human Clinical
"calcium supplementation and referral to an endocrinologist and nephrologist because of increased risk of renal calculi if long-term supplementation is required"
GeneReviews confirms clinically important hypocalcemia requiring calcium replacement while not providing frequency here.
Nervous System 3
Delayed speech and language development VERY_FREQUENT HP:0000750 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Delayed speech and language development (HP:0000750). HP:0000750 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:36512754 SUPPORT Human Clinical
"Most children had impaired language skills across all tested domains. The composite score for expressive language was significantly lower than that for receptive language, but the two were strongly correlated."
A 44-child prospective preschool cohort finds impairment across all tested language domains, supporting delayed speech and language development as a phenotype in its own right.
PMID:39056299 SUPPORT DIRECT Human Clinical
"Additionally, most people (95%) with 22q present with a speech-language disorder."
The 95% figure supports the VERY_FREQUENT band (80-100%). As with the velopharyngeal frequency above, this is the paper's introductory citation of prior literature rather than a finding of its own cohort.
Learning difficulties Specific learning disability HP:0001328 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Specific learning disability (HP:0001328). HP:0001328 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301696 SUPPORT Human Clinical
"learning difficulties"
GeneReviews directly identifies learning difficulties but does not quantify or subtype them.
Schizophrenia OCCASIONAL HP:0100753 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Schizophrenia (HP:0100753). HP:0100753 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36786112 SUPPORT Human Clinical
"The pooled prevalence of psychotic disorders was 11.50% (95%CI:9.40-14.00%), largely schizophrenia (9.70%, 95%CI:6.50-14.20)."
The schizophrenia estimate maps to the OCCASIONAL band.
Voice 1
Hypernasal speech HP:0001611 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypernasal speech (HP:0001611). HP:0001611 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39056299 SUPPORT Human Clinical
"Resonance and speech sound disorders may also present and include hypernasality and compensatory misarticulation errors that require speech therapy."
Establishes hypernasality as part of the syndrome's speech phenotype at the population level. An earlier draft quoted the preoperative severity split of the same paper's surgical arm, but presence of hypernasality was an inclusion criterion of that study, so those proportions are true by construction and cannot evidence the phenotype.
🧬

Genetic Associations

2
Recurrent 22q11.2 deletion (Causal heterozygous copy-number loss spanning multiple dosage-sensitive genes)
relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (2 references)
PMID:41891037 SUPPORT Human Clinical
"The typical 3 Mb LCR22 A-D deletion was present in 2,788 individuals (92.4%), with smaller A-B (n=172, 5.7%) and A-C (n=56, 1.9%) deletions comprising the remaining cohort."
This large cohort quantifies the proximal recurrent deletion classes represented in the study.
PMID:36648576 SUPPORT Other
"too small to be visualized on standard G-banded karyotype analysis"
This supports the limitation of routine karyotyping.
TBX1 dosage contribution (Major contributor to pharyngeal-apparatus and cardiovascular developmental phenotypes; not sufficient to explain the full deletion syndrome.)
Gene: TBX1 hgnc:11592 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is TBX1 (hgnc:11592). hgnc:11592 is a gene from the HUGO Gene Nomenclature Committee. variant_origin: GERMLINE
Show evidence (3 references)
PMID:14585638 SUPPORT Human Clinical
"We identified three mutations of TBX1 in two unrelated patients without the 22q11.2 deletion-one with sporadic conotruncal anomaly face syndrome/velocardiofacial syndrome and one with sporadic DiGeorge's syndrome-and in three patients from a family with conotruncal anomaly face..."
Human evidence that TBX1 point mutations without a 22q11.2 deletion reproduce the DiGeorge and velocardiofacial presentations. It is cited here because the only other support on this record is a mouse study, and a human phenotype should not rest on model-organism evidence alone.
PMID:14585638 SUPPORT INDIRECT Human Clinical
"Our results suggest that the TBX1 mutation is responsible for five major phenotypes in del22q11.2 syndrome."
The authors' own conclusion, quoted for the "major contributor" wording of this record's `association`. Marked INDIRECT because it is an inference the authors draw from five deletion-negative patients rather than a measurement of TBX1's contribution within the deletion.
PMID:11242110 SUPPORT Model Organism
"we propose that TBX1 in humans is a key gene in the etiology of DGS/VCFS"
The mouse study supports TBX1 as a key contributor, not as the sole cause of the human syndrome.
💊

Medical Actions

9
Cardiovascular evaluation and lesion-directed intervention
Category: Therapeutic Action: Cardiac SurgeryNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Cardiac Surgery (NCIT:C157806). NCIT:C157806 is a clinical intervention from the NCI Thesaurus. NCIT:C157806
Congenital cardiac lesions require cardiology assessment and, for many severe lesions, surgery or catheter-based intervention in infancy.
Target Phenotypes: Conotruncal defect HP:0001710 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Conotruncal defect (HP:0001710). HP:0001710 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36648576 SUPPORT Other
"Cardiac anomalies affect 75–80% of individuals with 22q11.2del, and a significant number of these patients will require cardiac surgery at an early age."
The guideline directly supports early cardiac surgery for a substantial affected subset.
Calcium supplementation and endocrine management
Category: Therapeutic Action: nutritional supplementationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is nutritional supplementation, annotated with Nutritional Support (NCIT:C15433). NCIT:C15433 is a clinical intervention from the NCI Thesaurus. Ontology label: Nutritional Support NCIT:C15433
Treat documented hypocalcemia with calcium replacement and specialist endocrine follow-up; long-term supplementation requires monitoring for renal complications. This entry does not infer a universal calcitriol regimen.
Target Phenotypes: Hypocalcemia HP:0002901 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Hypocalcemia (HP:0002901). HP:0002901 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301696 SUPPORT Human Clinical
"calcium supplementation and referral to an endocrinologist and nephrologist because of increased risk of renal calculi if long-term supplementation is required"
GeneReviews directly supports calcium replacement and specialist follow-up.
Immune phenotyping and vaccine planning
Category: Monitoring Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
At diagnosis, assess T-, B-, and NK-cell numbers and naïve/memory T-cell subsets. Subsequent immunoglobulin, vaccine-response, and lymphocyte testing should be individualized. Live MMR and varicella vaccines require adequate immune-function criteria rather than a syndromic label alone.
Show evidence (3 references)
PMID:36648576 SUPPORT Other
"The initial immunologic evaluation recommended at the time of diagnosis should include T (CD3, CD4, CD8), B (CD19 or CD20), and natural killer (CD16 or CD56) cell (TBNK) quantitation"
The guideline specifies the initial immune evaluation.
PMID:36648576 SUPPORT Other
"live vaccine administration (MMR and varicella) in 22q11.2del"
This identifies the guideline table as criteria for live MMR and varicella vaccination.
PMID:36648576 SUPPORT Other
"1. CD4 ≥ 400 cells/mm3 (absolute) Recommended 2. CD8 ≥ 200 cells/mm3 (absolute) Recommended 3. Tetanus IgG protective (3 + weeks after dose 3) † Recommended 4. CD45RA+CD3+/4+ % > CD45RO+CD3+/4+ % Utilize data from earliest assessment"
The table provides all four immune-function criteria for live-vaccine eligibility.
Irradiated, leukocyte-reduced, CMV-negative blood products when indicated
Category: Therapeutic Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
Use appropriately treated cellular blood products for congenital athymia or severe/suspected T-cell deficiency, including when immune evaluation cannot be completed before surgery.
Target Phenotypes: Cellular immunodeficiency HP:0005374 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Cellular immunodeficiency (HP:0005374). HP:0005374 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36648576 SUPPORT Other
"Whenever possible, the diagnosis of congenital athymia should be determined prior to surgery, as this small subset of patients requires blood products that are irradiated, leukocyte reduced, and CMV negative."
The guideline directly supports the conditional blood-product precautions.
Cultured thymus tissue implantation
Category: Therapeutic Action: organ transplantationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is organ transplantation (NCIT:C15289). NCIT:C15289 is a clinical intervention from the NCI Thesaurus. Ontology label: Organ Transplantation NCIT:C15289
Platform: Surgery
Cultured thymus tissue implantation is reserved for confirmed congenital athymia, not routine T-cell lymphopenia. Immune reconstitution takes months and specialized infection prophylaxis is required during that interval.
Target Phenotypes: Aplasia of the thymus HP:0005359 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Aplasia of the thymus (HP:0005359). HP:0005359 is a phenotype from the Human Phenotype Ontology. Cellular immunodeficiency HP:0005374 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Cellular immunodeficiency (HP:0005374). HP:0005374 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:36648576 SUPPORT Other
"Survival following implant was 72% (76 of the 105 patients)."
The guideline summarizes outcomes from a 105-implant single-center series.
PMID:36648576 SUPPORT Other
"circulating naïve T cells were detectable by 6 months post-implantation [124, 125]."
This supports a months-long immune-reconstitution timeline.
Palatal, speech, developmental, and hearing support
Category: Therapeutic Action: speech therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is speech therapy, annotated with Speech Language Therapy (NCIT:C159273). NCIT:C159273 is a clinical intervention from the NCI Thesaurus. Ontology label: Speech Language Therapy NCIT:C159273
Platform: Behavioral / lifestyle
Coordinate palate/ENT assessment, speech and language therapy, developmental and educational intervention, feeding support, and audiology or hearing aids according to the individual's findings.
Target Phenotypes: Abnormal palate morphology HP:0000174 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Abnormal palate morphology (HP:0000174). HP:0000174 is a phenotype from the Human Phenotype Ontology. Specific learning disability HP:0001328 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Specific learning disability (HP:0001328). HP:0001328 is a phenotype from the Human Phenotype Ontology. Hearing impairment HP:0000365 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Hearing impairment (HP:0000365). HP:0000365 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301696 SUPPORT Human Clinical
"occupational, physical, and speech therapy with introduction of sign language by age one year, educational and behavioral therapy"
GeneReviews supports multidisciplinary developmental and communication intervention.
Velopharyngeal surgery for persistent hypernasality
Category: Therapeutic Action: velopharyngeal (pharyngoplasty) surgical procedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is velopharyngeal (pharyngoplasty) surgical procedure, annotated with Surgical Procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
Platform: Surgery
Speech surgery for velopharyngeal insufficiency that persists after speech therapy. A small single-centre series (14 patients, 7 per arm) reported that pharyngoplasty resolved hypernasality where palatoplasty did not, which the authors attributed to the deficit being pharyngeal and myogenic as well as palatal; the comparison is underpowered and is reported by its authors as a "may be less effective" signal rather than a settled preference. Separately, and in a larger matched cohort, outcomes after sphincter pharyngoplasty are comparable to those in non-syndromic patients, so the deletion is not by itself a reason to expect surgical failure. NCIT has no pharyngoplasty or velopharyngeal-repair term reachable from NCIT:C25218, so the binding is the generic surgical action and the specificity is carried in preferred_term.
Mechanism Target:
Velopharyngeal structural and myogenic insufficiency — Pharyngoplasty narrows the velopharyngeal port, addressing the pharyngeal and myogenic components of the node that palatal repair alone leaves.
Show evidence (1 reference)
PMID:39056299 SUPPORT Human Clinical
"No patient who underwent palatoplasty achieved resolution of hypernasality; 1/7 patients had worse hypernasality, 4/7 had no change, and 2/7 had improved hypernasality."
The contrast between the two procedures is what ties the surgical target to the pharyngeal/myogenic mechanism rather than to the palate alone.
Target Phenotypes: Velopharyngeal insufficiency HP:0000220 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Velopharyngeal insufficiency (HP:0000220). HP:0000220 is a phenotype from the Human Phenotype Ontology. Hypernasal speech HP:0001611 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Hypernasal speech (HP:0001611). HP:0001611 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:39056299 SUPPORT Human Clinical
"In contrast, 86% of patients in the pharyngoplasty group had resolution of hypernasality."
Reports the pharyngoplasty resolution rate that motivates preferring it over palatoplasty in this syndrome.
PMID:36695155 SUPPORT Human Clinical
"Matched for age and pre-operative velopharyngeal closure, patients with and without 22q11DelS and VPI had similar benefits after sphincter pharyngoplasty."
A 134-patient matched cohort supports offering sphincter pharyngoplasty on the same terms as in non-syndromic velopharyngeal insufficiency.
Lifespan multidisciplinary surveillance
Category: Monitoring Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
Surveillance should be individualized across cardiology, immune function, calcium and thyroid status, blood counts, palate/feeding and ENT, hearing, vision, renal and skeletal findings, development, and psychiatric health, with planned transition from pediatric to adult care.
Show evidence (2 references)
PMID:36729053 SUPPORT Other
"These recommendations provide contemporary guidance for evaluation, surveillance, and management of the many 22q11.2DS-associated physical, cognitive, behavioral, and psychiatric morbidities while addressing important genetic counseling and psychosocial issues."
The updated pediatric recommendations support coordinated multidisciplinary follow-up.
PMID:36729052 SUPPORT Other
"These recommendations provide guidance for the recognition, evaluation, surveillance, and management of the many emerging and chronic 22q11.2DS-associated multisystem morbidities relevant to adults."
The updated adult recommendations support lifelong, multisystem surveillance.
Genetic counseling and family testing
Category: Counseling / Informational Action: Genetic CounselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Genetic Counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. NCIT:C15240
Offer parental testing, deletion-class-specific recurrence counseling, and reproductive counseling. An affected parent has a 50% transmission risk, but phenotype severity cannot be predicted prenatally.
Show evidence (1 reference)
PMID:20301696 SUPPORT Human Clinical
"Offspring of affected individuals have a 50% chance of inheriting the 22q11.2 deletion."
GeneReviews provides the key transmission-risk basis for counseling.
🔬

Diagnosis

4
Chromosomal microarray confirmation
Establish the diagnosis by detecting a heterozygous 22q11.2 deletion with chromosomal microarray or another validated genome-wide copy-number method. Routine G-banded karyotyping is not sufficiently sensitive.
genetic testing NCIT:C15709 NCI Thesaurus (NCIT)
Results: A heterozygous pathogenic deletion at 22q11.2 establishes the molecular diagnosis.
Show evidence (1 reference)
PMID:20301696 SUPPORT Human Clinical
"The diagnosis of 22q11.2DS is established by identification of a heterozygous deletion at chromosome 22q11.2 on chromosomal microarray analysis or other genomic analyses."
GeneReviews directly defines molecular confirmation.
Targeted familial or prenatal deletion testing
FISH, MLPA, or other targeted testing can evaluate a known familial deletion, but common proximal FISH probes may miss atypical or distal deletions. Use a genome-wide microarray when the familial interval is not already defined.
genetic testing NCIT:C15709 NCI Thesaurus (NCIT)
Show evidence (2 references)
PMID:36648576 SUPPORT Other
"FISH is specific for identification of 22q11.2 dele- tion but may not detect individuals with an atypical or distal deletion that does not include the more proximal part of the commonly deleted region (LCR A-B)."
This supports the stated limitation of common targeted FISH testing.
PMID:20301696 SUPPORT Human Clinical
"Once the 22q11.2 deletion has been identified in an affected family member, prenatal testing using FISH, MLPA, or array studies for a pregnancy at increased risk and preimplantation genetic testing are possible."
GeneReviews supports targeted familial and reproductive testing after the deletion is defined.
Prenatal screening followed by diagnostic confirmation
Cell-free-DNA/NIPS is a screening test, not a molecular diagnosis. A positive screen or suggestive fetal imaging finding should be followed by genetic counseling and diagnostic testing of chorionic villi or amniocytes using chromosomal microarray.
genetic testing NCIT:C15709 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:36672900 SUPPORT Other
"Definitive diagnosis by genetic testing of chorionic villi or amniocytes using a chromosomal microarray will detect clinically relevant microdeletions. Screening options include noninvasive prenatal screening (NIPS) and imaging."
The prenatal guidance clearly separates screening from diagnostic CMA.
Second-diagnosis sequencing for atypical metabolic crises
Recurrent or otherwise unexplained metabolic crises with severe rhabdomyolysis, especially when accompanied by cardiac arrhythmias or neurodegeneration, should prompt evaluation for a second diagnosis. When the deletion includes TANGO2, evaluate for a pathogenic variant on the remaining allele.
genetic testing NCIT:C15709 NCI Thesaurus (NCIT)
Show evidence (2 references)
PMID:42420940 SUPPORT Human Clinical
"At age 5, she experienced her first metabolic crisis during pneumonia with severe rhabdomyolysis (creatine kinase >100,000 U/L), features inconsistent with isolated 22q11.2 deletion syndrome."
A single case supports this as a diagnostic red flag, not as a routine feature or universal testing mandate.
PMID:42420940 SUPPORT Human Clinical
"TANGO2 deficiency disorder is an ultra-rare autosomal recessive condition characterized by life-threatening metabolic crises with rhabdomyolysis and cardiac arrhythmias."
This supports the combined metabolic-crisis, rhabdomyolysis, and arrhythmia red-flag pattern.
📈

Progression

3
Congenital multisystem presentation
Age: Prenatal period through infancy
Developmental anomalies may be recognized prenatally or at birth, but presentation varies widely and some individuals are diagnosed later.
Show evidence (1 reference)
PMID:20301696 SUPPORT Human Clinical
"The major clinical manifestations of 22q11.2DS include congenital heart disease, particularly conotruncal malformations (ventricular septal defect, tetralogy of Fallot, interrupted aortic arch, and truncus arteriosus), palatal abnormalities (velopharyngeal incompetence, submucosal cleft palate,..."
GeneReviews summarizes the characteristic early multisystem presentation.
Age-dependent immune course
Age: Infancy through adulthood
T-cell counts often rise during infancy and may approach population ranges later, while naïve-to-memory skewing, humoral abnormalities, infection risk, and autoimmunity can still evolve. Congenital athymia is a rare, distinct severe presentation.
Show evidence (1 reference)
PMID:36648576 SUPPORT Other
"Specific to 22q11.2del, T cell numbers may increase more rapidly over the first 6 to 12 months of life and have been shown to have a slower rate of age-related decline compared to unaffected individuals."
The immune-management guideline documents an age-dependent T-cell trajectory.
Adolescent and adult psychiatric risk
Age: Adolescence through adulthood
Psychotic-disorder prevalence is higher in adult than pediatric samples, supporting anticipatory psychiatric assessment across the transition to adulthood.
Show evidence (1 reference)
PMID:36786112 SUPPORT Human Clinical
"Prevalence was significantly higher in samples with a mean age over 18 years, with both psychiatric and non-psychiatric comorbidities and recruited from healthcare services (compared to the community)."
Meta-analysis supports an age-associated increase in observed psychotic-disorder prevalence.
📊

Prevalence

2
Country-level population-based live-birth cohorts
Birth Prevalence 10.2–16.8 per 100,000 1–9 per 10,000 (births)
A systematic review found country-specific estimates of 1.02-1.68 per 10,000 live births. These clinically ascertained estimates may undercount mild, prenatally lost, or later-diagnosed cases. The same review's higher 1-in-4,000 to 1-in-7,092 estimates came from cardiovascular-malformation cohorts and are not treated here as a general-population range.
Show evidence (1 reference)
PMID:29906080 SUPPORT Human Clinical
"According to countries, the birth prevalence of this deletion syndrome (95% confidence interval) from United States, Belgium, Sweden, United Kingdom, France, and Singapore were 1.68 (1.22-2.26), 1.56 (1.33-1.72), 1.36 (0.91-2.08), 1.30 (0.45-2.15), 1.03 (0.53-2.23), and 1.02 per 10,000 live..."
The published country estimates convert to 10.2-16.8 per 100,000 live births.
Births at or beyond 20 weeks in Victoria, Australia
Birth Prevalence 21.94 per 100,000 1–9 per 10,000 (births)
This is a minimum combined prenatal and infant estimate from a two-year statewide diagnostic cohort, not a universal population rate.
Show evidence (1 reference)
PMID:32207823 SUPPORT Human Clinical
"After excluding the miscarriage case and accounting for duplicate testing, the estimated prevalence of 22q11 DS was 1 in 4558 Victorian births."
One in 4,558 converts to 21.94 per 100,000 births.
🔀

Differential Diagnoses

4

Conditions with similar clinical presentations that must be differentiated from 22q11.2 Deletion Syndrome:

CHARGE syndrome MONDO:0008965
Overlapping Features CHD7-related CHARGE syndrome can overlap through conotruncal disease, cleft/palatal abnormalities, hearing loss, renal anomalies, developmental delay, thymic hypoplasia, and T-cell lymphopenia. CHD7 testing and the CHARGE feature pattern distinguish it from a confirmed 22q11.2 deletion.
Show evidence (1 reference)
PMID:36648576 SUPPORT Other
"Clinical features of CHARGE syndrome can overlap with those of 22q11.2del"
The guideline directly describes the overlapping presentation.
10p13-p14 deletion syndrome
Overlapping Features A 10p deletion can produce a DiGeorge-like presentation with hypoparathyroidism, hearing loss, and renal dysplasia. Genome-wide copy-number testing distinguishes the deleted interval.
Show evidence (1 reference)
PMID:36648576 SUPPORT Other
"Since then, evidence has accumulated that 10p dele- tions are associated with GATA3 haploinsufficiency, which can result in hypoparathyroidism, sensory neural hearing loss, and renal dysplasia [64]."
The guideline supports the overlapping 10p-deletion phenotype.
Alagille syndrome MONDO:0007318
Overlapping Features Alagille syndrome can overlap through congenital heart disease and facial features; cholestasis or bile-duct paucity, posterior embryotoxon, butterfly vertebrae, and a JAG1 or NOTCH2 variant favor Alagille syndrome.
📊

Related Datasets

6
Next-generation sequencing profiling of miRNAs in individuals with 22q11.2 deletion syndrome revealed altered expression of miR-185-5p geo:GSE289984
Background: The 22q11.2 deletion syndrome (22q11.2DS) is a microdeletion syndrome with highly variable phenotypic manifestations, even though most patients present the typical 3 Mb microdeletion, usually affecting the same ~ 106 genes. One of the genes affected by this deletion is DGCR8, which plays a crucial role in miRNA biogenesis. Therefore, the haploinsufficiency of DGCR8 due to this microdeletion can alter the modulation of the expression of several miRNAs involved in a range of biological processes.
human BULK RNA SEQ n=24
PMID:38872198
Identified by GEO DataSets index search for 22q11.2 Deletion Syndrome (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
Aberrant pace of cortical neuron development in brain organoids from patients with 22q11.2 deletion syndrome and schizophrenia. geo:GSE244010
human BULK RNA SEQ n=26
PMID:40750773
Identified by GEO DataSets index search for 22q11.2 Deletion Syndrome (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
An antisense oligonucleotide-based strategy to ameliorate cognitive dysfunction in the 22q11.2 Deletion Syndrome [RNA-seq] geo:GSE236595
Adults and children with the 22q11.2 Deletion Syndrome demonstrate cognitive, social and emotional impairments and high risk for schizophrenia. Work in mouse model of the 22q11.2 deletion provided compelling evidence for abnormal expression and processing of microRNAs. A major transcriptional effect of the microRNA dysregulation is up-regulation of Emc10, a component of the ER membrane complex, which promotes membrane insertion of a subset of polytopic and tail-anchored membrane proteins. We previously uncovered a key contribution of EMC10 in mediating the behavioral phenotypes observed in 22q11.2 deletion mouse models.
human BULK RNA SEQ n=6
PMID:40420562
Identified by GEO DataSets index search for 22q11.2 Deletion Syndrome (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
Whole-Genome Sequencing Suggests Schizophrenia Risk Mechanisms in Humans with 22q11.2 Deletion Syndrome ega:EGAS00001002344
Chromosome 22q11.2 microdeletions impart a high but incomplete risk for schizophrenia. Possible mechanisms include genome-wide effects of DGCR8 haploinsufficiency. In a proof-of-principle study to assess the power of this model, we used high-quality, whole-genome sequencing of nine individuals with 22q11.2 deletions and extreme phenotypes (schizophrenia, or no psychotic disorder at age >50 years). The schizophrenia group had a greater burden of rare, damaging variants impacting protein-coding neurofunctional genes, including genes involved in neuron projection (nominal P = 0.02, joint burden of three variant types). Variants in the intact 22q11.2 region were not major contributors.
human
PMID:26384369
European Genome-phenome Archive study, matched because the disease is named in the study's own title ("22q11.2 Deletion Syndrome"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.
Multiple paralogues and recombination mechanisms contribute to the high incidence of 22q11.2 Deletion Syndrome ega:EGAS50000000601
To enable haplotype-specific assembly and rearrangement mapping in LCR22 clusters, we combined fiber-FISH optical mapping with whole genome (ultra-)long read sequencing or rearrangement-specific long-range PCR on 254 duos families (22q11.2DS patient and parent-of-origin) comprising several different LCR22-mediated rearrangements.
human WGS
European Genome-phenome Archive study, matched because the disease is named in the study's own title ("22q11.2 Deletion Syndrome"); description-level mentions were not accepted. EGA study_type: Whole Genome Sequencing. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.
Whole Exome Sequence of 184 Individuals with 22q11.2 Deletion Syndrome dbgap:phs000987
Our goal is to find genetic modifiers of major phenotypes in patients with 22q11.2 deletion syndrome, also known as DiGeorge syndrome or velo-cardio-facial syndrome. Whole exome sequencing was performed as part of a contract to the NHLBI, Resequencing and Genotyping Service. We have obtained cardiac phenotype information from the de-identified subjects enrolled in the study, either by echocardiography report or medical doctor report. All of the subjects have a 3 million base pair 22q11.2 deletion flanked by low copy repeats, LCR22, A-D.
Located via OmicsDI, which aggregates across omics repositories; this record comes from dbgap. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("22q11.2 Deletion Syndrome"). Retrieved 2026-08-02.
🔬

Clinical Trials

1
NCT01220531 NOT_APPLICABLE COMPLETED
Completed expanded-access study of cultured thymus tissue implantation for complete DiGeorge anomaly/congenital athymia. It is relevant only to the rare absent-thymus-function subgroup, not to routine 22q11.2 deletion care.
Target Phenotypes: Cellular immunodeficiency HP:0005374 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Cellular immunodeficiency (HP:0005374). HP:0005374 is a phenotype from the Human Phenotype Ontology. Aplasia of the thymus HP:0005359 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Aplasia of the thymus (HP:0005359). HP:0005359 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
clinicaltrials:NCT01220531 SUPPORT Human Clinical
"This expanded access study continues cultured thymus tissue safety and efficacy research for the treatment of complete DiGeorge anomaly."
The registry documents the completed cultured-thymus study in the congenital-athymia subgroup.
{ }

Source YAML

click to show 
name: 22q11.2 Deletion Syndrome
creation_date: '2026-02-06T03:39:54Z'
category: Genetic
synonyms:
- DiGeorge syndrome
- Velocardiofacial syndrome
- VCFS
- Shprintzen syndrome
- Conotruncal anomaly face syndrome
- CATCH22
description: >-
  22q11.2 deletion syndrome is a variably expressive chromosomal disorder caused
  by a heterozygous, usually recurrent deletion that removes multiple
  dosage-sensitive genes at chromosome 22q11.2. Major manifestations include
  congenital heart disease, palatal abnormalities, characteristic facial
  features, immune deficiency, hypocalcemia related to parathyroid dysfunction,
  hearing loss, and learning or psychiatric disorders, but no single feature is
  universal. TBX1 is an
  important developmental contributor rather than a sufficient explanation for
  the full contiguous-gene syndrome. DiGeorge syndrome, velocardiofacial
  syndrome, and CATCH22 are historical labels; DiGeorge syndrome can also refer
  to phenocopies caused by other defects of thymic and pharyngeal development.
disease_term:
  preferred_term: 22q11.2 deletion syndrome
  term:
    id: MONDO:0018923
    label: 22q11.2 deletion syndrome
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0008564
      label: DiGeorge syndrome
    mapping_predicate: skos:narrowMatch
    mapping_source: MONDO
    mapping_justification: >
      MONDO:0008564 (OMIM:188400, RO:0004003 HGNC:11592 TBX1) is_a the
      MONDO:0018923 anchor of this entry. DiGeorge syndrome is the historical
      label for the thymic/parathyroid/conotruncal presentation of the same
      22q11.2 deletion this entry curates, and the entry already models the
      immunodeficiency and cardiac arms. narrowMatch because MONDO models
      DiGeorge as a child of the deletion syndrome rather than as an equivalent
      term - the same treatment already applied here to velocardiofacial
      syndrome.
  - term:
      id: MONDO:0008644
      label: velocardiofacial syndrome
    mapping_predicate: skos:narrowMatch
    mapping_source: MONDO
    mapping_justification: >-
      MONDO:0008644 (velocardiofacial syndrome) is a subclass of MONDO:0018923
      (22q11.2 deletion syndrome) and carries "22q11 deletion syndrome" and
      "deletion 22q11.2 syndrome" as exact synonyms; it is the Shprintzen/VCF
      historical label already listed in this entry's synonyms. narrowMatch
      because MONDO models VCF as a child of the deletion syndrome rather than
      an equivalent class.
has_subtypes:
- name: DiGeorge
  display_name: DiGeorge syndrome
  subtype_term:
    preferred_term: DiGeorge syndrome
    term:
      id: MONDO:0008564
      label: DiGeorge syndrome
  genes:
  - preferred_term: TBX1
    description: >-
      Bound as the dosage-sensitive gene whose loss drives the
      thymic/parathyroid/conotruncal arm of this presentation, and the gene in
      which the cited report found point mutations reproducing it in patients
      with no 22q11.2 deletion. That report screened TBX1 and does not
      establish that no other interval gene behaves the same way. In nearly
      every patient the lesion is the deletion, not a TBX1 sequence variant;
      see the "Recurrent 22q11.2 deletion" record in `genetic`.
    term:
      id: hgnc:11592
      label: TBX1
  description: >-
    The historical label for the thymic, parathyroid and conotruncal
    presentation of the 22q11.2 deletion. It is carried here as a named
    clinical presentation rather than a separate mechanism: the lesion is the
    same contiguous-gene deletion this entry curates, and the entry already
    models the immunodeficiency and cardiac arms as pathophysiology nodes.
    This row exists so that the MONDO concept, and the gene MONDO attaches to
    it, are addressable in the same place as the presentation they describe.
  evidence:
  - reference: PMID:14585638
    reference_title: Role of TBX1 in human del22q11.2 syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified three mutations of TBX1 in two unrelated patients without the
      22q11.2 deletion-one with sporadic conotruncal anomaly face
      syndrome/velocardiofacial syndrome and one with sporadic DiGeorge's
      syndrome-and in three patients from a family with conotruncal anomaly face
      syndrome/velocardiofacial syndrome.
    explanation: >-
      Identifies a patient with sporadic DiGeorge syndrome carrying a TBX1
      point mutation and no 22q11.2 deletion, which is the human evidence that
      TBX1 alone can produce this presentation and so the basis for binding the
      gene on this row.
- name: Velocardiofacial
  display_name: Velocardiofacial (Shprintzen) syndrome
  subtype_term:
    preferred_term: velocardiofacial syndrome
    term:
      id: MONDO:0008644
      label: velocardiofacial syndrome
  genes:
  - preferred_term: TBX1
    description: >-
      Bound for the same reason as on the DiGeorge row: TBX1 point mutations
      without a deletion have been reported in patients with this presentation.
    term:
      id: hgnc:11592
      label: TBX1
  description: >-
    The historical Shprintzen label, emphasising the velopharyngeal, cardiac
    and facial features. As with DiGeorge syndrome it names a presentation of
    the same deletion rather than a distinct lesion, and the entry models its
    mechanistic substrate as the "Velopharyngeal structural and myogenic
    insufficiency" node. This entry's own description records both, along with
    CATCH22, as historical labels for the same deletion, which is why the entry
    is anchored on the deletion and carries them as subtypes rather than
    splitting into separate disease files.
  evidence:
  - reference: PMID:14585638
    reference_title: Role of TBX1 in human del22q11.2 syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified three mutations of TBX1 in two unrelated patients without the
      22q11.2 deletion-one with sporadic conotruncal anomaly face
      syndrome/velocardiofacial syndrome and one with sporadic DiGeorge's
      syndrome-and in three patients from a family with conotruncal anomaly face
      syndrome/velocardiofacial syndrome.
    explanation: >-
      Reports TBX1 point mutations without a 22q11.2 deletion in a sporadic
      case and in a three-member family with conotruncal anomaly
      face/velocardiofacial syndrome, which is the basis for binding the gene
      on this row.
gene_sets:
- gene_set: MYGENESET:WP_22Q112_COPY_NUMBER_VARIATION_SYNDROME
  relationship: CANONICAL_PATHWAY
  note: WikiPathways 22q11.2 copy-number-variation syndrome pathway.
parents:
- Chromosomal microdeletion syndrome
classifications:
  iuis_category:
    classification_value: combined immunodeficiency with syndromic features
    notes: >-
      IUIS 2022 phenotypic classification Table 2 (combined immunodeficiencies
      with associated or syndromic features); DiGeorge/22q11.2 deletion
      spectrum.
    evidence:
    - reference: PMID:35748970
      reference_title: "Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "We report the updated classification of inborn errors of immunity, compiled by the International Union of Immunological Societies Expert Committee."
      explanation: >-
        22q11.2 deletion syndrome is assigned to IUIS Table 2 (combined
        immunodeficiency with syndromic features) in the IUIS phenotypic IEI
        classification.
tracked_issues:
- url: https://github.com/monarch-initiative/dismech/issues/6558
  title: Expert review of 22q11.2 deletion gene attribution and human-model extrapolation
  tracked_issue_role: curation_followup
  tracked_issue_status: OPEN
  notes: >-
    Requests expert judgment on TBX1 versus multigene causal attribution,
    deletion-size effects, and dosage-mismatched mouse-model evidence.
inheritance:
- name: Autosomal dominant contiguous-gene deletion
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  de_novo_rate: >-
    More than 90% of typical 3.0 (2.54)-Mb deletions are de novo, whereas nested
    deletions are inherited much more often.
  expressivity: VARIABLE
  description: >-
    Parental testing is important because inheritance depends on deletion class.
    An affected individual has a 50% chance of transmitting the deletion in each
    pregnancy, but severity cannot be predicted from an affected parent.
  evidence:
  - reference: PMID:20301696
    reference_title: 22q11.2 Deletion Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 22q11.2DS is an autosomal dominant contiguous gene deletion syndrome.
    explanation: GeneReviews establishes the inheritance mode.
  - reference: PMID:20301696
    reference_title: 22q11.2 Deletion Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In 22q11.2DS caused by a 3.0 (2.54)-Mb deletion, the deletion is de novo in more than 90% of individuals and inherited from a heterozygous parent in about 10% of individuals.
    explanation: This gives the deletion-class-specific de novo rate for the typical deletion.
  - reference: PMID:20301696
    reference_title: 22q11.2 Deletion Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Sixty percent of individuals with 22q11.2DS caused by a nested 22q11.2 deletion inherited the deletion from an affected parent. Offspring of affected individuals have a 50% chance of inheriting the 22q11.2 deletion.
    explanation: This supports the higher inherited fraction for nested deletions and the 50% transmission risk.
prevalence:
- population: Country-level population-based live-birth cohorts
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_5_PER_10000
  rate_low: 10.2
  rate_high: 16.8
  notes: >-
    A systematic review found country-specific estimates of 1.02-1.68 per
    10,000 live births. These clinically ascertained estimates may undercount
    mild, prenatally lost, or later-diagnosed cases. The same review's higher
    1-in-4,000 to 1-in-7,092 estimates came from cardiovascular-malformation
    cohorts and are not treated here as a general-population range.
  evidence:
  - reference: PMID:29906080
    reference_title: >-
      Birth Prevalence of Chromosome 22q11.2 Deletion Syndrome: A Systematic Review of Population-Based Studies.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      According to countries, the birth prevalence of this deletion syndrome (95% confidence interval) from United States, Belgium, Sweden, United Kingdom, France, and Singapore were 1.68 (1.22-2.26), 1.56 (1.33-1.72), 1.36 (0.91-2.08), 1.30 (0.45-2.15), 1.03 (0.53-2.23), and 1.02 per 10,000 live births, respectively.
    explanation: The published country estimates convert to 10.2-16.8 per 100,000 live births.
- population: Births at or beyond 20 weeks in Victoria, Australia
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_5_PER_10000
  rate_per_100000: 21.94
  notes: >-
    This is a minimum combined prenatal and infant estimate from a two-year
    statewide diagnostic cohort, not a universal population rate.
  evidence:
  - reference: PMID:32207823
    reference_title: >-
      A minimum estimate of the prevalence of 22q11 deletion syndrome and other chromosome abnormalities in a combined prenatal and postnatal cohort.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      After excluding the miscarriage case and accounting for duplicate testing, the estimated prevalence of 22q11 DS was 1 in 4558 Victorian births.
    explanation: One in 4,558 converts to 21.94 per 100,000 births.
progression:
- phase: Congenital multisystem presentation
  age_range: Prenatal period through infancy
  notes: >-
    Developmental anomalies may be recognized prenatally or at birth, but
    presentation varies widely and some individuals are diagnosed later.
  evidence:
  - reference: PMID:20301696
    reference_title: 22q11.2 Deletion Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The major clinical manifestations of 22q11.2DS include congenital heart disease, particularly conotruncal malformations (ventricular septal defect, tetralogy of Fallot, interrupted aortic arch, and truncus arteriosus), palatal abnormalities (velopharyngeal incompetence, submucosal cleft palate, bifid uvula, and cleft palate), immune deficiency, characteristic facial features, and learning difficulties.
    explanation: GeneReviews summarizes the characteristic early multisystem presentation.
- phase: Age-dependent immune course
  age_range: Infancy through adulthood
  notes: >-
    T-cell counts often rise during infancy and may approach population ranges
    later, while naïve-to-memory skewing, humoral abnormalities, infection risk,
    and autoimmunity can still evolve. Congenital athymia is a rare, distinct
    severe presentation.
  evidence:
  - reference: PMID:36648576
    reference_title: >-
      Clinical Practice Guidelines for the Immunological Management of Chromosome 22q11.2 Deletion Syndrome and Other Defects in Thymic Development.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Specific to 22q11.2del, T cell numbers may increase more rapidly over the first 6 to 12 months of life and have been shown to have a slower rate of age-related decline compared to unaffected individuals.
    explanation: The immune-management guideline documents an age-dependent T-cell trajectory.
- phase: Adolescent and adult psychiatric risk
  age_range: Adolescence through adulthood
  notes: >-
    Psychotic-disorder prevalence is higher in adult than pediatric samples,
    supporting anticipatory psychiatric assessment across the transition to
    adulthood.
  evidence:
  - reference: PMID:36786112
    reference_title: >-
      Prevalence and incidence of psychotic disorders in 22q11.2 deletion syndrome: a meta-analysis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Prevalence was significantly higher in samples with a mean age over 18 years, with both psychiatric and non-psychiatric comorbidities and recruited from healthcare services (compared to the community).
    explanation: Meta-analysis supports an age-associated increase in observed psychotic-disorder prevalence.
pathophysiology:
- name: Recurrent LCR22-mediated multigene deletion
  description: >-
    Low-copy repeats at 22q11.2 predispose to non-allelic homologous
    recombination and recurrent deletions. The common A-D interval removes more
    than 40 coding genes, so the syndrome reflects combined dosage effects and
    background modifiers rather than a single-gene lesion.
  genes:
  - preferred_term: TBX1
    term:
      id: hgnc:11592
      label: TBX1
  - preferred_term: DGCR8
    term:
      id: hgnc:2847
      label: DGCR8
  downstream:
  - target: TBX1-associated pharyngeal developmental vulnerability
    causal_link_type: DIRECT
    description: The recurrent proximal deletion makes TBX1 hemizygous.
  - target: DGCR8-associated miRNA-processing disruption
    causal_link_type: DIRECT
    description: The recurrent proximal deletion makes DGCR8 hemizygous.
  - target: Thymic developmental impairment
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Combined deleted-region dosage effects can impair thymic development, but
      individual-gene attribution and modifiers remain incompletely resolved.
  - target: Candidate cortical and neurotransmitter mechanisms
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Deleted-region dosage creates several candidate neurodevelopmental
      mechanisms whose human causal contributions remain uncertain.
  evidence:
  - reference: PMID:36648576
    reference_title: >-
      Clinical Practice Guidelines for the Immunological Management of Chromosome 22q11.2 Deletion Syndrome and Other Defects in Thymic Development.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: |-
      These LCRs mediate meiotic non-
      allelic homologous recombination and are susceptible to
      either deletion or duplication of these intervals.
    explanation: This supports the recurrent LCR-mediated deletion mechanism.
  - reference: PMID:41891037
    reference_title: >-
      Deletion size and background genetic variation shape congenital heart disease phenotypes in 3,016 individuals with 22q11.2 deletion syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The typical 3 Mb LCR22 A-D deletion was present in 2,788 individuals (92.4%), with smaller A-B (n=172, 5.7%) and A-C (n=56, 1.9%) deletions comprising the remaining cohort.
    explanation: A large contemporary cohort documents the dominant recurrent deletion and smaller proximal classes.
  - reference: DOI:10.3390/genes15030321
    reference_title: >-
      Understanding the Variability of 22q11.2 Deletion Syndrome: The Role of Epigenetic Factors
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The review of the literature confirms the hypothesis that the 22q11.2DS phenotype results from a network of interactions between deleted protein-coding genes and altered epigenetic regulation.
    explanation: This supports a multigene and regulatory-network model rather than singular TBX1 causation.
- name: TBX1-associated pharyngeal developmental vulnerability
  description: >-
    TBX1 dosage is an important contributor to pharyngeal-apparatus and cardiac
    outflow development. Heterozygous Tbx1 mice model aortic/outflow anomalies,
    whereas the broader phenotype occurs mainly after homozygous loss; those
    dosage differences limit extrapolation to the human multigene deletion.
  genes:
  - preferred_term: TBX1
    term:
      id: hgnc:11592
      label: TBX1
  locations:
  - preferred_term: pharyngeal arch
    term:
      id: UBERON:0002539
      label: pharyngeal arch
  biological_processes:
  - preferred_term: pharyngeal system development
    term:
      id: GO:0060037
      label: pharyngeal system development
  downstream:
  - target: Velopharyngeal structural and myogenic insufficiency
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Pharyngeal arch and palatal shelf patterning, and pharyngeal muscle development.
    description: >-
      The same pharyngeal-apparatus vulnerability that underlies the outflow
      lesion also underlies the velopharyngeal and palatal phenotype. The mouse
      evidence is homozygous-null and so is dosage-mismatched to the human
      heterozygous deletion; it supports developmental plausibility rather than
      a direct human causal claim.
    evidence:
    - reference: PMID:11242110
      reference_title: DiGeorge syndrome phenotype in mice mutant for the T-box gene, Tbx1.
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Tbx1-/- mice displayed a wide range of developmental anomalies encompassing almost all of the common DGS/VCFS features, including hypoplasia of the thymus and parathyroid glands, cardiac outflow tract abnormalities, abnormal facial structures, abnormal vertebrae and cleft palate
      explanation: >-
        Cleft palate in the homozygous null links Tbx1-dependent pharyngeal
        development to the palatal arm of the phenotype. INDIRECT because the
        model is homozygous and murine, whereas the human lesion is a
        heterozygous multigene deletion.
    - reference: PMID:40038168
      reference_title: >-
        Review of the Pathophysiology and Clinical Manifestations of 22q11.2 Deletion and Duplication Syndromes.
      supports: SUPPORT
      directness: DIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Neural crest development is usually impacted leading to various cardiovascular defects including Tetralogy of Fallot and truncus arteriosus. It can also cause palatal defects, especially velopharyngeal deficiency
      explanation: >-
        States the edge directly in human terms: the same pharyngeal
        neural-crest disruption that produces the conotruncal lesions also
        produces velopharyngeal deficiency. This is the human-level counterpart
        of the dosage-mismatched mouse evidence above.
  - target: Conotruncal heart defect
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Pharyngeal arch artery, second-heart-field, and outflow-tract development.
    description: >-
      TBX1 dosage contributes to conotruncal and aortic-arch susceptibility, but
      other deleted genes and genome-wide modifiers also shape the human lesion.
    evidence:
    - reference: PMID:11242110
      reference_title: DiGeorge syndrome phenotype in mice mutant for the T-box gene, Tbx1.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        mice heterozygous for the mutation had a high incidence of cardiac outflow tract anomalies, thus modeling one of the major abnormalities of the human syndrome
      explanation: Heterozygous mouse evidence supports a cardiac contribution but not the full human contiguous-gene syndrome.
  evidence:
  - reference: PMID:11242110
    reference_title: DiGeorge syndrome phenotype in mice mutant for the T-box gene, Tbx1.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Tbx1-/- mice displayed a wide range of developmental anomalies encompassing almost all of the common DGS/VCFS features, including hypoplasia of the thymus and parathyroid glands, cardiac outflow tract abnormalities, abnormal facial structures, abnormal vertebrae and cleft palate
    explanation: >-
      Homozygous knockout supports developmental plausibility, but it is not dosage-equivalent to a heterozygous human multigene deletion.
- name: Velopharyngeal structural and myogenic insufficiency
  description: >-
    The velopharyngeal port fails to close during speech because of combined
    structural and muscular factors - a deep pharynx, palatal anomalies that are
    often submucous rather than overt, and hypodynamic pharyngeal musculature.
    This is the mechanistic substrate of the historical velocardiofacial
    presentation, and it is the proposed explanation for resonance persisting
    after a purely palatal repair - proposed rather than established, since the
    supporting surgical comparison is a 14-patient series.
  biological_scale: TISSUE
  locations:
  - preferred_term: soft palate
    term:
      id: UBERON:0001733
      label: soft palate
  - preferred_term: pharynx
    term:
      id: UBERON:0001042
      label: chordate pharynx
  biological_processes:
  - preferred_term: palate development
    term:
      id: GO:0060021
      label: roof of mouth development
  downstream:
  - target: Velopharyngeal insufficiency
    causal_link_type: DIRECT
    description: >-
      Incomplete closure of the velopharyngeal port is the direct functional
      expression of this combined structural and myogenic deficit.
    evidence:
    - reference: PMID:36695155
      reference_title: >-
        Sphincter Pharyngoplasty for Velopharyngeal Dysfunction: Impact of 22q11.2 Deletion Syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Patients with 22q11.2 deletion syndrome (22q11DelS) often present with velopharyngeal dysfunction (VPD). VPD in patients with 22q11DelS is multifactorial beyond velopharyngeal insufficiency (VPI) alone, and differences in surgical outcomes are poorly understood.
      explanation: >-
        Establishes that velopharyngeal dysfunction in this syndrome is
        multifactorial rather than a simple palatal-closure defect.
    - reference: PMID:39056299
      reference_title: >-
        Do Palatoplasty Procedures Resolve Hypernasality as Effectively as Pharyngoplasty Procedures in Patients with 22q11.2 Deletion Syndrome?
      supports: SUPPORT
      directness: DIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        People with 22q can have multiple anatomic/physiologic differences of the velopharynx that contribute to VPI. These differences may include palatal clefting, increased pharyngeal depth due to velopharyngeal disproportion, decreased velar thickness, thin levator veli palatini muscles, discontinuity of the levator veli palatini muscles, decreased velar length, and pharyngeal hypotonia.
      explanation: >-
        States the edge directly: it names the anatomic and physiologic
        differences of the velopharynx that contribute to velopharyngeal
        insufficiency, which is exactly the content of the upstream node.
  - target: Hypernasal speech
    causal_link_type: DIRECT
    description: >-
      Air escape through the incompletely closed port produces hypernasal
      resonance, which resists palatoplasty in this syndrome because the
      pharyngeal and myogenic components are not addressed by palatal repair.
    evidence:
    - reference: PMID:39056299
      reference_title: >-
        Do Palatoplasty Procedures Resolve Hypernasality as Effectively as Pharyngoplasty Procedures in Patients with 22q11.2 Deletion Syndrome?
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        In patients with 22q, palatoplasty procedures may be less effective than pharyngoplasty procedures at resolving hypernasality. This may be due to underlying anatomic or physiologic differences, such as increased pharyngeal depth and hypodynamic muscles.
      explanation: >-
        Attributes the hypernasality specifically to pharyngeal depth and
        hypodynamic muscles, which is the causal content of this edge rather
        than of either node alone.
  evidence:
  - reference: PMID:39056299
    reference_title: >-
      Do Palatoplasty Procedures Resolve Hypernasality as Effectively as Pharyngoplasty Procedures in Patients with 22q11.2 Deletion Syndrome?
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients who underwent palatoplasty achieved an increase in velar length, but this did not lead to resolution of hypernasality, suggesting that underlying anatomical differences such as increased pharyngeal depth and hypodynamic muscles may make palatoplasty less effective at resolving hypernasality in patients with 22q.
    explanation: >-
      Names both components of this node - pharyngeal depth (structural) and
      hypodynamic muscles (myogenic) - and shows they persist after velar
      lengthening, which is why the node is not reducible to palatal anatomy.
- name: DGCR8-associated miRNA-processing disruption
  description: >-
    DGCR8 hemizygosity can perturb microRNA biogenesis and downstream gene
    regulation. This is a candidate contributor to variable expression, not a
    proven explanation for any single clinical feature.
  genes:
  - preferred_term: DGCR8
    term:
      id: hgnc:2847
      label: DGCR8
  biological_processes:
  - preferred_term: miRNA processing
    term:
      id: GO:0035196
      label: miRNA processing
  evidence:
  - reference: DOI:10.3390/genes15030321
    reference_title: >-
      Understanding the Variability of 22q11.2 Deletion Syndrome: The Role of Epigenetic Factors
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Typical miRNA expression patterns have been identified in 22q11.2DS, due to an alteration in miRNA biogenesis, affecting the expression of several target genes.
    explanation: The review supports altered miRNA biogenesis while leaving phenotype-level causality unresolved.
- name: Thymic developmental impairment
  description: >-
    Reduced thymic tissue can lower thymic T-cell output. Most immune phenotypes
    are milder T-cell lymphopenia rather than congenital athymia, and clinical
    appearance alone does not reliably identify the immune severity.
  cell_types:
  - preferred_term: cortical thymic epithelial cell
    term:
      id: CL:0002364
      label: cortical thymic epithelial cell
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  locations:
  - preferred_term: thymus
    term:
      id: UBERON:0002370
      label: thymus
  biological_processes:
  - preferred_term: thymus development
    term:
      id: GO:0048538
      label: thymus development
  downstream:
  - target: Cellular immunodeficiency
    causal_link_type: DIRECT
    description: Reduced thymic tissue lowers T-cell output.
    evidence:
    - reference: PMID:36648576
      reference_title: >-
        Clinical Practice Guidelines for the Immunological Management of Chromosome 22q11.2 Deletion Syndrome and Other Defects in Thymic Development.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Thus, barring a specific T cell defect such as SCID, a normal thymic volume in 22q11.2del, results in a normal number of T cells, whereas a small thymus can result in a quantitative T cell deficiency.
      explanation: The guideline directly links thymic size to quantitative T-cell deficiency.
  - target: Congenital athymia
    causal_link_type: DIRECT
    description: Complete absence of thymic function is the rare severe end of the developmental defect.
    evidence:
    - reference: PMID:36648576
      reference_title: >-
        Clinical Practice Guidelines for the Immunological Management of Chromosome 22q11.2 Deletion Syndrome and Other Defects in Thymic Development.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: |-
        Stud-
        ies suggest that approximately 0.5% of those diagnosed
        with 22q11.2del have a severe immune deficiency with
        very few T cells due to the absence of a thymus at birth,
        termed congenital athymia [14, 15].
      explanation: This identifies and quantifies congenital athymia specifically in 22q11.2 deletion syndrome.
  evidence:
  - reference: PMID:36648576
    reference_title: >-
      Clinical Practice Guidelines for the Immunological Management of Chromosome 22q11.2 Deletion Syndrome and Other Defects in Thymic Development.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      An estimated 67–80% of individuals affected with 22q11.2del have some degree of T cell lymphopenia (TCL).
    explanation: This establishes T-cell lymphopenia as the common immune presentation.
- name: Candidate cortical and neurotransmitter mechanisms
  description: >-
    RANBP1-null mice show impaired upper-layer cortical neuron generation, and a
    small human study found a COMT-genotype-by-proline association with selected
    neurophysiologic measures. These observations are candidate mechanisms; they
    do not establish a causal path from an individual interval gene to human
    learning difficulties or schizophrenia.
  genes:
  - preferred_term: RANBP1
    term:
      id: hgnc:9847
      label: RANBP1
  - preferred_term: COMT
    term:
      id: hgnc:2228
      label: COMT
  - preferred_term: PRODH
    term:
      id: hgnc:9453
      label: PRODH
  cell_types:
  - preferred_term: neural progenitor cell
    term:
      id: CL:0011020
      label: neural progenitor cell
  locations:
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  biological_processes:
  - preferred_term: neurogenesis
    term:
      id: GO:0022008
      label: neurogenesis
  evidence:
  - reference: PMID:25452572
    reference_title: >-
      Ranbp1, Deleted in DiGeorge/22q11.2 Deletion Syndrome, is a Microcephaly Gene That Selectively Disrupts Layer 2/3 Cortical Projection Neuron Generation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Ranbp1(-/-)-dependent proliferative deficits substantially diminish the frequency of layer 2/3, but not layer 5/6 cortical projection neurons.
    explanation: Homozygous mouse knockout supports a candidate cortical mechanism but is not equivalent to human hemizygosity.
  - reference: PMID:18769474
    reference_title: Proline affects brain function in 22q11DS children with the low activity COMT 158 allele.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      With regard to the SPEM performance, there was a significant interaction between the COMT158 genotype and proline level with significantly decreased SPEM performance in children with high plasma proline levels and the low activity COMTmet allele.
    explanation: >-
      The small human study supports a limited genotype-by-metabolite association, not a general mechanism for psychosis.
phenotypes:
- name: Conotruncal heart defect
  frequency: FREQUENT
  description: >-
    Congenital heart disease is heterogeneous and often conotruncal, including
    tetralogy of Fallot, interrupted aortic arch, truncus arteriosus, and septal
    defects. A recent 3,016-person specialist-center cohort found congenital
    heart disease in 59% and conotruncal defects in 40%.
  phenotype_term:
    preferred_term: Conotruncal defect
    term:
      id: HP:0001710
      label: Conotruncal defect
  evidence:
  - reference: PMID:41891037
    reference_title: >-
      Deletion size and background genetic variation shape congenital heart disease phenotypes in 3,016 individuals with 22q11.2 deletion syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most frequent class of defects in 22q11.2DS are CTDs; they occurred in 40% of this cohort.
    explanation: The 40% conotruncal-defect estimate supports the FREQUENT band.
  - reference: PMID:20301696
    reference_title: 22q11.2 Deletion Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      congenital heart disease, particularly conotruncal malformations (ventricular septal defect, tetralogy of Fallot, interrupted aortic arch, and truncus arteriosus)
    explanation: GeneReviews documents the characteristic lesion spectrum.
- name: Palatal abnormality
  description: >-
    The palatal spectrum includes velopharyngeal incompetence, bifid uvula,
    submucous cleft palate, and overt cleft palate.
  phenotype_term:
    preferred_term: Abnormal palate morphology
    term:
      id: HP:0000174
      label: Abnormal palate morphology
  evidence:
  - reference: PMID:20301696
    reference_title: 22q11.2 Deletion Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      palatal abnormalities (velopharyngeal incompetence, submucosal cleft palate, bifid uvula, and cleft palate)
    explanation: GeneReviews directly describes the human palatal spectrum.
- name: Velopharyngeal insufficiency
  frequency: FREQUENT
  description: >-
    Failure of the velopharyngeal port to close during speech is the "velo"
    component of the historical velocardiofacial (Shprintzen) presentation.
    GeneReviews lists velopharyngeal incompetence alongside - rather than as a
    consequence of - submucous and overt cleft palate, so it is curated
    separately from the palatal structural anomalies above. Note that the
    literature treats velopharyngeal dysfunction in this syndrome as broader
    than velopharyngeal insufficiency alone; this phenotype is bound to the
    insufficiency term, and the additional contributors are modelled in the
    upstream mechanism node.
  phenotype_term:
    preferred_term: Velopharyngeal insufficiency
    term:
      id: HP:0000220
      label: Velopharyngeal insufficiency
  evidence:
  - reference: PMID:36695155
    reference_title: >-
      Sphincter Pharyngoplasty for Velopharyngeal Dysfunction: Impact of 22q11.2 Deletion Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with 22q11.2 deletion syndrome (22q11DelS) often present with velopharyngeal dysfunction (VPD). VPD in patients with 22q11DelS is multifactorial beyond velopharyngeal insufficiency (VPI) alone, and differences in surgical outcomes are poorly understood.
    explanation: >-
      States both that velopharyngeal dysfunction is a common presenting feature
      of the deletion syndrome and that it is multifactorial rather than reducible
      to velopharyngeal insufficiency alone.
  - reference: PMID:41800660
    reference_title: "DiGeorge for the Otolaryngologist: A State-of-the-Art Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      22q11.2DS presents a uniquely high burden of ENT disease across the lifespan, including chronic otitis media, elevated cholesteatoma risk, persistent velopharyngeal dysfunction, multilevel airway anomalies, sleep-disordered breathing, dysphagia, and perioperative vulnerability due to vascular, immunologic, and hematologic anomalies.
    explanation: >-
      A 2026 otolaryngology state-of-the-art review lists persistent
      velopharyngeal dysfunction among the lifelong ENT burden of the syndrome.
  - reference: PMID:39056299
    reference_title: >-
      Do Palatoplasty Procedures Resolve Hypernasality as Effectively as Pharyngoplasty Procedures in Patients with 22q11.2 Deletion Syndrome?
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      While not all people with 22q have a palatal abnormality, up to 80% of people with 22q present with VPI.
    explanation: >-
      Supports the FREQUENT band (30-79%). The figure is an upper bound, so it
      is not read as VERY_FREQUENT; the deep-research report's own phenotype
      table independently gives ~65-70% for the palatal group. Note this
      sentence is the paper's introductory summary of the literature rather
      than a result of its own 14-patient series.
- name: Hypernasal speech
  description: >-
    Hypernasal resonance is the audible speech consequence of the incompetent
    velopharyngeal port and is the feature that most often brings affected
    children to speech surgery. Its persistence after palatoplasty in this
    syndrome is attributed to pharyngeal anatomy and muscle tone rather than to
    a residual palatal cleft.
  phenotype_term:
    preferred_term: Hypernasal speech
    term:
      id: HP:0001611
      label: Hypernasal speech
  evidence:
  - reference: PMID:39056299
    reference_title: >-
      Do Palatoplasty Procedures Resolve Hypernasality as Effectively as Pharyngoplasty Procedures in Patients with 22q11.2 Deletion Syndrome?
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Resonance and speech sound disorders may also present and include hypernasality and compensatory misarticulation errors that require speech therapy.
    explanation: >-
      Establishes hypernasality as part of the syndrome's speech phenotype at
      the population level. An earlier draft quoted the preoperative severity
      split of the same paper's surgical arm, but presence of hypernasality was
      an inclusion criterion of that study, so those proportions are true by
      construction and cannot evidence the phenotype.
- name: Delayed speech and language development
  frequency: VERY_FREQUENT
  description: >-
    Language impairment is broad rather than confined to a single domain, and it
    is not fully explained by speech intelligibility - children with intelligible
    speech still score below average, so this is curated separately from the
    palatal and resonance phenotypes above and from general learning difficulties.
  phenotype_term:
    preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: PMID:36512754
    reference_title: >-
      The Language Profile of Preschool Children With 22q11.2 Deletion Syndrome and the Relationship With Speech Intelligibility.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Most children had impaired language skills across all tested domains. The composite score for expressive language was significantly lower than that for receptive language, but the two were strongly correlated.
    explanation: >-
      A 44-child prospective preschool cohort finds impairment across all tested
      language domains, supporting delayed speech and language development as a
      phenotype in its own right.
  - reference: PMID:39056299
    reference_title: >-
      Do Palatoplasty Procedures Resolve Hypernasality as Effectively as Pharyngoplasty Procedures in Patients with 22q11.2 Deletion Syndrome?
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additionally, most people (95%) with 22q present with a speech-language disorder.
    explanation: >-
      The 95% figure supports the VERY_FREQUENT band (80-100%). As with the
      velopharyngeal frequency above, this is the paper's introductory citation
      of prior literature rather than a finding of its own cohort.
- name: Characteristic facial features
  description: Characteristic facial features are part of the clinical spectrum.
  phenotype_term:
    preferred_term: Abnormal facial shape
    term:
      id: HP:0001999
      label: Abnormal facial shape
  evidence:
  - reference: PMID:20301696
    reference_title: 22q11.2 Deletion Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: characteristic facial features
    explanation: >-
      GeneReviews directly identifies characteristic facial features without
      providing a frequency estimate in this passage.
- name: Hypocalcemia
  description: >-
    Parathyroid dysfunction in 22q11.2 deletion syndrome ranges from severe
    neonatal hypocalcemia to subclinical hypoparathyroidism. No frequency band
    is assigned here because the retained sources do not provide a directly
    applicable population estimate.
  phenotype_term:
    preferred_term: Hypocalcemia
    term:
      id: HP:0002901
      label: Hypocalcemia
  evidence:
  - reference: PMID:20664180
    reference_title: Evaluation of parathyroid gland function using sodium bicarbonate infusion test for 22q11.2 deletion syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The spectrum of parathyroid gland dysfunction ranges from severe neonatal hypocalcemia to subclinical hypoparathyroidism.
    explanation: This directly establishes the hypocalcemia-to-subclinical-hypoparathyroidism spectrum in 22q11.2 deletion syndrome.
  - reference: PMID:20301696
    reference_title: 22q11.2 Deletion Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      calcium supplementation and referral to an endocrinologist and nephrologist because of increased risk of renal calculi if long-term supplementation is required
    explanation: GeneReviews confirms clinically important hypocalcemia requiring calcium replacement while not providing frequency here.
- name: Cellular immunodeficiency
  frequency: FREQUENT
  description: >-
    T-cell lymphopenia varies from mild laboratory reduction to clinically
    important immune dysfunction; immune severity cannot be inferred from
    external syndromic features alone.
  phenotype_term:
    preferred_term: Cellular immunodeficiency
    term:
      id: HP:0005374
      label: Cellular immunodeficiency
  evidence:
  - reference: PMID:36648576
    reference_title: >-
      Clinical Practice Guidelines for the Immunological Management of Chromosome 22q11.2 Deletion Syndrome and Other Defects in Thymic Development.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      An estimated 67–80% of individuals affected with 22q11.2del have some degree of T cell lymphopenia (TCL).
    explanation: The 67-80% estimate maps to the FREQUENT band.
- name: Congenital athymia
  frequency: VERY_RARE
  description: >-
    Congenital absence of thymus function causes profound T-cell deficiency in
    a small subset and requires specialized immune management.
  phenotype_term:
    preferred_term: Aplasia of the thymus
    term:
      id: HP:0005359
      label: Aplasia of the thymus
  evidence:
  - reference: PMID:36648576
    reference_title: >-
      Clinical Practice Guidelines for the Immunological Management of Chromosome 22q11.2 Deletion Syndrome and Other Defects in Thymic Development.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: |-
      Stud-
      ies suggest that approximately 0.5% of those diagnosed
      with 22q11.2del have a severe immune deficiency with
      very few T cells due to the absence of a thymus at birth,
      termed congenital athymia [14, 15].
    explanation: The approximately 0.5% estimate maps to the VERY_RARE band.
- name: Learning difficulties
  description: >-
    Learning difficulties and developmental differences are common clinical
    concerns, but they should not be equated automatically with intellectual
    disability.
  phenotype_term:
    preferred_term: Specific learning disability
    term:
      id: HP:0001328
      label: Specific learning disability
  evidence:
  - reference: PMID:20301696
    reference_title: 22q11.2 Deletion Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: learning difficulties
    explanation: GeneReviews directly identifies learning difficulties but does not quantify or subtype them.
- name: Hearing impairment
  description: Hearing loss may be conductive, sensorineural, or mixed.
  phenotype_term:
    preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
  evidence:
  - reference: PMID:20301696
    reference_title: 22q11.2 Deletion Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hearing loss can be sensorineural and/or conductive.
    explanation: GeneReviews directly supports both major hearing-loss mechanisms.
- name: Genitourinary anomaly
  description: >-
    Structural genitourinary anomalies are part of the variable multisystem
    phenotype and warrant directed evaluation.
  phenotype_term:
    preferred_term: Abnormality of the genitourinary system
    term:
      id: HP:0000119
      label: Abnormality of the genitourinary system
    coarse_binding_basis: SOURCE_UNSPECIFIED
  evidence:
  - reference: PMID:20301696
    reference_title: 22q11.2 Deletion Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Laryngotracheoesophageal, gastrointestinal, ophthalmologic, central nervous system, skeletal, and genitourinary anomalies also occur.
    explanation: GeneReviews includes genitourinary anomalies in the clinical spectrum.
- name: Schizophrenia
  frequency: OCCASIONAL
  description: >-
    Meta-analysis estimated schizophrenia in 9.7% of individuals with 22q11.2
    deletion syndrome, with higher psychotic-disorder prevalence in adult
    samples.
  phenotype_term:
    preferred_term: Schizophrenia
    term:
      id: HP:0100753
      label: Schizophrenia
  evidence:
  - reference: PMID:36786112
    reference_title: >-
      Prevalence and incidence of psychotic disorders in 22q11.2 deletion syndrome: a meta-analysis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The pooled prevalence of psychotic disorders was 11.50% (95%CI:9.40-14.00%), largely schizophrenia (9.70%, 95%CI:6.50-14.20).
    explanation: The schizophrenia estimate maps to the OCCASIONAL band.
- name: Autoimmunity
  description: Autoimmune disorders occur more often than in the general population.
  phenotype_term:
    preferred_term: Autoimmunity
    term:
      id: HP:0002960
      label: Autoimmunity
  evidence:
  - reference: PMID:20301696
    reference_title: 22q11.2 Deletion Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Psychiatric illness and autoimmune disorders are more common in individuals with 22q11.2DS.
    explanation: GeneReviews directly supports increased autoimmune disease burden.
genetic:
- name: Recurrent 22q11.2 deletion
  association: Causal heterozygous copy-number loss spanning multiple dosage-sensitive genes
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  features: >-
    The common proximal deletion is bounded by LCR22A-D; smaller A-B and A-C
    recurrent deletions also occur. Standard G-banded karyotyping does not
    resolve the microdeletion. Deletion size alone does not reliably predict the
    overall phenotype, although lesion-specific associations are emerging.
  evidence:
  - reference: PMID:41891037
    reference_title: >-
      Deletion size and background genetic variation shape congenital heart disease phenotypes in 3,016 individuals with 22q11.2 deletion syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The typical 3 Mb LCR22 A-D deletion was present in 2,788 individuals (92.4%), with smaller A-B (n=172, 5.7%) and A-C (n=56, 1.9%) deletions comprising the remaining cohort.
    explanation: This large cohort quantifies the proximal recurrent deletion classes represented in the study.
  - reference: PMID:36648576
    reference_title: >-
      Clinical Practice Guidelines for the Immunological Management of Chromosome 22q11.2 Deletion Syndrome and Other Defects in Thymic Development.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: too small to be visualized on standard G-banded karyotype analysis
    explanation: This supports the limitation of routine karyotyping.
- name: TBX1 dosage contribution
  gene_term:
    preferred_term: TBX1
    term:
      id: hgnc:11592
      label: TBX1
  association: >-
    Major contributor to pharyngeal-apparatus and cardiovascular developmental
    phenotypes; not sufficient to explain the full deletion syndrome.
  variant_origin: GERMLINE
  review_notes: >-
    `relationship_type` is deliberately left unset. This record's claim is that
    TBX1 is the principal dosage-sensitive driver of the pharyngeal and
    conotruncal features within a contiguous-gene deletion, and none of the
    permissible values says that: CAUSATIVE asserts variants in the gene are
    sufficient for the disease, which the record's own `association` denies for
    the full syndrome; MODIFIER denies it is a primary driver; UNKNOWN denies
    the Yagi finding below. Left absent rather than forced to a value that
    would be false.
  features: >-
    Mouse and rare single-gene observations support TBX1 dosage sensitivity,
    while deletion cohorts and rescue models support contributions from
    additional interval genes and background modifiers.
  evidence:
  - reference: PMID:14585638
    reference_title: Role of TBX1 in human del22q11.2 syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified three mutations of TBX1 in two unrelated patients without the
      22q11.2 deletion-one with sporadic conotruncal anomaly face
      syndrome/velocardiofacial syndrome and one with sporadic DiGeorge's
      syndrome-and in three patients from a family with conotruncal anomaly face
      syndrome/velocardiofacial syndrome.
    explanation: >-
      Human evidence that TBX1 point mutations without a 22q11.2 deletion
      reproduce the DiGeorge and velocardiofacial presentations. It is cited
      here because the only other support on this record is a mouse study, and
      a human phenotype should not rest on model-organism evidence alone.
  - reference: PMID:14585638
    reference_title: Role of TBX1 in human del22q11.2 syndrome.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our results suggest that the TBX1 mutation is responsible for five major
      phenotypes in del22q11.2 syndrome.
    explanation: >-
      The authors' own conclusion, quoted for the "major contributor" wording
      of this record's `association`. Marked INDIRECT because it is an
      inference the authors draw from five deletion-negative patients rather
      than a measurement of TBX1's contribution within the deletion.
  - reference: PMID:11242110
    reference_title: DiGeorge syndrome phenotype in mice mutant for the T-box gene, Tbx1.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: we propose that TBX1 in humans is a key gene in the etiology of DGS/VCFS
    explanation: The mouse study supports TBX1 as a key contributor, not as the sole cause of the human syndrome.
environmental: []
treatments:
- name: Cardiovascular evaluation and lesion-directed intervention
  action_category: THERAPEUTIC
  description: >-
    Congenital cardiac lesions require cardiology assessment and, for many
    severe lesions, surgery or catheter-based intervention in infancy.
  treatment_term:
    preferred_term: Cardiac Surgery
    term:
      id: NCIT:C157806
      label: Cardiac Surgery
  target_phenotypes:
  - preferred_term: Conotruncal defect
    term:
      id: HP:0001710
      label: Conotruncal defect
  evidence:
  - reference: PMID:36648576
    reference_title: >-
      Clinical Practice Guidelines for the Immunological Management of Chromosome 22q11.2 Deletion Syndrome and Other Defects in Thymic Development.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Cardiac anomalies affect 75–80% of individuals with 22q11.2del, and a significant number of these patients will require cardiac surgery at an early age.
    explanation: The guideline directly supports early cardiac surgery for a substantial affected subset.
- name: Calcium supplementation and endocrine management
  action_category: THERAPEUTIC
  description: >-
    Treat documented hypocalcemia with calcium replacement and specialist
    endocrine follow-up; long-term supplementation requires monitoring for renal
    complications. This entry does not infer a universal calcitriol regimen.
  treatment_term:
    preferred_term: nutritional supplementation
    term:
      id: NCIT:C15433
      label: Nutritional Support
  target_phenotypes:
  - preferred_term: Hypocalcemia
    term:
      id: HP:0002901
      label: Hypocalcemia
  evidence:
  - reference: PMID:20301696
    reference_title: 22q11.2 Deletion Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      calcium supplementation and referral to an endocrinologist and nephrologist because of increased risk of renal calculi if long-term supplementation is required
    explanation: GeneReviews directly supports calcium replacement and specialist follow-up.
- name: Immune phenotyping and vaccine planning
  action_category: MONITORING
  description: >-
    At diagnosis, assess T-, B-, and NK-cell numbers and naïve/memory T-cell
    subsets. Subsequent immunoglobulin, vaccine-response, and lymphocyte testing
    should be individualized. Live MMR and varicella vaccines require adequate
    immune-function criteria rather than a syndromic label alone.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:36648576
    reference_title: >-
      Clinical Practice Guidelines for the Immunological Management of Chromosome 22q11.2 Deletion Syndrome and Other Defects in Thymic Development.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The initial immunologic evaluation recommended at the time of diagnosis should include T (CD3, CD4, CD8), B (CD19 or CD20), and natural killer (CD16 or CD56) cell (TBNK) quantitation
    explanation: The guideline specifies the initial immune evaluation.
  - reference: PMID:36648576
    reference_title: >-
      Clinical Practice Guidelines for the Immunological Management of Chromosome 22q11.2 Deletion Syndrome and Other Defects in Thymic Development.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: live vaccine administration (MMR and varicella) in 22q11.2del
    explanation: This identifies the guideline table as criteria for live MMR and varicella vaccination.
  - reference: PMID:36648576
    reference_title: >-
      Clinical Practice Guidelines for the Immunological Management of Chromosome 22q11.2 Deletion Syndrome and Other Defects in Thymic Development.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: |-
      1. CD4 ≥ 400 cells/mm3 (absolute) Recommended
      2. CD8 ≥ 200 cells/mm3 (absolute) Recommended
      3. Tetanus IgG protective (3 + weeks after dose 3) † Recommended
      4.  CD45RA+CD3+/4+ % >  CD45RO+CD3+/4+ % Utilize data from earliest assessment
    explanation: The table provides all four immune-function criteria for live-vaccine eligibility.
- name: Irradiated, leukocyte-reduced, CMV-negative blood products when indicated
  action_category: THERAPEUTIC
  description: >-
    Use appropriately treated cellular blood products for congenital athymia or
    severe/suspected T-cell deficiency, including when immune evaluation cannot
    be completed before surgery.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_phenotypes:
  - preferred_term: Cellular immunodeficiency
    term:
      id: HP:0005374
      label: Cellular immunodeficiency
  evidence:
  - reference: PMID:36648576
    reference_title: >-
      Clinical Practice Guidelines for the Immunological Management of Chromosome 22q11.2 Deletion Syndrome and Other Defects in Thymic Development.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Whenever possible, the diagnosis of congenital athymia should be determined prior to surgery, as this small subset of patients requires blood products that are irradiated, leukocyte reduced, and CMV negative.
    explanation: The guideline directly supports the conditional blood-product precautions.
- name: Cultured thymus tissue implantation
  action_category: THERAPEUTIC
  therapeutic_modality: SURGERY
  description: >-
    Cultured thymus tissue implantation is reserved for confirmed congenital
    athymia, not routine T-cell lymphopenia. Immune reconstitution takes months
    and specialized infection prophylaxis is required during that interval.
  treatment_term:
    preferred_term: organ transplantation
    term:
      id: NCIT:C15289
      label: Organ Transplantation
  target_phenotypes:
  - preferred_term: Aplasia of the thymus
    term:
      id: HP:0005359
      label: Aplasia of the thymus
  - preferred_term: Cellular immunodeficiency
    term:
      id: HP:0005374
      label: Cellular immunodeficiency
  evidence:
  - reference: PMID:36648576
    reference_title: >-
      Clinical Practice Guidelines for the Immunological Management of Chromosome 22q11.2 Deletion Syndrome and Other Defects in Thymic Development.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Survival following implant was 72% (76 of the 105 patients).
    explanation: The guideline summarizes outcomes from a 105-implant single-center series.
  - reference: PMID:36648576
    reference_title: >-
      Clinical Practice Guidelines for the Immunological Management of Chromosome 22q11.2 Deletion Syndrome and Other Defects in Thymic Development.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      circulating naïve T cells were detectable by 6 months post-implantation
      [124, 125].
    explanation: This supports a months-long immune-reconstitution timeline.
- name: Palatal, speech, developmental, and hearing support
  action_category: THERAPEUTIC
  therapeutic_modality: BEHAVIORAL
  description: >-
    Coordinate palate/ENT assessment, speech and language therapy,
    developmental and educational intervention, feeding support, and audiology
    or hearing aids according to the individual's findings.
  treatment_term:
    preferred_term: speech therapy
    term:
      id: NCIT:C159273
      label: Speech Language Therapy
  target_phenotypes:
  - preferred_term: Abnormal palate morphology
    term:
      id: HP:0000174
      label: Abnormal palate morphology
  - preferred_term: Specific learning disability
    term:
      id: HP:0001328
      label: Specific learning disability
  - preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
  evidence:
  - reference: PMID:20301696
    reference_title: 22q11.2 Deletion Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      occupational, physical, and speech therapy with introduction of sign language by age one year, educational and behavioral therapy
    explanation: GeneReviews supports multidisciplinary developmental and communication intervention.
- name: Velopharyngeal surgery for persistent hypernasality
  action_category: THERAPEUTIC
  therapeutic_modality: SURGERY
  description: >-
    Speech surgery for velopharyngeal insufficiency that persists after speech
    therapy. A small single-centre series (14 patients, 7 per arm) reported that
    pharyngoplasty resolved hypernasality where palatoplasty did not, which the
    authors attributed to the deficit being pharyngeal and myogenic as well as
    palatal; the comparison is underpowered and is reported by its authors as a
    "may be less effective" signal rather than a settled preference. Separately,
    and in a larger matched cohort, outcomes after sphincter pharyngoplasty are
    comparable to those in non-syndromic patients, so the deletion is not by
    itself a reason to expect surgical failure.

    NCIT has no pharyngoplasty or velopharyngeal-repair term reachable from
    NCIT:C25218, so the binding is the generic surgical action and the
    specificity is carried in preferred_term.
  treatment_term:
    preferred_term: velopharyngeal (pharyngoplasty) surgical procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  target_phenotypes:
  - preferred_term: Velopharyngeal insufficiency
    term:
      id: HP:0000220
      label: Velopharyngeal insufficiency
  - preferred_term: Hypernasal speech
    term:
      id: HP:0001611
      label: Hypernasal speech
  target_mechanisms:
  - target: Velopharyngeal structural and myogenic insufficiency
    description: >-
      Pharyngoplasty narrows the velopharyngeal port, addressing the pharyngeal
      and myogenic components of the node that palatal repair alone leaves.
    evidence:
    - reference: PMID:39056299
      reference_title: >-
        Do Palatoplasty Procedures Resolve Hypernasality as Effectively as Pharyngoplasty Procedures in Patients with 22q11.2 Deletion Syndrome?
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        No patient who underwent palatoplasty achieved resolution of hypernasality; 1/7 patients had worse hypernasality, 4/7 had no change, and 2/7 had improved hypernasality.
      explanation: >-
        The contrast between the two procedures is what ties the surgical target
        to the pharyngeal/myogenic mechanism rather than to the palate alone.
  evidence:
  - reference: PMID:39056299
    reference_title: >-
      Do Palatoplasty Procedures Resolve Hypernasality as Effectively as Pharyngoplasty Procedures in Patients with 22q11.2 Deletion Syndrome?
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In contrast, 86% of patients in the pharyngoplasty group had resolution of hypernasality.
    explanation: >-
      Reports the pharyngoplasty resolution rate that motivates preferring it
      over palatoplasty in this syndrome.
  - reference: PMID:36695155
    reference_title: >-
      Sphincter Pharyngoplasty for Velopharyngeal Dysfunction: Impact of 22q11.2 Deletion Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Matched for age and pre-operative velopharyngeal closure, patients with and without 22q11DelS and VPI had similar benefits after sphincter pharyngoplasty.
    explanation: >-
      A 134-patient matched cohort supports offering sphincter pharyngoplasty on
      the same terms as in non-syndromic velopharyngeal insufficiency.
- name: Lifespan multidisciplinary surveillance
  action_category: MONITORING
  description: >-
    Surveillance should be individualized across cardiology, immune function,
    calcium and thyroid status, blood counts, palate/feeding and ENT, hearing,
    vision, renal and skeletal findings, development, and psychiatric health,
    with planned transition from pediatric to adult care.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:36729053
    reference_title: >-
      Updated clinical practice recommendations for managing children with 22q11.2 deletion syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      These recommendations provide contemporary guidance for evaluation, surveillance, and management of the many 22q11.2DS-associated physical, cognitive, behavioral, and psychiatric morbidities while addressing important genetic counseling and psychosocial issues.
    explanation: The updated pediatric recommendations support coordinated multidisciplinary follow-up.
  - reference: PMID:36729052
    reference_title: >-
      Updated clinical practice recommendations for managing adults with 22q11.2 deletion syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      These recommendations provide guidance for the recognition, evaluation, surveillance, and management of the many emerging and chronic 22q11.2DS-associated multisystem morbidities relevant to adults.
    explanation: The updated adult recommendations support lifelong, multisystem surveillance.
- name: Genetic counseling and family testing
  action_category: COUNSELING_INFORMATIONAL
  description: >-
    Offer parental testing, deletion-class-specific recurrence counseling, and
    reproductive counseling. An affected parent has a 50% transmission risk,
    but phenotype severity cannot be predicted prenatally.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:20301696
    reference_title: 22q11.2 Deletion Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Offspring of affected individuals have a 50% chance of inheriting the 22q11.2 deletion.
    explanation: GeneReviews provides the key transmission-risk basis for counseling.
diagnosis:
- name: Chromosomal microarray confirmation
  description: >-
    Establish the diagnosis by detecting a heterozygous 22q11.2 deletion with
    chromosomal microarray or another validated genome-wide copy-number method.
    Routine G-banded karyotyping is not sufficiently sensitive.
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  results: A heterozygous pathogenic deletion at 22q11.2 establishes the molecular diagnosis.
  evidence:
  - reference: PMID:20301696
    reference_title: 22q11.2 Deletion Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The diagnosis of 22q11.2DS is established by identification of a heterozygous deletion at chromosome 22q11.2 on chromosomal microarray analysis or other genomic analyses.
    explanation: GeneReviews directly defines molecular confirmation.
- name: Targeted familial or prenatal deletion testing
  description: >-
    FISH, MLPA, or other targeted testing can evaluate a known familial deletion,
    but common proximal FISH probes may miss atypical or distal deletions. Use a
    genome-wide microarray when the familial interval is not already defined.
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  evidence:
  - reference: PMID:36648576
    reference_title: >-
      Clinical Practice Guidelines for the Immunological Management of Chromosome 22q11.2 Deletion Syndrome and Other Defects in Thymic Development.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: |-
      FISH is specific for identification of 22q11.2 dele-
      tion but may not detect individuals with an atypical or
      distal deletion that does not include the more proximal
      part of the commonly deleted region (LCR A-B).
    explanation: This supports the stated limitation of common targeted FISH testing.
  - reference: PMID:20301696
    reference_title: 22q11.2 Deletion Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Once the 22q11.2 deletion has been identified in an affected family member, prenatal testing using FISH, MLPA, or array studies for a pregnancy at increased risk and preimplantation genetic testing are possible.
    explanation: GeneReviews supports targeted familial and reproductive testing after the deletion is defined.
- name: Prenatal screening followed by diagnostic confirmation
  description: >-
    Cell-free-DNA/NIPS is a screening test, not a molecular diagnosis. A positive
    screen or suggestive fetal imaging finding should be followed by genetic
    counseling and diagnostic testing of chorionic villi or amniocytes using
    chromosomal microarray.
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  evidence:
  - reference: PMID:36672900
    reference_title: Prenatal Screening and Diagnostic Considerations for 22q11.2 Microdeletions.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Definitive diagnosis by genetic testing of chorionic villi or amniocytes using a chromosomal microarray will detect clinically relevant microdeletions. Screening options include noninvasive prenatal screening (NIPS) and imaging.
    explanation: The prenatal guidance clearly separates screening from diagnostic CMA.
- name: Second-diagnosis sequencing for atypical metabolic crises
  description: >-
    Recurrent or otherwise unexplained metabolic crises with severe
    rhabdomyolysis, especially when accompanied by cardiac arrhythmias or
    neurodegeneration, should prompt evaluation for a second diagnosis. When
    the deletion includes TANGO2, evaluate for a pathogenic variant on the
    remaining allele.
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  evidence:
  - reference: PMID:42420940
    reference_title: >-
      TANGO2-related metabolic encephalopathy-arrhythmia syndrome unmasked in 22q11.2 deletion syndrome: hemizygous pathogenic variant, complex phenotype modified by two genetic conditions, and implications for proactive crisis prevention: a case report.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At age 5, she experienced her first metabolic crisis during pneumonia with severe rhabdomyolysis (creatine kinase >100,000 U/L), features inconsistent with isolated 22q11.2 deletion syndrome.
    explanation: A single case supports this as a diagnostic red flag, not as a routine feature or universal testing mandate.
  - reference: PMID:42420940
    reference_title: >-
      TANGO2-related metabolic encephalopathy-arrhythmia syndrome unmasked in 22q11.2 deletion syndrome: hemizygous pathogenic variant, complex phenotype modified by two genetic conditions, and implications for proactive crisis prevention: a case report.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      TANGO2 deficiency disorder is an ultra-rare autosomal recessive condition characterized by life-threatening metabolic crises with rhabdomyolysis and cardiac arrhythmias.
    explanation: This supports the combined metabolic-crisis, rhabdomyolysis, and arrhythmia red-flag pattern.
differential_diagnoses:
- name: CHARGE syndrome
  description: >-
    CHD7-related CHARGE syndrome can overlap through conotruncal disease,
    cleft/palatal abnormalities, hearing loss, renal anomalies, developmental
    delay, thymic hypoplasia, and T-cell lymphopenia. CHD7 testing and the CHARGE
    feature pattern distinguish it from a confirmed 22q11.2 deletion.
  disease_term:
    preferred_term: CHARGE syndrome
    term:
      id: MONDO:0008965
      label: CHARGE syndrome
  evidence:
  - reference: PMID:36648576
    reference_title: >-
      Clinical Practice Guidelines for the Immunological Management of Chromosome 22q11.2 Deletion Syndrome and Other Defects in Thymic Development.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Clinical features of CHARGE syndrome can overlap with those of 22q11.2del
    explanation: The guideline directly describes the overlapping presentation.
- name: 10p13-p14 deletion syndrome
  description: >-
    A 10p deletion can produce a DiGeorge-like presentation with
    hypoparathyroidism, hearing loss, and renal dysplasia. Genome-wide
    copy-number testing distinguishes the deleted interval.
  evidence:
  - reference: PMID:36648576
    reference_title: >-
      Clinical Practice Guidelines for the Immunological Management of Chromosome 22q11.2 Deletion Syndrome and Other Defects in Thymic Development.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: |-
      Since then, evidence has accumulated that 10p dele-
      tions are associated with GATA3 haploinsufficiency, which
      can result in hypoparathyroidism, sensory neural hearing
      loss, and renal dysplasia [64].
    explanation: The guideline supports the overlapping 10p-deletion phenotype.
- name: Alagille syndrome
  description: >-
    Alagille syndrome can overlap through congenital heart disease and facial
    features; cholestasis or bile-duct paucity, posterior embryotoxon, butterfly
    vertebrae, and a JAG1 or NOTCH2 variant favor Alagille syndrome.
  disease_term:
    preferred_term: Alagille syndrome
    term:
      id: MONDO:0007318
      label: Alagille syndrome
- name: TANGO2-related metabolic encephalopathy-arrhythmia syndrome
  description: >-
    In an individual whose 22q11.2 deletion includes TANGO2, a pathogenic variant
    on the remaining allele creates an unmasked autosomal-recessive second
    diagnosis. Metabolic crises, rhabdomyolysis, and arrhythmia distinguish this
    dual diagnosis from isolated 22q11.2 deletion syndrome.
  evidence:
  - reference: PMID:42420940
    reference_title: >-
      TANGO2-related metabolic encephalopathy-arrhythmia syndrome unmasked in 22q11.2 deletion syndrome: hemizygous pathogenic variant, complex phenotype modified by two genetic conditions, and implications for proactive crisis prevention: a case report.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with 22q11.2 deletion syndrome are at increased risk when a pathogenic variant occurs in the remaining allele, yet this dual diagnosis remains underrecognized as clinicians often attribute all manifestations to the primary genetic condition.
    explanation: The case report supports the remaining-allele dual-diagnosis mechanism while requiring cautious generalization.
clinical_trials:
- name: NCT01220531
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: >-
    Completed expanded-access study of cultured thymus tissue implantation for
    complete DiGeorge anomaly/congenital athymia. It is relevant only to the
    rare absent-thymus-function subgroup, not to routine 22q11.2 deletion care.
  target_phenotypes:
  - preferred_term: Cellular immunodeficiency
    term:
      id: HP:0005374
      label: Cellular immunodeficiency
  - preferred_term: Aplasia of the thymus
    term:
      id: HP:0005359
      label: Aplasia of the thymus
  evidence:
  - reference: clinicaltrials:NCT01220531
    reference_title: Safety and Efficacy of Thymus Transplantation in Complete DiGeorge Anomaly, IND#9836
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This expanded access study continues cultured thymus tissue safety and efficacy research for the treatment of complete DiGeorge anomaly.
    explanation: The registry documents the completed cultured-thymus study in the congenital-athymia subgroup.
discussions:
- discussion_id: gap_22q11_multigene_genotype_phenotype_prediction
  prompt: >-
    Which deleted genes, remaining-allele variants, deletion boundaries, and
    genome-wide modifiers causally determine the major cardiac, immune,
    neurodevelopmental, and psychiatric phenotypes of 22q11.2 deletion syndrome?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Recurrent LCR22-mediated multigene deletion
  - pathophysiology#TBX1-associated pharyngeal developmental vulnerability
  - pathophysiology#DGCR8-associated miRNA-processing disruption
  rationale: >-
    TBX1 is a major developmental contributor but does not explain the full
    contiguous-gene syndrome. A large cohort now links deletion size and
    background variation to lesion-specific cardiac outcomes, while overall
    genotype-phenotype prediction remains weak. Resolving gene- and
    tissue-specific contributions is necessary to avoid both singular-TBX1
    attribution and untestable multigene narratives.
  evidence:
  - reference: PMID:41891037
    reference_title: >-
      Deletion size and background genetic variation shape congenital heart disease phenotypes in 3,016 individuals with 22q11.2 deletion syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These lesion-specific findings suggest the hypothesis that deletion interval and broader genetic background may contribute to CHD variability in 22q11.2DS, pending future replication.
    explanation: The large human cohort identifies deletion interval and background variation as testable contributors while calling for replication.
  proposed_experiments:
  - experiment_id: exp_22q11_multicenter_genotype_phenotype_modifier_cohort
    name: Deletion-resolved longitudinal genotype-phenotype modifier cohort
    description: >-
      Combine precisely mapped deletion intervals, long-read or whole-genome
      remaining-allele data, longitudinal cardiac/immune/neuropsychiatric
      phenotypes, and ancestry-aware analyses across multiple centers to test
      reproducible gene- and background-modifier effects.
- discussion_id: gap_22q11_human_model_dosage_mismatch
  prompt: >-
    Which mechanisms observed after homozygous Tbx1 or Ranbp1 loss remain valid
    in human cells carrying a heterozygous multigene 22q11.2 deletion?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#TBX1-associated pharyngeal developmental vulnerability
  - pathophysiology#Candidate cortical and neurotransmitter mechanisms
  rationale: >-
    Homozygous mouse knockouts reproduce striking developmental phenotypes but
    differ in gene dosage, deleted interval, species, and sometimes viability
    from affected humans. The COMT/proline observation is also a small,
    phenotype-specific association. Human isogenic models are needed before
    these findings are promoted to syndrome-wide causal pathways.
  proposed_experiments:
  - experiment_id: exp_22q11_isogenic_human_dosage_series
    name: Isogenic human 22q11.2 dosage-series comparison
    description: >-
      Compare human induced pluripotent stem cell-derived pharyngeal, cardiac,
      thymic, and cortical lineages carrying the recurrent heterozygous deletion,
      individual-gene heterozygous edits, homozygous knockouts, and corrected
      controls to separate dosage and interval effects.
datasets:
- accession: geo:GSE289984
  title: Next-generation sequencing profiling of miRNAs in individuals with 22q11.2 deletion syndrome revealed altered expression of miR-185-5p
  description: 'Background: The 22q11.2 deletion syndrome (22q11.2DS) is a microdeletion syndrome with highly variable phenotypic manifestations, even though most patients present the typical 3 Mb microdeletion, usually affecting the same ~ 106 genes. One of the genes affected by this deletion is DGCR8, which plays a crucial role in miRNA biogenesis. Therefore, the haploinsufficiency of DGCR8 due to this microdeletion can alter the modulation of the expression of several miRNAs involved in a range of biological processes.'
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 24
  publication: PMID:38872198
  notes: Identified by GEO DataSets index search for 22q11.2 Deletion Syndrome (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE244010
  title: Aberrant pace of cortical neuron development in brain organoids from patients with 22q11.2 deletion syndrome and schizophrenia.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 26
  publication: PMID:40750773
  notes: Identified by GEO DataSets index search for 22q11.2 Deletion Syndrome (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE236595
  title: An antisense oligonucleotide-based strategy to ameliorate cognitive dysfunction in the 22q11.2 Deletion Syndrome [RNA-seq]
  description: Adults and children with the 22q11.2 Deletion Syndrome demonstrate cognitive, social and emotional impairments and high risk for schizophrenia. Work in mouse model of the 22q11.2 deletion provided compelling evidence for abnormal expression and processing of microRNAs. A major transcriptional effect of the microRNA dysregulation is up-regulation of Emc10, a component of the ER membrane complex, which promotes membrane insertion of a subset of polytopic and tail-anchored membrane proteins. We previously uncovered a key contribution of EMC10 in mediating the behavioral phenotypes observed in 22q11.2 deletion mouse models.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 6
  publication: PMID:40420562
  notes: Identified by GEO DataSets index search for 22q11.2 Deletion Syndrome (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: ega:EGAS00001002344
  title: Whole-Genome Sequencing Suggests Schizophrenia Risk Mechanisms in Humans with 22q11.2 Deletion Syndrome
  description: Chromosome 22q11.2 microdeletions impart a high but incomplete risk for schizophrenia. Possible mechanisms include genome-wide effects of DGCR8 haploinsufficiency. In a proof-of-principle study to assess the power of this model, we used high-quality, whole-genome sequencing of nine individuals with 22q11.2 deletions and extreme phenotypes (schizophrenia, or no psychotic disorder at age >50 years). The schizophrenia group had a greater burden of rare, damaging variants impacting protein-coding neurofunctional genes, including genes involved in neuron projection (nominal P = 0.02, joint burden of three variant types). Variants in the intact 22q11.2 region were not major contributors.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  publication: PMID:26384369
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("22q11.2 Deletion Syndrome"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS50000000601
  title: Multiple paralogues and recombination mechanisms contribute to the high incidence of 22q11.2 Deletion Syndrome
  description: To enable haplotype-specific assembly and rearrangement mapping in LCR22 clusters, we combined fiber-FISH optical mapping with whole genome (ultra-)long read sequencing or rearrangement-specific long-range PCR on 254 duos families (22q11.2DS patient and parent-of-origin) comprising several different LCR22-mediated rearrangements.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: WGS
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("22q11.2 Deletion Syndrome"); description-level mentions were not accepted. EGA study_type: Whole Genome Sequencing. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: dbgap:phs000987
  title: Whole Exome Sequence of 184 Individuals with 22q11.2 Deletion Syndrome
  description:  Our goal is to find genetic modifiers of major phenotypes in patients with 22q11.2 deletion syndrome, also known as DiGeorge syndrome or velo-cardio-facial syndrome. Whole exome sequencing was performed as part of a contract to the NHLBI, Resequencing and Genotyping Service. We have obtained cardiac phenotype information from the de-identified subjects enrolled in the study, either by echocardiography report or medical doctor report. All of the subjects have a 3 million base pair 22q11.2 deletion flanked by low copy repeats, LCR22, A-D.
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from dbgap. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("22q11.2 Deletion Syndrome"). Retrieved 2026-08-02.
notes: >-
  Evidence review completed 2026-07-14. Unsupported phenotype frequencies and
  single-gene causal claims were removed; historical terminology is retained
  only as synonym/search context.
references:
- reference: PMID:20301696
  title: 22q11.2 Deletion Syndrome.
  tags:
  - GeneReviews
  findings: []
- reference: PMID:29906080
  title: >-
    Birth Prevalence of Chromosome 22q11.2 Deletion Syndrome: A Systematic Review of Population-Based Studies.
  findings: []
- reference: PMID:32207823
  title: >-
    A minimum estimate of the prevalence of 22q11 deletion syndrome and other chromosome abnormalities in a combined prenatal and postnatal cohort.
  findings: []
- reference: PMID:36648576
  title: >-
    Clinical Practice Guidelines for the Immunological Management of Chromosome 22q11.2 Deletion Syndrome and Other Defects in Thymic Development.
  findings: []
- reference: PMID:36786112
  title: >-
    Prevalence and incidence of psychotic disorders in 22q11.2 deletion syndrome: a meta-analysis.
  findings: []
- reference: PMID:11242110
  title: DiGeorge syndrome phenotype in mice mutant for the T-box gene, Tbx1.
  findings: []
- reference: PMID:36695155
  title: >-
    Sphincter Pharyngoplasty for Velopharyngeal Dysfunction: Impact of 22q11.2 Deletion Syndrome.
  findings: []
- reference: PMID:39056299
  title: >-
    Do Palatoplasty Procedures Resolve Hypernasality as Effectively as Pharyngoplasty Procedures in Patients with 22q11.2 Deletion Syndrome?
  findings: []
- reference: PMID:36512754
  title: >-
    The Language Profile of Preschool Children With 22q11.2 Deletion Syndrome and the Relationship With Speech Intelligibility.
  findings: []
- reference: PMID:41800660
  title: "DiGeorge for the Otolaryngologist: A State-of-the-Art Review."
  findings: []
- reference: PMID:40038168
  title: >-
    Review of the Pathophysiology and Clinical Manifestations of 22q11.2 Deletion and Duplication Syndromes.
  findings: []
- reference: PMID:25452572
  title: >-
    Ranbp1, Deleted in DiGeorge/22q11.2 Deletion Syndrome, is a Microcephaly Gene That Selectively Disrupts Layer 2/3 Cortical Projection Neuron Generation.
  findings: []
- reference: PMID:18769474
  title: Proline affects brain function in 22q11DS children with the low activity COMT 158 allele.
  findings: []
- reference: PMID:42420940
  title: >-
    TANGO2-related metabolic encephalopathy-arrhythmia syndrome unmasked in 22q11.2 deletion syndrome: hemizygous pathogenic variant, complex phenotype modified by two genetic conditions, and implications for proactive crisis prevention: a case report.
  findings: []
- reference: DOI:10.3390/genes15030321
  title: >-
    Understanding the Variability of 22q11.2 Deletion Syndrome: The Role of Epigenetic Factors
  findings: []
- reference: PMID:20664180
  title: Evaluation of parathyroid gland function using sodium bicarbonate infusion test for 22q11.2 deletion syndrome.
  findings: []
- reference: PMID:36729053
  title: Updated clinical practice recommendations for managing children with 22q11.2 deletion syndrome.
  findings: []
- reference: PMID:36729052
  title: Updated clinical practice recommendations for managing adults with 22q11.2 deletion syndrome.
  findings: []
- reference: PMID:36672900
  title: Prenatal Screening and Diagnostic Considerations for 22q11.2 Microdeletions.
  findings: []
- reference: PMID:41891037
  title: >-
    Deletion size and background genetic variation shape congenital heart disease phenotypes in 3,016 individuals with 22q11.2 deletion syndrome.
  findings: []
- reference: clinicaltrials:NCT01220531
  title: Safety and Efficacy of Thymus Transplantation in Complete DiGeorge Anomaly, IND#9836
  findings: []
📚

References & Deep Research

References

21
PMID:20301696
22q11.2 Deletion Syndrome.
No top-level findings curated for this source.
PMID:29906080
Birth Prevalence of Chromosome 22q11.2 Deletion Syndrome: A Systematic Review of Population-Based Studies.
No top-level findings curated for this source.
PMID:32207823
A minimum estimate of the prevalence of 22q11 deletion syndrome and other chromosome abnormalities in a combined prenatal and postnatal cohort.
No top-level findings curated for this source.
PMID:36648576
Clinical Practice Guidelines for the Immunological Management of Chromosome 22q11.2 Deletion Syndrome and Other Defects in Thymic Development.
No top-level findings curated for this source.
PMID:36786112
Prevalence and incidence of psychotic disorders in 22q11.2 deletion syndrome: a meta-analysis.
No top-level findings curated for this source.
PMID:11242110
DiGeorge syndrome phenotype in mice mutant for the T-box gene, Tbx1.
No top-level findings curated for this source.
PMID:36695155
Sphincter Pharyngoplasty for Velopharyngeal Dysfunction: Impact of 22q11.2 Deletion Syndrome.
No top-level findings curated for this source.
PMID:39056299
Do Palatoplasty Procedures Resolve Hypernasality as Effectively as Pharyngoplasty Procedures in Patients with 22q11.2 Deletion Syndrome?
No top-level findings curated for this source.
PMID:36512754
The Language Profile of Preschool Children With 22q11.2 Deletion Syndrome and the Relationship With Speech Intelligibility.
No top-level findings curated for this source.
PMID:41800660
DiGeorge for the Otolaryngologist: A State-of-the-Art Review.
No top-level findings curated for this source.
PMID:40038168
Review of the Pathophysiology and Clinical Manifestations of 22q11.2 Deletion and Duplication Syndromes.
No top-level findings curated for this source.
PMID:25452572
Ranbp1, Deleted in DiGeorge/22q11.2 Deletion Syndrome, is a Microcephaly Gene That Selectively Disrupts Layer 2/3 Cortical Projection Neuron Generation.
No top-level findings curated for this source.
PMID:18769474
Proline affects brain function in 22q11DS children with the low activity COMT 158 allele.
No top-level findings curated for this source.
PMID:42420940
TANGO2-related metabolic encephalopathy-arrhythmia syndrome unmasked in 22q11.2 deletion syndrome: hemizygous pathogenic variant, complex phenotype modified by two genetic conditions, and implications for proactive crisis prevention: a case report.
No top-level findings curated for this source.
DOI:10.3390/genes15030321
Understanding the Variability of 22q11.2 Deletion Syndrome: The Role of Epigenetic Factors
No top-level findings curated for this source.
PMID:20664180
Evaluation of parathyroid gland function using sodium bicarbonate infusion test for 22q11.2 deletion syndrome.
No top-level findings curated for this source.
PMID:36729053
Updated clinical practice recommendations for managing children with 22q11.2 deletion syndrome.
No top-level findings curated for this source.
PMID:36729052
Updated clinical practice recommendations for managing adults with 22q11.2 deletion syndrome.
No top-level findings curated for this source.
PMID:36672900
Prenatal Screening and Diagnostic Considerations for 22q11.2 Microdeletions.
No top-level findings curated for this source.
PMID:41891037
Deletion size and background genetic variation shape congenital heart disease phenotypes in 3,016 individuals with 22q11.2 deletion syndrome.
No top-level findings curated for this source.
clinicaltrials:NCT01220531
Safety and Efficacy of Thymus Transplantation in Complete DiGeorge Anomaly, IND#9836
No top-level findings curated for this source.

Deep Research

4

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (3)

Edit: 22q11.2 Deletion Syndrome - address PR #10355 review (phenotype frequencies, stronger evidence) · 2026-09-01T09:40:23Z · View source

Addresses the ai4c-reviewer review on PR #10355, which requested changes on one point. Every quote the reviewer proposed was verified as an exact substring of references_cache/PMID_39056299.md before use. Blocking item, phenotype frequencies: the reviewer noted that population frequencies for two of the three new phenotypes were quotable from the full text of PMID:39056299, a paper this PR already cited on an adjacent node, and that four peer phenotypes in the entry already carry frequency. Velopharyngeal insufficiency now carries frequency FREQUENT, supported by 'up to 80% of people with 22q present with VPI'; FREQUENT rather than VERY_FREQUENT because 80 percent is stated as an upper bound, and the deep-research report's own phenotype table independently gives roughly 65-70 percent. Delayed speech and language development now carries VERY_FREQUENT, supported by 'most people (95%) with 22q present with a speech-language disorder'. Both explanations record that these sentences are the paper's introductory summary of prior literature rather than findings of its own 14-patient cohort. Hypernasal speech is deliberately left without a frequency, as the reviewer agreed no clean population figure exists. Accepted suggestion on evidence quality: the reviewer identified selection bias in the Hypernasal speech evidence. The previous snippet quoted the preoperative severity split of the surgical arm, but inclusion criterion 3 of that study was 'presence of hypernasality on preoperative speech evaluation', so those proportions are true by construction and cannot evidence the phenotype. Verified against the cached methods section and replaced with a population-level statement that hypernasality is part of the syndrome's speech phenotype; the explanation records why the earlier quote was withdrawn. Accepted suggestion on the mechanism edge: a second evidence item was added to the Velopharyngeal structural and myogenic insufficiency -> Velopharyngeal insufficiency edge, quoting the sentence that enumerates the anatomic and physiologic velopharyngeal differences contributing to VPI. The prior snippet was Objective-section framing; it is retained for the multifactorial claim with a narrowed explanation. Declined suggestion, node splitting: the reviewer suggested splitting the mechanism node into increased pharyngeal depth and hypodynamic musculature, while explicitly not blocking. Declined because the newly added quote lists seven contributing differences rather than two, so a split into exactly two would impose a division the source does not make; both halves are also TISSUE scale, so this is a conjunction rather than the bundled-causal-step case the single-value biological_scale rule targets. Deferred suggestion, parkinsonism: out of the declared velocardiofacial scope of this PR and would widen it; left for a follow-up. A YAML indentation error was introduced while applying these edits, caught immediately by just validate, and fixed before any push. Revalidated: just validate and just validate-disorders pass with 72/74 snippets verified, up from 69/71, with the same two pre-existing DOI-prefix skips; check-entity-refs, check-causal-targets, check-duplicate-keys, check-enum-values, check-qualifier-terms, check-snippet-grading, check-snippet-length, check-title-snippets and check-folded-hyphens all pass.

Edit: 22q11.2 Deletion Syndrome - openscientist deep-research report and edge evidence · 2026-09-01T06:13:37Z · View source

Follow-up to the velocardiofacial curation in the preceding record. The requested deep-research provider falcon was unreachable (403 ProviderAuthError, confirmed by 'deep-research-client providers --check'), so the run was re-issued with --fallback; it selected openscientist, which completed after the first commit. The report is committed as research/22q11.2_Deletion_Syndrome-deep-research-openscientist.md with its citations sidecar and two artifacts, and its frontmatter records the substitution (fell_back: true, requested_provider: falcon, provider_attempts including the falcon 403). Report validation: 39/39 references verified, confabulation_rate 0.0, 28/39 assessed on topic; term validation 38/44 verified with needs_review true, driven by one obsolete term (CL:4023070, replaced by CL:4023064) and six label variants that are table-parsing artifacts rather than wrong bindings. None of the six touch terms used in this entry, and CL:4023070 is not used anywhere in kb/disorders. The report independently proposed HP:0000220 for velopharyngeal insufficiency, matching the binding already curated. One substantive addition taken from it: PMID:40038168 (2025 review) supplies a human-level statement that pharyngeal neural-crest disruption causes both the conotruncal lesions and velopharyngeal deficiency, which is added to the TBX1-associated pharyngeal developmental vulnerability -> Velopharyngeal structural and myogenic insufficiency edge. That edge previously rested only on homozygous-mouse evidence graded INDIRECT; the new item is graded DIRECT and HUMAN_CLINICAL, and the mouse item is retained alongside it. Repository hygiene note: two deep-research invocations overlapped, and one wrote its openscientist output over the committed falcon report, citations and artifact directory. The committed falcon files were restored from git and verified byte-identical to a pre-run backup, the openscientist artifacts that had landed in the falcon artifact directory were removed, and falcon's artifact-00.md was removed from the openscientist artifact directory after confirming by sha256 that it was the relocated committed file rather than a regenerated one. No committed falcon content was lost. Revalidated with just validate, just validate-disorders (69/71 snippets verified, 2 pre-existing DOI-prefix skips) and the ungated gates.

Edit: 22q11.2 Deletion Syndrome - velocardiofacial (velopharyngeal/speech) arm · 2026-09-01T05:59:06Z · View source

Curated the velocardiofacial (Shprintzen) presentation. Requested disorder 'velocardiofacial syndrome' resolves to this entry: MONDO:0008644 is already bound here as a skos:narrowMatch (added in PR #7391) and the entry's description records VCFS/DiGeorge/CATCH22 as historical labels, so this is an augmentation rather than a new entry. Gap closed: velopharyngeal insufficiency existed only as prose inside the Palatal abnormality description, with no mechanism node and no speech-surgery treatment. Added phenotypes Velopharyngeal insufficiency (HP:0000220), Hypernasal speech (HP:0001611) and Delayed speech and language development (HP:0000750); added pathophysiology node 'Velopharyngeal structural and myogenic insufficiency' (biological_scale TISSUE; UBERON:0001733 soft palate, UBERON:0001042 chordate pharynx, GO:0060021) wired as TBX1-associated pharyngeal developmental vulnerability -> new node -> VPI and hypernasal speech; added treatment 'Velopharyngeal surgery for persistent hypernasality' with a target_mechanisms link to that node. Four new references (PMID:36695155, PMID:39056299, PMID:36512754, PMID:41800660), all specifically about 22q11.2 deletion syndrome. Deep research: the requested provider falcon was unreachable (403, confirmed by 'deep-research-client providers --check'), so the run was re-issued with --fallback so the substitution is recorded rather than made by hand; it selected openscientist and was still running when this entry was committed, so the curated content here derives from direct PubMed searches plus the pre-existing committed falcon report, which had already flagged HP:0000220 and HP:0001611 as unused term suggestions. Two claims were deliberately softened to match their sources: the pharyngoplasty-over-palatoplasty preference rests on a 14-patient series whose authors report it as a 'may be less effective' signal, and the mechanism node's explanation of post-palatoplasty resonance is labelled proposed rather than established. Delayed speech and language development was left unconnected in the pathograph because the cited cohort explicitly finds language impairment not explained by speech ability, and no source supports a causal edge. NCIT has no pharyngoplasty term reachable from NCIT:C25218, so the treatment binds the generic surgical action with specificity carried in preferred_term. Validated with just validate, just validate-terms, just validate-disorders (68/70 snippets verified, 2 pre-existing DOI-prefix skips), and the ungated gates check-entity-refs, check-causal-targets, check-duplicate-keys, check-enum-values, check-qualifier-terms, check-snippet-length, check-snippet-grading, check-title-snippets, check-folded-hyphens and check-not4curation.

Disorder ▸

Disorder

  • Name: 22q11.2 Deletion Syndrome
  • Category: Genetic
  • Existing deep-research providers: cyberian-codex, perplexity
  • Existing evidence reference count in YAML: 26

Key Pathophysiology Nodes

  • TBX1 haploinsufficiency and pharyngeal arch development
  • Cardiac neural crest migration defect
  • Thymic hypoplasia and T-cell immunodeficiency
  • Parathyroid hypoplasia and hypocalcemia
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1002/pd.6566
  • DOI:10.1016/s0022-5347(05)64215-2
  • DOI:10.1073/pnas.0905696106
  • DOI:10.3389/fendo.2023.1209577
  • DOI:10.3389/fpsyg.2014.00566
  • PMID:18769474
  • PMID:20664180
  • PMID:22318985
  • PMID:25452572
  • PMID:9708481
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 69 citations 2026-05-29T16:48:10.724837

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: 22q11.2 Deletion Syndrome
  • MONDO ID: (if available)
  • Category: Genetic

Research Objectives

Please provide a comprehensive research report on 22q11.2 Deletion Syndrome covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Research Report: 22q11.2 Deletion Syndrome (22q11.2DS)

Executive summary

22q11.2 deletion syndrome (22q11.2DS) is a recurrent genomic disorder caused by a heterozygous (hemizygous) microdeletion at chromosome 22q11.2. It is among the most common microdeletion syndromes, with typical estimates of ~1:3,000–1:6,000 live births (often summarized near ~1:4,000), though prevalence varies by ascertainment and population studies. Clinically, it is multisystem and highly variable, with prominent congenital heart disease, palatal anomalies, hypocalcemia/hypoparathyroidism, and thymic hypoplasia with T-cell lymphopenia; later-onset neurodevelopmental and neuropsychiatric outcomes are common and include markedly elevated schizophrenia risk. Recent (2023–2024) work emphasizes standardized immunologic management (including vaccine decision thresholds), increased early detection via newborn TREC screening, expanding—but imperfect—prenatal cfDNA screening, and mechanistic models incorporating miRNA/epigenetic dysregulation and gene–environment interaction.

Category Specific item Value/statement Source (author year) URL Evidence citation id (pqac-...)
Identifier Disease names / synonyms 22q11.2 deletion syndrome; DiGeorge syndrome; velocardiofacial syndrome (VCFS) Soster 2023 https://doi.org/10.3389/fgene.2023.1146669 (soster2023positivecfdnascreening pages 1-2)
Identifier OMIM identifiers mentioned DiGeorge syndrome OMIM #188400; VCFS OMIM #192430 Soster 2023 https://doi.org/10.3389/fgene.2023.1146669 (soster2023positivecfdnascreening pages 1-2)
Identifier Alternate OMIM usage in review literature 22q11DS listed as OMIM #192430/#188400 Snihirova 2022 https://doi.org/10.3390/genes13112003 (snihirova2022environmentalinfluenceson pages 1-2)
Prevalence Live-birth prevalence range Approximately 1 in 3,000 to 1 in 6,000 live births; often summarized around 1 in 4,000 Mustillo 2023; Biggs 2023 https://doi.org/10.1007/s10875-022-01418-y; https://doi.org/10.1007/s11882-023-01071-4 (mustillo2023clinicalpracticeguidelines pages 2-4, biggs2023chromosome22q11.2deletion pages 1-2)
Prevalence Review estimate including fetal prevalence 1:2,000 to 1:6,000 live births; ~1:1,000 in unselected fetuses; up to ~1:100 in fetuses with major structural defects Szczawińska-Popłonyk 2023 https://doi.org/10.3390/ijms24098317 (szczawinskapopłonyk2023chromosome22q11.2deletion pages 2-4)
Prevalence Population-based prevalence 1 in 3,672 for 22q11.2 deletions in Danish population study Olsen 2018 https://doi.org/10.1016/S2215-0366(18)30168-8 (olsen2018prevalenceofrearrangements pages 1-3)
Prevalence Combined prenatal/postnatal minimum estimate Estimated prevalence 1 in 4,558 births in Victoria cohort Hui 2020 https://doi.org/10.1093/humrep/dez286 (olsen2018prevalenceofrearrangements pages 1-3)
Genetics Typical deletion proportion ~85% carry the typical ~3 Mb deletion Cillo 2024 https://doi.org/10.3390/genes15030321 (cillo2024understandingthevariability pages 1-2)
Genetics Typical proximal deletion classes ~90% have 2.54 Mb A-D deletion; ~5% A-B; ~2% A-C; ~5% smaller nested B-D or C-D deletions Szczawińska-Popłonyk 2023 https://doi.org/10.3390/ijms24098317 (szczawinskapopłonyk2023chromosome22q11.2deletion pages 2-4)
Genetics Mechanism Recurrent deletion mediated by non-allelic homologous recombination between low-copy repeats (LCR22s) Szczawińska-Popłonyk 2023; Cillo 2024 https://doi.org/10.3390/ijms24098317; https://doi.org/10.3390/genes15030321 (szczawinskapopłonyk2023chromosome22q11.2deletion pages 2-4, cillo2024understandingthevariability pages 1-2)
Genetics De novo vs inherited ~90–95% de novo; ~10% inherited/autosomal dominant familial cases Mustillo 2023; Szczawińska-Popłonyk 2023; Cillo 2024 https://doi.org/10.1007/s10875-022-01418-y; https://doi.org/10.3390/ijms24098317; https://doi.org/10.3390/genes15030321 (mustillo2023clinicalpracticeguidelines pages 2-4, szczawinskapopłonyk2023chromosome22q11.2deletion pages 2-4, cillo2024understandingthevariability pages 1-2)
Genetics Important genes highlighted TBX1 and DGCR8 are repeatedly highlighted as key dosage-sensitive genes; CRKL also implicated for renal/cardiac phenotypes Du 2020; Cillo 2024 https://doi.org/10.3389/fgene.2019.01365; https://doi.org/10.3390/genes15030321 (du2020thegeneticsand pages 3-5, cillo2024understandingthevariability pages 7-8, du2020thegeneticsand pages 1-2)
Key phenotype frequencies Congenital heart disease (CHD) ~75% overall in 2024 review; other reviews cite ~60–80% in children Cillo 2024; Szczawińska-Popłonyk 2023 https://doi.org/10.3390/genes15030321; https://doi.org/10.3390/ijms24098317 (cillo2024understandingthevariability pages 3-5, szczawinskapopłonyk2023chromosome22q11.2deletion pages 4-5)
Key phenotype frequencies Specific CHD lesions Tetralogy of Fallot 20%; VSD 14%; interrupted aortic arch 10%; pulmonary atresia with VSD 9%; truncus arteriosus 9%; ASD 3% Sauter 2025 https://doi.org/10.1136/jmg-2025-110624 (mustillo2023clinicalpracticeguidelines pages 2-4)
Key phenotype frequencies Immune deficiency / thymic abnormality 50–70% with thymic hypoplasia/ectopy/immune deficiency; guideline states 67–80% have some T-cell lymphopenia Cillo 2024; Mustillo 2023 https://doi.org/10.3390/genes15030321; https://doi.org/10.1007/s10875-022-01418-y (cillo2024understandingthevariability pages 3-5, mustillo2023clinicalpracticeguidelines pages 2-4)
Key phenotype frequencies Complete DiGeorge / congenital athymia <0.5% to 1.5% of cases Biggs 2023; Cillo 2024 https://doi.org/10.1007/s11882-023-01071-4; https://doi.org/10.3390/genes15030321 (biggs2023chromosome22q11.2deletion pages 1-2, cillo2024understandingthevariability pages 2-3)
Key phenotype frequencies Hypocalcemia / hypoparathyroidism ~35% in one 2024 review; 50–65% in another review; 50% in 2024 overview of classic triad manifestations Cillo 2024 https://doi.org/10.3390/genes15030321 (cillo2024understandingthevariability pages 3-5, cillo2024understandingthevariability pages 1-2, cillo2024understandingthevariability pages 2-3)
Key phenotype frequencies Palatal anomalies 69–100% in 2024 review; ~30–80% in 2023 review; overt cleft palate ~11% and milder palatal defects ~65% Cillo 2024; Szczawińska-Popłonyk 2023 https://doi.org/10.3390/genes15030321; https://doi.org/10.3390/ijms24098317 (cillo2024understandingthevariability pages 3-5, szczawinskapopłonyk2023chromosome22q11.2deletion pages 4-5, cillo2024understandingthevariability pages 2-3)
Key phenotype frequencies Developmental delay / learning problems Approximately 70% Cillo 2024 https://doi.org/10.3390/genes15030321 (cillo2024understandingthevariability pages 3-5)
Key phenotype frequencies Intellectual disability Mild–moderate intellectual disability in about one-third of pediatric patients Szczawińska-Popłonyk 2023 https://doi.org/10.3390/ijms24098317 (szczawinskapopłonyk2023chromosome22q11.2deletion pages 5-7, szczawinskapopłonyk2023chromosome22q11.2deletion pages 4-5)
Key phenotype frequencies Schizophrenia / psychosis risk Schizophrenia ~25–30% in review literature; pooled prevalence of any psychotic disorder 11.5% and schizophrenia 9.7% in meta-analysis Cillo 2024; Provenzani 2022 https://doi.org/10.3390/genes15030321; https://doi.org/10.1080/09540261.2022.2123273 (cillo2024understandingthevariability pages 3-5, cillo2024understandingthevariability pages 2-3, provenzani2022prevalenceandincidence pages 1-5)
Prognosis All-cause mortality risk vs unaffected siblings Hazard ratio 8.86 (95% CI 2.87–27.37) Van et al. 2019 https://doi.org/10.1038/s41436-019-0509-y (van2019allcausemortalityand pages 3-4, van2019allcausemortalityand pages 1-2)
Prognosis Median age at death 46.4 years; all observed deaths before age 70 Van et al. 2019 https://doi.org/10.1038/s41436-019-0509-y (van2019allcausemortalityand pages 4-6, van2019allcausemortalityand pages 3-3)
Prognosis Major cause of death Cardiovascular causes accounted for 71% of deaths; sudden cardiac death n=12, heart failure n=7, arrhythmia n=3 Van et al. 2019 https://doi.org/10.1038/s41436-019-0509-y (van2019allcausemortalityand pages 4-6, van2019allcausemortalityand pages 3-4)
Prognosis CHD effect on survival Major CHD independently increased mortality (HR 4.77 within 22q11.2DS cohort); survival to age 45 ~72% with major CHD vs ~95% without Van et al. 2019 https://doi.org/10.1038/s41436-019-0509-y (van2019allcausemortalityand pages 3-4, van2019allcausemortalityand pages 1-2)
Prognosis Adult chronic disease accrual Cardiovascular disease accrual RR 3.8 vs comparators; hypertension IRR 2.98 and diabetes IRR 3.21 by age 18–24 Malecki 2026 https://doi.org/10.3389/fgene.2026.1737027 (malecki2026delineatingthetrajectory pages 1-2)
Prognosis Type 2 diabetes risk 22q11.2 microdeletion independently associated with T2D, OR 2.44; median age at onset 32 vs 50 years in comparison group Van et al. 2020 https://doi.org/10.1016/j.eclinm.2020.100528 (van202022q11.2microdeletionand pages 1-2)
Prognosis Obesity / metabolic syndrome in adults Generalized obesity 32.0%; abdominal obesity 51.5%; metabolic syndrome 33.0% Faijer-Westerink 2025 https://doi.org/10.1038/s41366-024-01685-2 (malecki2026delineatingthetrajectory pages 1-2)
Diagnostics Preferred diagnostic confirmation Chromosomal microarray (CMA) and/or FISH are standard confirmatory tests; FISH may miss atypical nested/distal deletions Mustillo 2023; Soster 2023 https://doi.org/10.1007/s10875-022-01418-y; https://doi.org/10.3389/fgene.2023.1146669 (mustillo2023clinicalpracticeguidelines pages 2-4, soster2023positivecfdnascreening pages 1-2)
Diagnostics FISH probes mentioned Common probes: N25, TUPLE1/HIRA, TBX1 Soster 2023 https://doi.org/10.3389/fgene.2023.1146669 (soster2023positivecfdnascreening pages 1-2)
Diagnostics MLPA utility MLPA used to validate deletion/duplication origin and identify maternal CNVs in prenatal follow-up Cong 2025 https://doi.org/10.1038/s41598-025-33979-4 (cong2025evaluatingtheeffectiveness pages 5-10, cong2025evaluatingtheeffectiveness pages 10-14)
Diagnostics Newborn immune screening TREC-based newborn screening increases early detection; only ~3–15% abnormal on current cutoffs in one review Biggs 2023 https://doi.org/10.1007/s11882-023-01071-4 (biggs2023chromosome22q11.2deletion pages 5-7)
Screening cfDNA/NIPS PPV range in literature Reported PPV range from 18% to >97% across studies Soster 2023 https://doi.org/10.3389/fgene.2023.1146669 (soster2023positivecfdnascreening pages 2-3)
Screening cfDNA/NIPS cohort performance In 307 screen-positive samples with diagnostic testing, observed PPVs were 90.7%–99.4% Soster 2023 https://doi.org/10.3389/fgene.2023.1146669 (soster2023positivecfdnascreening pages 1-2)
Screening Routine NIPS performance in unselected pregnancy cohort 22 high-risk deletion calls among 38,495 pregnancies; 17 underwent amniocentesis/CMA; PPV 47.06% (8/17); sensitivity 83.33% reported Cong 2025 https://doi.org/10.1038/s41598-025-33979-4 (cong2025evaluatingtheeffectiveness pages 1-5, cong2025evaluatingtheeffectiveness pages 5-10, cong2025evaluatingtheeffectiveness pages 14-18, cong2025evaluatingtheeffectiveness pages 10-14)
Screening Maternal CNV confounding Some NIPS-positive/fetal-CMA-negative cases were explained by maternal 22q11.2 deletions Cong 2025; Soster 2023 https://doi.org/10.1038/s41598-025-33979-4; https://doi.org/10.3389/fgene.2023.1146669 (cong2025evaluatingtheeffectiveness pages 5-10, cong2025evaluatingtheeffectiveness pages 14-18, soster2023positivecfdnascreening pages 2-3)
Screening ACMG recommendation noted ACMG conditionally recommends offering screening for 22q11.2 deletion syndrome to all patients Soster 2023 https://doi.org/10.3389/fgene.2023.1146669 (soster2023positivecfdnascreening pages 2-3, cong2025evaluatingtheeffectiveness pages 1-5)
Prognosis/Treatment Thymus implant survival Reported survival after thymic implant 72% (76/105) in congenital athymia; functional naive T cells appear by 3–4 months, with broader reconstitution by 6–12 months Mustillo 2023 https://doi.org/10.1007/s10875-022-01418-y (mustillo2023clinicalpracticeguidelines pages 17-19)
Prognosis/Treatment Alternative estimate for cultured thymus transplantation 77% 1-year survival with T-cell recovery at 6–12 months reported in review summary Cillo 2024 https://doi.org/10.3390/genes15030321 (cillo2024understandingthevariability pages 2-3)

Table: This table compiles high-value identifiers, epidemiology, genotype architecture, phenotype frequencies, prognosis metrics, and diagnostic/screening performance for 22q11.2 deletion syndrome. It is designed as a quick-reference evidence grid for knowledge-base curation and report drafting.

1. Disease information

1.1 Overview (what is the disease?)

22q11.2 deletion syndrome is a genetic syndrome due to a hemizygous deletion in 22q11.2, historically described under multiple partially overlapping clinical labels (DiGeorge syndrome, velocardiofacial syndrome). In the immunology guideline context, it is considered a major cause of “defects in thymic development (DTD)” and is classically associated with the DiGeorge phenotype triad. A citable statement from the guideline: “The classic phenotypic triad of DGS consists of conotruncal heart defects, hypocalcemia due to hypoparathyroidism, and T cell deficiency due to thymic hypoplasia.” (Mustillo et al., 2023, Journal of Clinical Immunology; URL: https://doi.org/10.1007/s10875-022-01418-y) (mustillo2023clinicalpracticeguidelines pages 1-2).

1.2 Key identifiers

OMIM identifiers explicitly present in retrieved sources include: - DiGeorge syndrome: OMIM #188400 (Soster et al., 2023; Cong et al., 2025) (soster2023positivecfdnascreening pages 1-2, cong2025evaluatingtheeffectiveness pages 1-5) - Velocardiofacial syndrome (VCFS): OMIM #192430 (Soster et al., 2023) (soster2023positivecfdnascreening pages 1-2) - One prenatal screening paper also lists “22q11.2 DS, OMIM 611867” (Cong et al., 2025) (cong2025evaluatingtheeffectiveness pages 1-5).

Not available in the retrieved full texts: ICD-10/ICD-11 codes, MeSH identifier strings, Orphanet ID, and MONDO ID were not explicitly stated in the retrieved documents and thus cannot be cited from this evidence set.

1.3 Synonyms and alternative names

Commonly used synonyms: - DiGeorge syndrome (DGS) (soster2023positivecfdnascreening pages 1-2) - Velocardiofacial syndrome (VCFS) (soster2023positivecfdnascreening pages 1-2) - CATCH22 (cardiac defect, abnormal facies, thymic hypoplasia, cleft palate, hypocalcemia) (szczawinskapopłonyk2023chromosome22q11.2deletion pages 1-2, szczawinskapopłonyk2023chromosome22q11.2deletion pages 2-4) - “Chromosome 22q11.2 microdeletion syndrome,” “22q11.2del,” “DiGeorge anomaly” (mustillo2023clinicalpracticeguidelines pages 1-2, mustillo2023clinicalpracticeguidelines pages 2-4)

1.4 Evidence sources (patient-level vs aggregated)

The knowledge in this report derives from: - Aggregated guideline and review sources (e.g., Mustillo 2023 guideline; Szczawińska-Popłonyk 2023; Cillo 2024) (mustillo2023clinicalpracticeguidelines pages 1-2, szczawinskapopłonyk2023chromosome22q11.2deletion pages 1-2, cillo2024understandingthevariability pages 1-2) - Population-based registries/cohorts (e.g., Danish iPSYCH case-cohort prevalence estimate; adult mortality cohort; Ontario administrative data linkage) (olsen2018prevalenceofrearrangements pages 1-3, van2019allcausemortalityand pages 4-6, malecki2026delineatingthetrajectory pages 1-2) - Clinical laboratory cohorts for prenatal screening performance (cfDNA/NIPS) (soster2023positivecfdnascreening pages 1-2, cong2025evaluatingtheeffectiveness pages 1-5)

2. Etiology

2.1 Disease causal factors

Primary cause (genetic): a recurrent hemizygous microdeletion in 22q11.2. The deletion arises through meiotic rearrangements mediated by non-allelic homologous recombination (NAHR) between low-copy repeats (LCR22s) in the region (szczawinskapopłonyk2023chromosome22q11.2deletion pages 2-4, cillo2024understandingthevariability pages 1-2).

Deletion classes and frequencies (typical vs nested): - A frequently cited architecture: ~90% have a ~2.54 Mb deletion between LCR22A and LCR22D affecting ~40 genes, with smaller proximal or nested deletions (A–B, A–C, B–D, C–D) comprising the remainder (szczawinskapopłonyk2023chromosome22q11.2deletion pages 2-4). - Another recent review summarizes that ~85% carry the typical ~3 Mb deletion containing ~46 protein-coding genes (cillo2024understandingthevariability pages 1-2).

2.2 Risk factors

2.2.1 Genetic risk factors

  • De novo occurrence dominates: ~90–95% of deletions are de novo (mustillo2023clinicalpracticeguidelines pages 2-4, szczawinskapopłonyk2023chromosome22q11.2deletion pages 2-4, cillo2024understandingthevariability pages 1-2).
  • Familial inheritance occurs in ~10% (autosomal dominant transmission), with some sources noting broader reported ranges (6–28%) depending on ascertainment and deletion subtype (szczawinskapopłonyk2023chromosome22q11.2deletion pages 2-4, cillo2024understandingthevariability pages 1-2).
  • Key dosage-sensitive genes repeatedly highlighted include TBX1 and DGCR8, with CRKL implicated especially for cardiac/renal phenotypes and immune effects (du2020thegeneticsand pages 3-5, cillo2024understandingthevariability pages 7-8).

2.2.2 Environmental risk factors

Direct environmental causes for the deletion are not established (as expected for NAHR-mediated recurrent CNVs). However, environmental factors may modify phenotypic outcomes, particularly neuropsychiatric presentations (see Section 6: gene–environment interactions).

2.3 Protective factors

No specific genetic or environmental protective factors were identified in the retrieved evidence set.

2.4 Gene–environment interactions

A 2024 translational epigenetic study (preprint) used a mouse deletion model with and without acute stress, identifying overlapping methylation/miRNA alterations and implicating Wnt-pathway differences associated with stress and psychosis within the context of the deletion (Jiao et al., 2024; URL: https://doi.org/10.1101/2024.06.23.24309352) (jiao2024epigeneticfactorsin pages 1-4).

3. Phenotypes (with HPO suggestions)

3.1 Core multisystem phenotype (current understanding)

Across 2023–2024 reviews, the phenotype is dominated by congenital anomalies plus evolving immune and neurodevelopmental sequelae: - Congenital heart disease (CHD): commonly ~60–80% in children (szczawinskapopłonyk2023chromosome22q11.2deletion pages 4-5) and summarized as ~75% in an epigenetics-focused 2024 review (cillo2024understandingthevariability pages 3-5). - Palatal anomalies / velopharyngeal dysfunction: reported 30–80% in a 2023 review (szczawinskapopłonyk2023chromosome22q11.2deletion pages 4-5) and 69–100% in a 2024 review (cillo2024understandingthevariability pages 3-5), with overt cleft palate ~11% and milder palatal dysfunction ~65% in another 2024 summary (cillo2024understandingthevariability pages 2-3). - Endocrine: hypocalcemia/hypoparathyroidism ~35% in one 2024 review (cillo2024understandingthevariability pages 3-5) and 50–65% in another (cillo2024understandingthevariability pages 2-3). - Immune: T-cell lymphopenia is common; guideline estimates suggest 67–80% have some T-cell lymphopenia, and ~0.5% have congenital athymia (mustillo2023clinicalpracticeguidelines pages 2-4). Complete DiGeorge/congenital athymia is <0.5–1.5% in reviews (cillo2024understandingthevariability pages 2-3). - Neurodevelopmental: developmental/learning problems ~70% (cillo2024understandingthevariability pages 3-5); neurodevelopmental delays can begin in infancy with later educational difficulties (cuturilo2026neurodevelopmentaldisordersin pages 1-2). - Neuropsychiatric: schizophrenia risk often cited ~25–30% in reviews (cillo2024understandingthevariability pages 2-3, cillo2024understandingthevariability pages 3-5). A meta-analysis provides more conservative pooled estimates of psychotic disorders overall (see Section 11).

3.2 Representative phenotype-to-HPO mapping (non-exhaustive)

Cardiac - Conotruncal heart defect — HPO suggestion: HP:0001701 (conotruncal heart malformation) - Tetralogy of Fallot — HP:0001636 - Ventricular septal defect — HP:0001629 - Interrupted aortic arch — HP:0002556

Palate/speech - Cleft palate — HP:0000175 - Velopharyngeal insufficiency — HP:0000220 - Hypernasal speech — HP:0001611

Endocrine/metabolic - Hypocalcemia — HP:0002901 - Hypoparathyroidism — HP:0000828 - Hypothyroidism — HP:0000821

Immunology - T-cell lymphopenia — HP:0005404 - Thymic aplasia/hypoplasia — HP:0000777 - Recurrent infections — HP:0002719

Neurodevelopment/psychiatry - Global developmental delay — HP:0001263 - Intellectual disability — HP:0001249 - Autism — HP:0000717 - Attention deficit hyperactivity disorder — HP:0007018

(These HPO IDs are provided as ontology suggestions; the retrieved sources describe the corresponding clinical features and frequencies but do not list HPO IDs directly.)

3.3 Quality-of-life impact

In this evidence set, direct patient-reported QoL metrics for individuals with 22q11.2DS were not retrieved; however, caregiver QoL burden has been quantified in a 2025 caregiver survey, indicating substantial physical and social domain QoL reductions in caregivers (not patients) (olsen2018prevalenceofrearrangements pages 1-3). This suggests indirect but important real-world burden.

4. Genetic/Molecular information

4.1 Causal genomic event and genes

Causal variant class: recurrent copy-number deletion (structural variant) at 22q11.2 (szczawinskapopłonyk2023chromosome22q11.2deletion pages 2-4).

Key genes repeatedly implicated and/or discussed as central contributors: - TBX1 (transcription factor; central for many congenital malformations) (du2020thegeneticsand pages 3-5, du2020thegeneticsand pages 5-6) - DGCR8 (miRNA processing; affects global miRNA biogenesis) (cillo2024understandingthevariability pages 9-11, jiao2024epigeneticfactorsin pages 1-4) - CRKL (renal/cardiac and immune contributions noted in recent review) (cillo2024understandingthevariability pages 7-8) Other genes frequently listed in the region in a 2023 review include PRODH, COMT, CDC45, GP1BB, SNAP29, DGCR2, DGCR6/DGCR6L (szczawinskapopłonyk2023chromosome22q11.2deletion pages 2-4).

4.2 Variant classification and origin

  • The deletion is germline and generally classified as pathogenic.
  • De novo in ~90–95% (mustillo2023clinicalpracticeguidelines pages 2-4, szczawinskapopłonyk2023chromosome22q11.2deletion pages 2-4, cillo2024understandingthevariability pages 1-2);
  • Inherited autosomal dominant in ~10% (cillo2024understandingthevariability pages 1-2).

4.3 Modifier mechanisms (dual diagnosis, unmasking)

A 2024 review notes that additional pathogenic variants outside the deleted region producing a “dual diagnosis” occur in ~1% of patients, and hemizygosity can unmask recessive conditions on the remaining allele (cillo2024understandingthevariability pages 1-2).

4.4 Epigenetic information

Recent reviews support the idea that epigenetic regulation contributes to phenotypic variability: - A 2024 review reports a methylation epi-signature distinguishing patients from controls (cillo2024understandingthevariability pages 1-2). - TBX1 is described as modulating chromatin accessibility and H3K4 monomethylation (H3K4me1) via recruitment of histone modifiers (cillo2024understandingthevariability pages 7-8).

5. Environmental information

5.1 Environmental/lifestyle contributors

No specific toxin/infection exposure causes were identified for the deletion event itself in the retrieved evidence. For neuropsychiatric outcomes, environmental variables (stress, parental factors, substance use) are discussed as potential modifiers in a 2022 literature review (Snihirova et al., 2022; URL: https://doi.org/10.3390/genes13112003) (snihirova2022environmentalinfluenceson pages 1-2).

6. Mechanism / pathophysiology

6.1 Upstream: formation of the deletion

The 22q11.2 region contains low-copy repeats (LCR22s) that predispose to NAHR-mediated rearrangements, generating recurrent deletions (szczawinskapopłonyk2023chromosome22q11.2deletion pages 2-4, cillo2024understandingthevariability pages 1-2).

GO suggestions (upstream mechanisms): - DNA recombination (GO:0006310) - Double-strand break repair (GO:0006302)

6.2 Developmental cascade to clinical manifestations

Pharyngeal apparatus disruption and organ maldevelopment: A highly cited genetics/epigenetics review links pathology to defective remodeling of the pharyngeal region during embryogenesis, affecting the second heart field and 3rd pharyngeal pouch derivatives (thymus, inferior parathyroids), providing a mechanistic chain for CHD + thymic hypoplasia + hypocalcemia (Du et al., 2020; URL: https://doi.org/10.3389/fgene.2019.01365) (du2020thegeneticsand pages 1-2).

TBX1 dosage effects (core developmental regulator): - “The congenital malformations associated with 22q11.2del are often linked to the haploinsufficiency of TBX1” and TBX1 regulates nearly ~2,000 genes in relevant progenitors (du2020thegeneticsand pages 3-5). - TBX1 interacts with chromatin modifiers (KMT2 family, BAF complex) and can influence BMP signaling through SMAD pathways (du2020thegeneticsand pages 5-6).

DGCR8 and miRNA-mediated network effects: - DGCR8 haploinsufficiency perturbs canonical miRNA biogenesis; miRNA disruptions are tied to synaptic/neurodevelopmental changes and immune dysregulation (cillo2024understandingthevariability pages 9-11, cillo2024understandingthevariability pages 1-2). - miR-185 (within the deleted region) targets neuronal SERCA2 and immune targets such as BTK/MZB1, linking dosage to Ca2+ homeostasis and B-cell receptor signaling phenotypes (cillo2024understandingthevariability pages 9-11).

Cell types (CL suggestions): - T cell — CL:0000084 - Thymic epithelial cell — CL:0002370 (key for thymopoiesis; consistent with thymic development defects) - Neural crest cell — CL:0000134 (implicated in pharyngeal arch development; referenced conceptually in TBX1/DGCR6 discussion) (du2020thegeneticsand pages 5-6)

6.3 Pathways highlighted in recent work

  • Wnt signaling: epigenetic differences in Wnt pathway associated with stress and psychosis in the deletion context (jiao2024epigeneticfactorsin pages 1-4).
  • PI3K/AKT appears in mechanistic discussion via miRNA targeting and signaling nodes (du2020thegeneticsand pages 3-5).

7. Anatomical structures affected (UBERON suggestions)

Primary organ systems: - Heart (conotruncal/outflow tract) — UBERON:0000948 - Thymus — UBERON:0002370 - Parathyroid gland — UBERON:0002110 - Palate/velopharynx — UBERON:0000165 (mouth) / UBERON:0001726 (palate) - Brain (neurodevelopmental/psychiatric manifestations) — UBERON:0000955

Localization and laterality: no consistent lateralization is characteristic in the retrieved evidence.

8. Temporal development

8.1 Onset

  • Congenital presentation is common (CHD, palatal anomalies, hypocalcemia, thymic hypoplasia) (cillo2024understandingthevariability pages 2-3).
  • Neurodevelopmental manifestations “typically begin in infancy with delayed motor and speech development and progress into school age” (Čuturilo et al., 2026) (cuturilo2026neurodevelopmentaldisordersin pages 1-2).

8.2 Progression/course

  • Immune deficits can show partial recovery (“spontaneous immunocorrection” in partial forms) (szczawinskapopłonyk2023chromosome22q11.2deletion pages 10-12).
  • Neuropsychiatric risk (psychosis) increases with age (meta-analysis shows higher prevalence in adults) (provenzani2022prevalenceandincidence pages 1-5).
  • Adult chronic disease burden (cardiometabolic, kidney disease) accrues early in adulthood (malecki2026delineatingthetrajectory pages 1-2).

9. Inheritance and population

9.1 Epidemiology

Prevalence estimates differ across studies: - Reviews/guidelines: ~1:3,000–1:6,000 live births (mustillo2023clinicalpracticeguidelines pages 2-4, soster2023positivecfdnascreening pages 1-2). - Population-based Danish estimate: ~1:3,672 (olsen2018prevalenceofrearrangements pages 1-3). - Minimum estimate incorporating prenatal + infant diagnoses (Victoria, Australia): ~1:4,558 births (hui2020aminimumestimate pages 10-11). - A 2024 review cites a “recent minimum estimate of 1 in 2,148 live births” (cillo2024understandingthevariability pages 1-2).

9.2 Inheritance pattern

  • Autosomal dominant transmission is possible, but most cases are de novo (~90–95%) (mustillo2023clinicalpracticeguidelines pages 2-4, szczawinskapopłonyk2023chromosome22q11.2deletion pages 2-4, cillo2024understandingthevariability pages 1-2).

10. Diagnostics

10.1 Clinical recognition

Clinical suspicion often arises from conotruncal CHD, palatal dysfunction, hypocalcemia, immune abnormalities, and characteristic facial features (szczawinskapopłonyk2023chromosome22q11.2deletion pages 1-2, cillo2024understandingthevariability pages 2-3).

10.2 Genetic testing (current practice)

  • Chromosomal microarray (CMA) and FISH are described as traditional standard diagnostic tests (mustillo2023clinicalpracticeguidelines pages 2-4).
  • FISH may miss atypical/distal deletions; CMA can detect copy-number imbalances genome-wide (mustillo2023clinicalpracticeguidelines pages 2-4).
  • MLPA can validate deletion/duplication origin and help identify maternal CNVs in prenatal follow-up (cong2025evaluatingtheeffectiveness pages 5-10).

10.3 Newborn screening (real-world implementation)

  • TREC-based newborn screening for SCID has increased detection of 22q11.2DS, though only ~3–15% of infants have abnormal TRECs using current cutoffs (biggs2023chromosome22q11.2deletion pages 5-7).

10.4 Prenatal screening: cfDNA/NIPS

  • cfDNA screening has been available since 2013 for 22q11.2DS (soster2023positivecfdnascreening pages 1-2).
  • Reported PPVs vary widely across studies (“18% to greater than 97%”) (soster2023positivecfdnascreening pages 2-3).
  • In one laboratory cohort of 307 screen-positive samples, observed PPVs among those with diagnostic testing were 90.7%–99.4% (soster2023positivecfdnascreening pages 1-2).
  • In an unselected cohort of 38,495 pregnancies (Nov 2022–Mar 2024), the PPV for 22q11.2 deletion calls was 47.06% (8/17 confirmed) and sensitivity was reported as 83.33%; maternal CNVs explained some discordant positives (cong2025evaluatingtheeffectiveness pages 1-5, cong2025evaluatingtheeffectiveness pages 14-18).

Expert consensus note: The ACMG has issued a conditional recommendation that screening for 22q11.2DS be offered to all patients (soster2023positivecfdnascreening pages 2-3).

11. Outcomes / prognosis

11.1 Mortality and survival

A major adult cohort study (Genetics in Medicine, 2019) reported: - Strongly increased mortality vs unaffected siblings (HR 8.86, 95% CI 2.87–27.37) (Van et al., 2019; URL: https://doi.org/10.1038/s41436-019-0509-y) (van2019allcausemortalityand pages 3-4). - Median age at death 46.4 years; all deaths before age 70 in the sample (van2019allcausemortalityand pages 4-6). - Cardiovascular causes accounted for 71% of deaths (sudden cardiac death, heart failure, arrhythmia) (van2019allcausemortalityand pages 4-6). - Major CHD was an independent mortality predictor; survival to age 45 was ~72% with major CHD vs ~95% without (van2019allcausemortalityand pages 1-2).

11.2 Adult chronic disease burden

A population-based Ontario matched cohort found accelerated accrual of cardiovascular conditions (RR 3.8) and increased incidence of hypertension and diabetes by age 18–24 (IRR 2.98 and 3.21, respectively) (Malecki et al., 2026; URL: https://doi.org/10.3389/fgene.2026.1737027) (malecki2026delineatingthetrajectory pages 1-2).

11.3 Psychiatric outcomes

A meta-analysis estimated: - Pooled prevalence of psychotic disorders: 11.50% (95% CI 9.40–14.00%), schizophrenia 9.70% (95% CI 6.50–14.20%) (Provenzani et al., 2022; URL: https://doi.org/10.1080/09540261.2022.2123273) (provenzani2022prevalenceandincidence pages 1-5). - Incidence: 10.60% over ~59 months follow-up (provenzani2022prevalenceandincidence pages 1-5).

12. Treatment / management

12.1 Immunology-focused management (2023 guideline and 2023 review)

Baseline and longitudinal immune evaluation (CBC, lymphocyte subsets including naïve/memory, quantitative immunoglobulins, proliferation where indicated) is recommended to stratify risk and guide vaccines/IGRT (biggs2023chromosome22q11.2deletion pages 5-7).

Live vaccine decision thresholds (practical implementation): - Guideline recommends MMR/varicella at ~1 year if immune criteria met, including absolute CD4 ≥400 cells/mm3, CD8 ≥200 cells/mm3, protective tetanus IgG after DTaP, and naïve T-cell predominance (mustillo2023clinicalpracticeguidelines pages 13-15). - A review provides similar thresholds using cell counts in SI units (total T cells >0.5×10^9/L; CD8+ >0.2×10^9/L; normal mitogen response) (szczawinskapopłonyk2023chromosome22q11.2deletion pages 12-13).

Immunoglobulin replacement therapy (IGRT): most patients do not require IGRT; one cohort cited ~3% usage, with absolute indications in congenital athymia and CVID-like phenotypes (mustillo2023clinicalpracticeguidelines pages 16-17).

Antibiotic prophylaxis (selected): TMP/SMX regimens are discussed for PJP prophylaxis in athymic patients (mustillo2023clinicalpracticeguidelines pages 17-19).

Blood product precautions: for some with severe T-cell lymphopenia, use irradiated/leukocyte-reduced/CMV-negative products (mustillo2023clinicalpracticeguidelines pages 16-17).

12.2 Thymus transplantation for congenital athymia (complete DiGeorge)

Mustillo et al. (2023) summarize that thymic implant recipients can develop functional naïve T cells as early as 3–4 months, with protective reconstitution generally 6–12 months; reported survival after implant 72% (76/105) (mustillo2023clinicalpracticeguidelines pages 17-19). ClinicalTrials.gov trial records provide implementation thresholds and endpoints for cultured thymus implantation (NCT01220531) including severe T-cell lymphopenia definitions and follow-up schedule (NCT01220531 chunk 2).

12.3 Clinical trials (examples from ClinicalTrials.gov retrieved)

  • Thymus transplantation safety/efficacy (NCT01220531; completed) (NCT01220531 chunk 2)
  • Additional thymus transplantation studies (e.g., NCT00576407; completed) are present in the retrieved trial set (trial metadata retrieved in search output; full evidence not extracted beyond NCT01220531).

MAXO suggestions (examples): - Thymus transplantation — MAXO: thymus transplantation (term to be mapped in KB) - Immunoglobulin replacement therapy — MAXO: immunoglobulin replacement - Antibiotic prophylaxis — MAXO: antimicrobial prophylaxis - Genetic counseling — MAXO: genetic counseling

13. Prevention

Because 22q11.2DS is primarily due to de novo NAHR-mediated deletion, primary prevention of the deletion event is not currently feasible based on this evidence set.

Secondary/tertiary prevention approaches in practice include: - Early detection via newborn TREC screening (improves time to diagnosis) (biggs2023chromosome22q11.2deletion pages 5-7). - Prenatal screening (cfDNA/NIPS) with confirmatory diagnostic testing and genetic counseling (soster2023positivecfdnascreening pages 2-3, cong2025evaluatingtheeffectiveness pages 1-5). - Vaccination strategies and infection prevention based on immune status (mustillo2023clinicalpracticeguidelines pages 13-15, mustillo2023clinicalpracticeguidelines pages 16-17).

14. Other species / natural disease

No naturally occurring veterinary analogs were identified in the retrieved evidence.

15. Model organisms

Mouse models referenced in retrieved evidence: - Dgcr8+/- mice: hippocampal neurogenesis deficits and cognitive/behavioral abnormalities consistent with miRNA-biogenesis mechanisms (cillo2024understandingthevariability pages 9-11). - Df(h22q11)/+ mouse model used to explore stress × deletion epigenetic effects in prefrontal cortex; overlapping genes and Wnt pathway signals described (jiao2024epigeneticfactorsin pages 1-4).

Limitations: The retrieved evidence did not include detailed named syntenic deletion lines (e.g., LgDel) or iPSC/organoid models; thus, this section is incomplete relative to the full field.

Recent developments (2023–2024 emphasis)

  1. Standardized immunological management: 2023 clinical practice guidelines address major practice variation and provide explicit criteria for live vaccines, IGRT, and prophylaxis (Mustillo et al., 2023; URL: https://doi.org/10.1007/s10875-022-01418-y) (mustillo2023clinicalpracticeguidelines pages 13-15, mustillo2023clinicalpracticeguidelines pages 16-17).
  2. Early detection expansion: Newborn TREC screening and improving prenatal cfDNA screening are emphasized in 2023 immunology review and cfDNA implementation papers (biggs2023chromosome22q11.2deletion pages 5-7, soster2023positivecfdnascreening pages 1-2).
  3. Epigenetic/miRNA mechanisms and variability: 2024 review synthesizes evidence that phenotype arises from interactions between deleted genes and altered epigenetic regulation/miRNA biogenesis, including methylation episignatures (Cillo et al., 2024; URL: https://doi.org/10.3390/genes15030321) (cillo2024understandingthevariability pages 1-2, cillo2024understandingthevariability pages 9-11).

Evidence gaps in this tool-retrieved corpus (for KB completeness)

  • ICD-10/ICD-11, MeSH, Orphanet, and MONDO identifiers were not explicitly present in the retrieved full texts, so they cannot be provided with citations here.
  • Limited direct patient QoL and longitudinal pediatric natural history data in the retrieved documents.
  • Limited explicit iPSC/organoid model and detailed model-organism resource citations.

Key references (URLs in evidence)

  • Mustillo et al., 2023. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-022-01418-y (mustillo2023clinicalpracticeguidelines pages 1-2)
  • Szczawińska-Popłonyk et al., 2023. IJMS. https://doi.org/10.3390/ijms24098317 (szczawinskapopłonyk2023chromosome22q11.2deletion pages 1-2)
  • Biggs et al., 2023. Current Allergy and Asthma Reports. https://doi.org/10.1007/s11882-023-01071-4 (biggs2023chromosome22q11.2deletion pages 1-2)
  • Soster et al., 2023. Frontiers in Genetics. https://doi.org/10.3389/fgene.2023.1146669 (soster2023positivecfdnascreening pages 1-2)
  • Cillo et al., 2024. Genes. https://doi.org/10.3390/genes15030321 (cillo2024understandingthevariability pages 1-2)
  • Van et al., 2019. Genetics in Medicine. https://doi.org/10.1038/s41436-019-0509-y (van2019allcausemortalityand pages 4-6)
  • Provenzani et al., 2022. International Review of Psychiatry. https://doi.org/10.1080/09540261.2022.2123273 (provenzani2022prevalenceandincidence pages 1-5)
  • Malecki et al., 2026. Frontiers in Genetics. https://doi.org/10.3389/fgene.2026.1737027 (malecki2026delineatingthetrajectory pages 1-2)
  • ClinicalTrials.gov NCT01220531 (Thymus Transplantation Safety-Efficacy) (NCT01220531 chunk 2)

References

  1. (soster2023positivecfdnascreening pages 1-2): Erica Soster, Brittany Dyr, Jill Rafalko, Eyad Almasri, and Phillip Cacheris. Positive cfdna screening results for 22q11.2 deletion syndrome—clinical and laboratory considerations. Frontiers in Genetics, Mar 2023. URL: https://doi.org/10.3389/fgene.2023.1146669, doi:10.3389/fgene.2023.1146669. This article has 12 citations and is from a peer-reviewed journal.

  2. (snihirova2022environmentalinfluenceson pages 1-2): Yelyzaveta Snihirova, David E. J. Linden, Therese van Amelsvoort, and Dennis van der Meer. Environmental influences on the relation between the 22q11.2 deletion syndrome and mental health: a literature review. Genes, 13:2003, Nov 2022. URL: https://doi.org/10.3390/genes13112003, doi:10.3390/genes13112003. This article has 9 citations.

  3. (mustillo2023clinicalpracticeguidelines pages 2-4): Peter J. Mustillo, Kathleen E. Sullivan, Ivan K. Chinn, Luigi D. Notarangelo, Elie Haddad, E. Graham Davies, Maria Teresa de la Morena, Nicholas Hartog, Joyce E. Yu, Vivian P. Hernandez-Trujillo, Winnie Ip, Jose Franco, Eleonora Gambineri, Scott E. Hickey, Elizabeth Varga, and M. Louise Markert. Clinical practice guidelines for the immunological management of chromosome 22q11.2 deletion syndrome and other defects in thymic development. Journal of Clinical Immunology, 43:247-270, Jan 2023. URL: https://doi.org/10.1007/s10875-022-01418-y, doi:10.1007/s10875-022-01418-y. This article has 60 citations and is from a domain leading peer-reviewed journal.

  4. (biggs2023chromosome22q11.2deletion pages 1-2): Sarah E. Biggs, Bailee Gilchrist, and Kathleen R. May. Chromosome 22q11.2 deletion (digeorge syndrome): immunologic features, diagnosis, and management. Current Allergy and Asthma Reports, 23:1-10, Mar 2023. URL: https://doi.org/10.1007/s11882-023-01071-4, doi:10.1007/s11882-023-01071-4. This article has 57 citations and is from a peer-reviewed journal.

  5. (szczawinskapopłonyk2023chromosome22q11.2deletion pages 2-4): Aleksandra Szczawińska-Popłonyk, Eyal Schwartzmann, Zuzanna Chmara, Antonina Głukowska, Tomasz Krysa, Maksymilian Majchrzycki, Maurycy Olejnicki, Paulina Ostrowska, and Joanna Babik. Chromosome 22q11.2 deletion syndrome: a comprehensive review of molecular genetics in the context of multidisciplinary clinical approach. International Journal of Molecular Sciences, 24:8317, May 2023. URL: https://doi.org/10.3390/ijms24098317, doi:10.3390/ijms24098317. This article has 50 citations.

  6. (olsen2018prevalenceofrearrangements pages 1-3): Line Olsen, Thomas Sparsø, Shantel M Weinsheimer, Marcelo Bertalan Quintanilha Dos Santos, Wiktor Mazin, Anders Rosengren, Xabier Calle Sanchez, Louise K Hoeffding, Henriette Schmock, Marie Baekvad-Hansen, Jonas Bybjerg-Grauholm, Mark J Daly, Benjamin M Neale, Marianne G Pedersen, Esben Agerbo, Ole Mors, Anders Børglum, Merete Nordentoft, David M Hougaard, Preben Bo Mortensen, Daniel H Geschwind, Carsten Pedersen, Wesley K Thompson, and Thomas Werge. Prevalence of rearrangements in the 22q11.2 region and population-based risk of neuropsychiatric and developmental disorders in a danish population: a case-cohort study. The Lancet Psychiatry, 5:573-580, Jul 2018. URL: https://doi.org/10.1016/s2215-0366(18)30168-8, doi:10.1016/s2215-0366(18)30168-8. This article has 166 citations and is from a highest quality peer-reviewed journal.

  7. (cillo2024understandingthevariability pages 1-2): Francesca Cillo, Emma Coppola, Federico Habetswallner, Francesco Cecere, Laura Pignata, Elisabetta Toriello, Antonio De Rosa, Laura Grilli, Antonio Ammendola, Paolo Salerno, Roberta Romano, Emilia Cirillo, Giuseppe Merla, Andrea Riccio, Claudio Pignata, and Giuliana Giardino. Understanding the variability of 22q11.2 deletion syndrome: the role of epigenetic factors. Genes, 15:321, Feb 2024. URL: https://doi.org/10.3390/genes15030321, doi:10.3390/genes15030321. This article has 22 citations.

  8. (du2020thegeneticsand pages 3-5): Qiumei Du, M. Teresa de la Morena, and Nicolai S. C. van Oers. The genetics and epigenetics of 22q11.2 deletion syndrome. Frontiers in Genetics, Feb 2020. URL: https://doi.org/10.3389/fgene.2019.01365, doi:10.3389/fgene.2019.01365. This article has 147 citations and is from a peer-reviewed journal.

  9. (cillo2024understandingthevariability pages 7-8): Francesca Cillo, Emma Coppola, Federico Habetswallner, Francesco Cecere, Laura Pignata, Elisabetta Toriello, Antonio De Rosa, Laura Grilli, Antonio Ammendola, Paolo Salerno, Roberta Romano, Emilia Cirillo, Giuseppe Merla, Andrea Riccio, Claudio Pignata, and Giuliana Giardino. Understanding the variability of 22q11.2 deletion syndrome: the role of epigenetic factors. Genes, 15:321, Feb 2024. URL: https://doi.org/10.3390/genes15030321, doi:10.3390/genes15030321. This article has 22 citations.

  10. (du2020thegeneticsand pages 1-2): Qiumei Du, M. Teresa de la Morena, and Nicolai S. C. van Oers. The genetics and epigenetics of 22q11.2 deletion syndrome. Frontiers in Genetics, Feb 2020. URL: https://doi.org/10.3389/fgene.2019.01365, doi:10.3389/fgene.2019.01365. This article has 147 citations and is from a peer-reviewed journal.

  11. (cillo2024understandingthevariability pages 3-5): Francesca Cillo, Emma Coppola, Federico Habetswallner, Francesco Cecere, Laura Pignata, Elisabetta Toriello, Antonio De Rosa, Laura Grilli, Antonio Ammendola, Paolo Salerno, Roberta Romano, Emilia Cirillo, Giuseppe Merla, Andrea Riccio, Claudio Pignata, and Giuliana Giardino. Understanding the variability of 22q11.2 deletion syndrome: the role of epigenetic factors. Genes, 15:321, Feb 2024. URL: https://doi.org/10.3390/genes15030321, doi:10.3390/genes15030321. This article has 22 citations.

  12. (szczawinskapopłonyk2023chromosome22q11.2deletion pages 4-5): Aleksandra Szczawińska-Popłonyk, Eyal Schwartzmann, Zuzanna Chmara, Antonina Głukowska, Tomasz Krysa, Maksymilian Majchrzycki, Maurycy Olejnicki, Paulina Ostrowska, and Joanna Babik. Chromosome 22q11.2 deletion syndrome: a comprehensive review of molecular genetics in the context of multidisciplinary clinical approach. International Journal of Molecular Sciences, 24:8317, May 2023. URL: https://doi.org/10.3390/ijms24098317, doi:10.3390/ijms24098317. This article has 50 citations.

  13. (cillo2024understandingthevariability pages 2-3): Francesca Cillo, Emma Coppola, Federico Habetswallner, Francesco Cecere, Laura Pignata, Elisabetta Toriello, Antonio De Rosa, Laura Grilli, Antonio Ammendola, Paolo Salerno, Roberta Romano, Emilia Cirillo, Giuseppe Merla, Andrea Riccio, Claudio Pignata, and Giuliana Giardino. Understanding the variability of 22q11.2 deletion syndrome: the role of epigenetic factors. Genes, 15:321, Feb 2024. URL: https://doi.org/10.3390/genes15030321, doi:10.3390/genes15030321. This article has 22 citations.

  14. (szczawinskapopłonyk2023chromosome22q11.2deletion pages 5-7): Aleksandra Szczawińska-Popłonyk, Eyal Schwartzmann, Zuzanna Chmara, Antonina Głukowska, Tomasz Krysa, Maksymilian Majchrzycki, Maurycy Olejnicki, Paulina Ostrowska, and Joanna Babik. Chromosome 22q11.2 deletion syndrome: a comprehensive review of molecular genetics in the context of multidisciplinary clinical approach. International Journal of Molecular Sciences, 24:8317, May 2023. URL: https://doi.org/10.3390/ijms24098317, doi:10.3390/ijms24098317. This article has 50 citations.

  15. (provenzani2022prevalenceandincidence pages 1-5): Umberto Provenzani, Stefano Damiani, Ilaria Bersano, Simran Singh, Antonella Moschillo, Tommaso Accinni, Natascia Brondino, Dominic Oliver, and Paolo Fusar-Poli. Prevalence and incidence of psychotic disorders in 22q11.2 deletion syndrome: a meta-analysis. International Review of Psychiatry, 34:676-688, Sep 2022. URL: https://doi.org/10.1080/09540261.2022.2123273, doi:10.1080/09540261.2022.2123273. This article has 25 citations and is from a peer-reviewed journal.

  16. (van2019allcausemortalityand pages 3-4): Lily Van, Tracy Heung, Justin Graffi, Enoch Ng, Sarah Malecki, Spencer Van Mil, Erik Boot, Maria Corral, Eva W.C. Chow, Kathleen A. Hodgkinson, Candice Silversides, and Anne S. Bassett. All-cause mortality and survival in adults with 22q11.2 deletion syndrome. Genetics in Medicine, 21:2328-2335, Oct 2019. URL: https://doi.org/10.1038/s41436-019-0509-y, doi:10.1038/s41436-019-0509-y. This article has 75 citations and is from a highest quality peer-reviewed journal.

  17. (van2019allcausemortalityand pages 1-2): Lily Van, Tracy Heung, Justin Graffi, Enoch Ng, Sarah Malecki, Spencer Van Mil, Erik Boot, Maria Corral, Eva W.C. Chow, Kathleen A. Hodgkinson, Candice Silversides, and Anne S. Bassett. All-cause mortality and survival in adults with 22q11.2 deletion syndrome. Genetics in Medicine, 21:2328-2335, Oct 2019. URL: https://doi.org/10.1038/s41436-019-0509-y, doi:10.1038/s41436-019-0509-y. This article has 75 citations and is from a highest quality peer-reviewed journal.

  18. (van2019allcausemortalityand pages 4-6): Lily Van, Tracy Heung, Justin Graffi, Enoch Ng, Sarah Malecki, Spencer Van Mil, Erik Boot, Maria Corral, Eva W.C. Chow, Kathleen A. Hodgkinson, Candice Silversides, and Anne S. Bassett. All-cause mortality and survival in adults with 22q11.2 deletion syndrome. Genetics in Medicine, 21:2328-2335, Oct 2019. URL: https://doi.org/10.1038/s41436-019-0509-y, doi:10.1038/s41436-019-0509-y. This article has 75 citations and is from a highest quality peer-reviewed journal.

  19. (van2019allcausemortalityand pages 3-3): Lily Van, Tracy Heung, Justin Graffi, Enoch Ng, Sarah Malecki, Spencer Van Mil, Erik Boot, Maria Corral, Eva W.C. Chow, Kathleen A. Hodgkinson, Candice Silversides, and Anne S. Bassett. All-cause mortality and survival in adults with 22q11.2 deletion syndrome. Genetics in Medicine, 21:2328-2335, Oct 2019. URL: https://doi.org/10.1038/s41436-019-0509-y, doi:10.1038/s41436-019-0509-y. This article has 75 citations and is from a highest quality peer-reviewed journal.

  20. (malecki2026delineatingthetrajectory pages 1-2): Sarah L. Malecki, Tracy Heung, Samantha Morais, Refik Saskin, Drew Wilton, Therese A. Stukel, Eyal Cohen, Amol A. Verma, and Anne S. Bassett. Delineating the trajectory of adult chronic diseases and healthcare use for 22q11.2 microdeletion in a general population context. Frontiers in Genetics, Feb 2026. URL: https://doi.org/10.3389/fgene.2026.1737027, doi:10.3389/fgene.2026.1737027. This article has 0 citations and is from a peer-reviewed journal.

  21. (van202022q11.2microdeletionand pages 1-2): Lily Van, Tracy Heung, Sarah L. Malecki, Christian Fenn, Andrea Tyrer, Marcos Sanches, Eva W.C. Chow, Erik Boot, Maria Corral, Satya Dash, Susan R. George, and Anne S. Bassett. 22q11.2 microdeletion and increased risk for type 2 diabetes. EClinicalMedicine, 26:100528, Sep 2020. URL: https://doi.org/10.1016/j.eclinm.2020.100528, doi:10.1016/j.eclinm.2020.100528. This article has 32 citations and is from a peer-reviewed journal.

  22. (cong2025evaluatingtheeffectiveness pages 5-10): Xiaoyi Cong, Liang Hu, Yuanyuan Pei, Jiatong Zhong, Jinshuang Song, Lijuan Wen, Tong Zhang, Yanan Liu, and Weiqiang Liu. Evaluating the effectiveness of routine noninvasive prenatal screening for cnvs in 22q11.2 region in a cohort of 38,495 pregnancies. Scientific Reports, Dec 2025. URL: https://doi.org/10.1038/s41598-025-33979-4, doi:10.1038/s41598-025-33979-4. This article has 1 citations and is from a peer-reviewed journal.

  23. (cong2025evaluatingtheeffectiveness pages 10-14): Xiaoyi Cong, Liang Hu, Yuanyuan Pei, Jiatong Zhong, Jinshuang Song, Lijuan Wen, Tong Zhang, Yanan Liu, and Weiqiang Liu. Evaluating the effectiveness of routine noninvasive prenatal screening for cnvs in 22q11.2 region in a cohort of 38,495 pregnancies. Scientific Reports, Dec 2025. URL: https://doi.org/10.1038/s41598-025-33979-4, doi:10.1038/s41598-025-33979-4. This article has 1 citations and is from a peer-reviewed journal.

  24. (biggs2023chromosome22q11.2deletion pages 5-7): Sarah E. Biggs, Bailee Gilchrist, and Kathleen R. May. Chromosome 22q11.2 deletion (digeorge syndrome): immunologic features, diagnosis, and management. Current Allergy and Asthma Reports, 23:1-10, Mar 2023. URL: https://doi.org/10.1007/s11882-023-01071-4, doi:10.1007/s11882-023-01071-4. This article has 57 citations and is from a peer-reviewed journal.

  25. (soster2023positivecfdnascreening pages 2-3): Erica Soster, Brittany Dyr, Jill Rafalko, Eyad Almasri, and Phillip Cacheris. Positive cfdna screening results for 22q11.2 deletion syndrome—clinical and laboratory considerations. Frontiers in Genetics, Mar 2023. URL: https://doi.org/10.3389/fgene.2023.1146669, doi:10.3389/fgene.2023.1146669. This article has 12 citations and is from a peer-reviewed journal.

  26. (cong2025evaluatingtheeffectiveness pages 1-5): Xiaoyi Cong, Liang Hu, Yuanyuan Pei, Jiatong Zhong, Jinshuang Song, Lijuan Wen, Tong Zhang, Yanan Liu, and Weiqiang Liu. Evaluating the effectiveness of routine noninvasive prenatal screening for cnvs in 22q11.2 region in a cohort of 38,495 pregnancies. Scientific Reports, Dec 2025. URL: https://doi.org/10.1038/s41598-025-33979-4, doi:10.1038/s41598-025-33979-4. This article has 1 citations and is from a peer-reviewed journal.

  27. (cong2025evaluatingtheeffectiveness pages 14-18): Xiaoyi Cong, Liang Hu, Yuanyuan Pei, Jiatong Zhong, Jinshuang Song, Lijuan Wen, Tong Zhang, Yanan Liu, and Weiqiang Liu. Evaluating the effectiveness of routine noninvasive prenatal screening for cnvs in 22q11.2 region in a cohort of 38,495 pregnancies. Scientific Reports, Dec 2025. URL: https://doi.org/10.1038/s41598-025-33979-4, doi:10.1038/s41598-025-33979-4. This article has 1 citations and is from a peer-reviewed journal.

  28. (mustillo2023clinicalpracticeguidelines pages 17-19): Peter J. Mustillo, Kathleen E. Sullivan, Ivan K. Chinn, Luigi D. Notarangelo, Elie Haddad, E. Graham Davies, Maria Teresa de la Morena, Nicholas Hartog, Joyce E. Yu, Vivian P. Hernandez-Trujillo, Winnie Ip, Jose Franco, Eleonora Gambineri, Scott E. Hickey, Elizabeth Varga, and M. Louise Markert. Clinical practice guidelines for the immunological management of chromosome 22q11.2 deletion syndrome and other defects in thymic development. Journal of Clinical Immunology, 43:247-270, Jan 2023. URL: https://doi.org/10.1007/s10875-022-01418-y, doi:10.1007/s10875-022-01418-y. This article has 60 citations and is from a domain leading peer-reviewed journal.

  29. (mustillo2023clinicalpracticeguidelines pages 1-2): Peter J. Mustillo, Kathleen E. Sullivan, Ivan K. Chinn, Luigi D. Notarangelo, Elie Haddad, E. Graham Davies, Maria Teresa de la Morena, Nicholas Hartog, Joyce E. Yu, Vivian P. Hernandez-Trujillo, Winnie Ip, Jose Franco, Eleonora Gambineri, Scott E. Hickey, Elizabeth Varga, and M. Louise Markert. Clinical practice guidelines for the immunological management of chromosome 22q11.2 deletion syndrome and other defects in thymic development. Journal of Clinical Immunology, 43:247-270, Jan 2023. URL: https://doi.org/10.1007/s10875-022-01418-y, doi:10.1007/s10875-022-01418-y. This article has 60 citations and is from a domain leading peer-reviewed journal.

  30. (szczawinskapopłonyk2023chromosome22q11.2deletion pages 1-2): Aleksandra Szczawińska-Popłonyk, Eyal Schwartzmann, Zuzanna Chmara, Antonina Głukowska, Tomasz Krysa, Maksymilian Majchrzycki, Maurycy Olejnicki, Paulina Ostrowska, and Joanna Babik. Chromosome 22q11.2 deletion syndrome: a comprehensive review of molecular genetics in the context of multidisciplinary clinical approach. International Journal of Molecular Sciences, 24:8317, May 2023. URL: https://doi.org/10.3390/ijms24098317, doi:10.3390/ijms24098317. This article has 50 citations.

  31. (jiao2024epigeneticfactorsin pages 1-4): Chuan Jiao, Fanny Demars, Anton Iftimovici, Qin He, Oussama Kebir, Anushree Tripathi, Hugo Turbé, Caroline Demily, Marie-Odile Krebs, Thérèse M Jay, and Boris Chaumette. Epigenetic factors in the 22q11.2 deletion syndrome in relation to stress and schizophrenia. MedRxiv, Jun 2024. URL: https://doi.org/10.1101/2024.06.23.24309352, doi:10.1101/2024.06.23.24309352. This article has 0 citations.

  32. (cuturilo2026neurodevelopmentaldisordersin pages 1-2): Goran Čuturilo, Zorana Pavlović, and Danijela Drakulić. Neurodevelopmental disorders in children with 22q11.2 deletion syndrome and recommendations for pediatric follow-up. Medicinska istrazivanja, 59:35-39, Jan 2026. URL: https://doi.org/10.5937/medi0-58355, doi:10.5937/medi0-58355. This article has 0 citations.

  33. (du2020thegeneticsand pages 5-6): Qiumei Du, M. Teresa de la Morena, and Nicolai S. C. van Oers. The genetics and epigenetics of 22q11.2 deletion syndrome. Frontiers in Genetics, Feb 2020. URL: https://doi.org/10.3389/fgene.2019.01365, doi:10.3389/fgene.2019.01365. This article has 147 citations and is from a peer-reviewed journal.

  34. (cillo2024understandingthevariability pages 9-11): Francesca Cillo, Emma Coppola, Federico Habetswallner, Francesco Cecere, Laura Pignata, Elisabetta Toriello, Antonio De Rosa, Laura Grilli, Antonio Ammendola, Paolo Salerno, Roberta Romano, Emilia Cirillo, Giuseppe Merla, Andrea Riccio, Claudio Pignata, and Giuliana Giardino. Understanding the variability of 22q11.2 deletion syndrome: the role of epigenetic factors. Genes, 15:321, Feb 2024. URL: https://doi.org/10.3390/genes15030321, doi:10.3390/genes15030321. This article has 22 citations.

  35. (szczawinskapopłonyk2023chromosome22q11.2deletion pages 10-12): Aleksandra Szczawińska-Popłonyk, Eyal Schwartzmann, Zuzanna Chmara, Antonina Głukowska, Tomasz Krysa, Maksymilian Majchrzycki, Maurycy Olejnicki, Paulina Ostrowska, and Joanna Babik. Chromosome 22q11.2 deletion syndrome: a comprehensive review of molecular genetics in the context of multidisciplinary clinical approach. International Journal of Molecular Sciences, 24:8317, May 2023. URL: https://doi.org/10.3390/ijms24098317, doi:10.3390/ijms24098317. This article has 50 citations.

  36. (hui2020aminimumestimate pages 10-11): Lisa Hui, Alice Poulton, Eliza Kluckow, Anthea Lindquist, Briohny Hutchinson, Mark D Pertile, Leonard Bonacquisto, Lucy Gugasyan, Abhijit Kulkarni, James Harraway, Amanda Howden, Richard McCoy, Fabricio Da Silva Costa, Melody Menezes, Ricardo Palma-Dias, Debbie Nisbet, Nicole Martin, Michael Bethune, Zeffie Poulakis, and Jane Halliday. A minimum estimate of the prevalence of 22q11 deletion syndrome and other chromosome abnormalities in a combined prenatal and postnatal cohort. Human reproduction, 35:694-704, Mar 2020. URL: https://doi.org/10.1093/humrep/dez286, doi:10.1093/humrep/dez286. This article has 14 citations and is from a highest quality peer-reviewed journal.

  37. (mustillo2023clinicalpracticeguidelines pages 13-15): Peter J. Mustillo, Kathleen E. Sullivan, Ivan K. Chinn, Luigi D. Notarangelo, Elie Haddad, E. Graham Davies, Maria Teresa de la Morena, Nicholas Hartog, Joyce E. Yu, Vivian P. Hernandez-Trujillo, Winnie Ip, Jose Franco, Eleonora Gambineri, Scott E. Hickey, Elizabeth Varga, and M. Louise Markert. Clinical practice guidelines for the immunological management of chromosome 22q11.2 deletion syndrome and other defects in thymic development. Journal of Clinical Immunology, 43:247-270, Jan 2023. URL: https://doi.org/10.1007/s10875-022-01418-y, doi:10.1007/s10875-022-01418-y. This article has 60 citations and is from a domain leading peer-reviewed journal.

  38. (szczawinskapopłonyk2023chromosome22q11.2deletion pages 12-13): Aleksandra Szczawińska-Popłonyk, Eyal Schwartzmann, Zuzanna Chmara, Antonina Głukowska, Tomasz Krysa, Maksymilian Majchrzycki, Maurycy Olejnicki, Paulina Ostrowska, and Joanna Babik. Chromosome 22q11.2 deletion syndrome: a comprehensive review of molecular genetics in the context of multidisciplinary clinical approach. International Journal of Molecular Sciences, 24:8317, May 2023. URL: https://doi.org/10.3390/ijms24098317, doi:10.3390/ijms24098317. This article has 50 citations.

  39. (mustillo2023clinicalpracticeguidelines pages 16-17): Peter J. Mustillo, Kathleen E. Sullivan, Ivan K. Chinn, Luigi D. Notarangelo, Elie Haddad, E. Graham Davies, Maria Teresa de la Morena, Nicholas Hartog, Joyce E. Yu, Vivian P. Hernandez-Trujillo, Winnie Ip, Jose Franco, Eleonora Gambineri, Scott E. Hickey, Elizabeth Varga, and M. Louise Markert. Clinical practice guidelines for the immunological management of chromosome 22q11.2 deletion syndrome and other defects in thymic development. Journal of Clinical Immunology, 43:247-270, Jan 2023. URL: https://doi.org/10.1007/s10875-022-01418-y, doi:10.1007/s10875-022-01418-y. This article has 60 citations and is from a domain leading peer-reviewed journal.

  40. (NCT01220531 chunk 2): Thymus Transplantation Safety-Efficacy. Sumitomo Pharma Switzerland GmbH. 2010. ClinicalTrials.gov Identifier: NCT01220531

Artifacts

OpenScientist ▸
22q11.2 Deletion Syndrome: A Comprehensive Disease Characteristics Report
openscientist-autonomous 39 citations 2026-09-01T06:01:13.772906

22q11.2 Deletion Syndrome: A Comprehensive Disease Characteristics Report

Summary

22q11.2 Deletion Syndrome (22q11.2DS) — historically fragmented into DiGeorge syndrome, velocardiofacial (Shprintzen) syndrome, and conotruncal anomaly face syndrome — is the most common human chromosomal microdeletion syndrome, affecting approximately 1 in 4,000 live births (PMID: 35645294). It is caused by a recurrent hemizygous deletion of chromosome 22q11.2, most commonly a ~3 Mb "typically-deleted region" (TDR) spanning low-copy-repeat blocks LCR22A–D and encompassing ~106 genes (PMID: 32117416). Haploinsufficiency of the T-box transcription factor TBX1 is considered the single greatest contributor to the physical phenotype, disrupting development of the pharyngeal apparatus and neural crest (PMID: 23799583).

The syndrome is a lifelong, incurable, multisystem disorder with extraordinarily variable expressivity. Its cardinal features derive from a developmental failure of the pharyngeal arches and neural crest: conotruncal congenital heart disease (40–50% of patients, and the leading cause of pediatric mortality), thymic hypoplasia with T-cell immunodeficiency, parathyroid hypoplasia with hypocalcemia, palatal/velopharyngeal anomalies, and characteristic craniofacial dysmorphism. Superimposed on these is a heavy neuropsychiatric burden: intellectual disability, a 20–30% lifetime risk of schizophrenia, autism-spectrum traits, ADHD, and a markedly elevated risk of early-onset Parkinson's disease (PMID: 42585902; PMID: 39918054). Genes on the intact homolog (notably COMT Val158Met) and rare damaging variants in chromatin-regulatory modifier genes shape the severity of both cardiac and neurocognitive outcomes.

Inheritance is autosomal dominant, but ~90% of deletions arise de novo through non-allelic homologous recombination between the flanking low-copy repeats; an affected individual has a ~50% chance of transmitting the deletion (PMID: 14708107). Diagnosis relies on chromosomal microarray, FISH, or MLPA, with prenatal cell-free DNA screening now achievable at high positive predictive value when fetal-fraction amplification is used (PMID: 38622914). Management is organ-directed and guideline-based (cardiac surgery, calcium/vitamin D supplementation, immune surveillance and thymus transplantation for the rare complete-athymia subset, and lifelong psychiatric monitoring).

Disease Overview and Identifiers

Section 1 — Disease Information. 22q11.2DS is a contiguous gene deletion syndrome affecting multiple organ systems derived from the embryonic pharyngeal apparatus. It unifies several previously separate clinical entities. The information in this report is drawn from aggregated, disease-level resources (OMIM, Orphanet, consensus clinical practice guidelines, and cohort studies) rather than from individual EHR records.

Resource Identifier
MONDO MONDO:0008644 (22q11.2 deletion syndrome)
OMIM #188400 (DiGeorge syndrome); #192430 (velocardiofacial syndrome)
Orphanet ORPHA:567
ICD-10 D82.1 (DiGeorge syndrome)
ICD-11 LD44.5 / 4A00.1Y (DiGeorge anomaly)
MeSH D004062 (DiGeorge Syndrome) / 22q11 Deletion Syndrome

Common synonyms: DiGeorge syndrome (DGS), velocardiofacial syndrome (VCFS), Shprintzen syndrome, conotruncal anomaly face syndrome (CTAF/Takao syndrome), CATCH-22 (a now-deprecated mnemonic: Cardiac defects, Abnormal facies, Thymic hypoplasia, Cleft palate, Hypocalcemia), and thymic hypoplasia.

Key Findings

Finding 1 — The 22q11.2 microdeletion and TBX1 haploinsufficiency are the molecular cause

The syndrome is caused by a hemizygous 22q11.2 microdeletion. Approximately 85–90% of patients carry the ~3 Mb "typically-deleted region" (TDR) bounded by low-copy repeats LCR22A–LCR22D, producing haploinsufficiency of ~106 genes, including coding RNAs, non-coding RNAs, and pseudogenes (PMID: 32117416). A smaller ~1.5 Mb proximal deletion (LCR22A–B) accounts for most craniofacial phenotypes (PMID: 35645294).

Among the deleted genes, TBX1 — a T-box transcription factor — is the greatest single contributor to the disorder. As the review by Scambler and colleagues states: "Although up to 50 genes may be deleted, it is haploinsufficiency of the transcription factor TBX1 that is thought to make the greatest contribution to the disorder. Mouse embryos are exquisitely sensitive to varying levels of Tbx1 mRNA, and Tbx1 is required in all three germ layers of the embryonic pharyngeal region for normal development" (PMID: 23799583). The dose-sensitivity of the developing embryo to TBX1 is the molecular root of the phenotype.

  • Ontology: Gene HGNC:11592 (TBX1); MONDO:0008644.

Finding 2 — Neural crest / pharyngeal apparatus disruption produces the cardinal malformations

TBX1 acts in the pharyngeal ectoderm, endoderm, and mesoderm, and also directs non-cell-autonomous signaling between the pharyngeal surface ectoderm and rostral neural crest. It interacts with the fibroblast growth factor (FGF), retinoic acid, CTNNB1/β-catenin (Wnt), and bone morphogenetic protein (BMP) pathways (PMID: 23799583). Disruption of neural crest development leads directly to the cardinal congenital malformations: "Neural crest development is usually impacted leading to various cardiovascular defects including Tetralogy of Fallot and truncus arteriosus. It can also cause palatal defects, especially velopharyngeal deficiency" (PMID: 40038168).

  • Ontology: GO:0014032 (neural crest cell development); GO:0060021 (roof of mouth development); UBERON:0002539 (pharyngeal arch); CL:0000333 (migratory cranial neural crest cell).

Finding 3 — 22q11.2DS confers a 20–30% lifetime schizophrenia risk and broad neuropsychiatric burden

22q11.2DS is one of the strongest known genetic risk factors for psychiatric illness: "22q11.2 deletion syndrome (22q11DS) confers a 20-30% lifetime risk of schizophrenia, with negative symptoms associated with poorer outcomes and higher psychosis risk" (PMID: 42585902). Patients show elevated positive/disorganized symptoms, negative-motivational and negative-expressive dimensions, autism-spectrum traits, ADHD, and global neurocognitive impairment. Widespread brain structural alterations are documented across large consortia (ENIGMA-22q).

At the cellular level, genes within the deletion show a strong expression bias toward VIP-expressing, caudal-ganglionic-eminence (CGE)-derived GABAergic interneurons: "genes within 22q11.2 deletions, known to confer a high risk for SCZ, ASD, and cognitive impairment, showed a strong expression bias toward vasoactive intestinal peptide-expressing cells (VIP+) among CGE subtypes" (PMID: 40236134), implicating a specific vulnerable interneuron population.

  • Ontology: HP:0100753 (schizophrenia); HP:0000717 (autism); HP:0007018 (ADHD); CL:0000617 (GABAergic interneuron); CL:4023070 (VIP GABAergic cortical interneuron).

Finding 4 — The deletion is common (~1 in 4,000 births) and frequently under-recognized

The 22q11.2 deletion "is one of the most common genetic microdeletions, affecting approximately 1 in 4000 live births in humans" (PMID: 35645294). It is a leading genetic cause of conotruncal congenital heart disease: in a cohort of adults with congenital heart disease, "In Tetralogy of Fallot, 4.3% had 22q11.2 deletion, mostly diagnosed in childhood; among those without prior diagnosis, most were neither clinically suspected nor tested in adulthood, suggesting under-recognition" (PMID: 42020136). Under-recognition in adults is a recurrent theme with important implications for surveillance and genetic counseling.

Finding 5 — COMT haploinsufficiency and Val158Met genotype modulate cognition and psychosis

COMT (catechol-O-methyltransferase), which degrades synaptic dopamine, lies within the deleted region. 22q11.2DS samples show "an approximately 50% reduction in COMT mRNA, protein, and enzyme activity levels" (PMID: 23992923). Because only one COMT allele remains, the functional Val158Met (rs4680) polymorphism on the intact allele has an outsized effect. In a cohort of 92 patients, "22q11.2DS subjects with Met allele displayed higher IQ scores in all age groups compared to Val carriers, reaching significance in both adolescents and adults. The Met allele carriers performed better than Val carriers in EF tasks" (PMID: 24853458). A longitudinal imaging study further found that COMT-Met carriers showed greater dorsal prefrontal cortex gray-matter reduction over time, linking COMT genotype to structural brain trajectories predicting psychosis (PMID: 20817203).

  • Ontology: Gene HGNC:2228 (COMT); CHEBI:18243 (dopamine); GO:0042420 (dopamine catabolic process).

Finding 6 — Chromatin-regulatory modifier genes influence conotruncal heart defect risk

Conotruncal CHD occurs in 40–50% of patients, but not all deletion carriers develop it — pointing to modifiers. Whole-genome sequencing of 456 conotruncal-defect cases vs 537 controls (all with 22q11.2DS) identified rare damaging variants in 37 chromatin regulatory genes (including EP400, KAT6A, KMT2C, KMT2D, NSD1, CHD7, PHF21A, EZH2): "we identified 37 chromatin regulatory genes, that may increase risk for conotruncal heart defects in 8.5% of 22q11.2DS cases" (PMID: 37463940). These genes are co-expressed with TBX1 in cardiac progenitor cells and genetically interact with Tbx1 in mice.

Direct experimental confirmation comes from a mouse model: "conditional inactivation of Kmt2d in the Tbx1 lineage in Tbx1-heterozygous mice leads to fully penetrant perinatal lethality and increased incidence of craniofacial dysmorphism, thymus and parathyroid gland hypoplasia, and aortic arch anomalies" (PMID: 42635044). This establishes KMT2D as a bona fide genetic modifier of TBX1 haploinsufficiency.

  • Ontology: GO:0006338 (chromatin remodeling); Genes HGNC:7133 (KMT2D), HGNC:15851 (KMT2C).

Finding 7 — Congenital heart disease is the leading cause of pediatric mortality; mouse models recapitulate core features

"Congenital heart diseases (CHDs) and cardiovascular abnormalities are one of the pillars of clinical diagnosis of 22q11.2 deletion syndrome (22q11.2DS) and still represent the main cause of mortality in the affected children" (PMID: 29663641). As survival improves, the adult population has grown, bringing acquired cardiovascular problems and multisystem comorbidity into focus.

Tbx1-haploinsufficient mice recapitulate the syndrome's core features — craniofacial anomalies, thymus/parathyroid hypoplasia, and aortic arch/conotruncal anomalies — and also CNS phenotypes: "In mice, this paraflocculus/flocculus dysplasia is associated with haploinsufficiency of the Tbx1 gene. Tbx1 haploinsufficiency also leads to impaired cerebellar synaptic plasticity and motor learning" (PMID: 39638997).

Finding 8 — Autosomal dominant, mostly de novo (~90%), with ~50% offspring transmission risk

"The majority of deletions are de novo, with 10% or less inherited from an affected parent" (PMID: 14708107). The recurrent deletion arises via non-allelic homologous recombination (NAHR) between the low-copy-repeat blocks LCR22A–D. Inheritance is autosomal dominant — an affected individual has a ~50% chance of transmitting the deletion. Recurrence risk to unaffected parents is low; independent de novo events have been documented even in first cousins, and germline mosaicism is rare.

Finding 9 — Diagnosis by CMA/FISH/MLPA; prenatal cfDNA with fetal-fraction amplification achieves high PPV

The small size of the microdeletion makes standard prenatal cell-free DNA (cfDNA) screening technically challenging. A cfDNA assay incorporating fetal-fraction amplification screened 379,428 patients; of 76 screen-positives for de novo 22q11.2 microdeletion, "22 (29.7%) had diagnostic testing results available, and all 22 cases were confirmed as true positives, for a PPV of 100% (95% CI 84.6%-100%)" (PMID: 38622914). A multiplex digital-PCR cffDNA assay achieved 73.3% sensitivity / 96.5% specificity (PMID: 37684689). Current professional guidance (SMFM Consult Series #74, 2025) is cautious: "we do not recommend routine general population screening for any microdeletion condition. Patients who choose to undergo cfDNA screening for 22q11.2 deletion specifically should do so only after appropriate pretest counseling" (PMID: 42597105).

Finding 10 — Thymic hypoplasia causes T-cell immunodeficiency, autoimmunity, and atopy; complete athymia requires thymus transplant

Impaired thymus development is central to the immune phenotype: "This thymic dysfunction impairs T-cell development and maturation, leading to a spectrum of T-cell lymphopenia, a restricted T-cell receptor repertoire and defects relating to regulatory T cells. Consequently, patients exhibit increased susceptibility to recurrent infections, particularly of the respiratory tract and a higher prevalence of autoimmune conditions and atopic diseases" (PMID: 41730804). Most patients have partial DiGeorge — mild-to-moderate T-cell lymphopenia that tends to improve with age. A small subset (<1%) have complete athymia, for which "Thymus implantation is the definitive treatment" (PMID: 41902846); allogeneic hematopoietic cell transplantation is an alternative. Impaired T-cell surveillance can permit EBV-associated complications, including chronic facial granulomatous dermatitis and, rarely, early Hodgkin lymphoma (PMID: 42114650; PMID: 41942950).

  • Ontology: HP:0002721 (immunodeficiency); HP:0005359 (thymic hypoplasia); CL:0000084 (T cell); CL:0000815 (regulatory T cell); UBERON:0002370 (thymus).

Finding 11 — Parathyroid/thyroid dysgenesis causes hypocalcemia and thyroid dysfunction; hemizygosity can unmask recessive disease

"Individuals may also present with hypocalcemia and thyroid dysfunction due to impaired parathyroid gland formation and thyroid dysgenesis, respectively" (PMID: 40038168). Neonatal hypocalcemia may present with seizures or tetany and can be refractory to conventional therapy (PMID: 40866089). Uniquely, hemizygosity of the region can unmask recessive disease from a variant on the non-deleted homolog: "Variations in genes on the non-deleted homologous chromosome in the critical 22q11.2 region can further influence phenotypes by revealing recessive diseases. This effect has been documented for several genes in this area, such as SNAP29 and GP1BB" (PMID: 40038168) — e.g., CEDNIK syndrome (SNAP29) and Bernard-Soulier syndrome (GP1BB).

  • Ontology: HP:0002917 (hypocalcemia); HP:0000829 (hypoparathyroidism); UBERON:0001132 (parathyroid gland); UBERON:0002046 (thyroid gland).

Finding 12 — 22q11.2DS markedly elevates the risk of early-onset Parkinson's disease

In a multicenter study of 856 adults with 22q11.2DS: "PD was present in 1.8% (95% CI: 0.9-2.6%) of the sample, 3.4% (95% CI: 2.2-4.6%) when including uncertain PD (clinical diagnosis or suspicion, but not meeting all criteria), and 14.0% (95% CI: 6.9-21.0%) of those aged ≥50 years. Median age at motor onset was 45 (range 20-66) years" (PMID: 39918054). This early onset (median ~45 years vs ~60 in idiopathic PD) has prompted proposals for periodic motor evaluation from age 40. A candidate biomarker exists: salivary monomeric α-synuclein is reduced in parkinsonian 22q11.2DS patients (AUC 0.86 discriminating Park+ from Park−) (PMID: 38661486). A Del(3.0 Mb)/+ mouse shows "reduced axon innervation of dopaminergic neurons into the prefrontal cortex" (PMID: 37238632), a dopaminergic deficit relevant to both parkinsonian and psychiatric phenotypes.

  • Ontology: HP:0001300 (parkinsonism); CL:0000700 (dopaminergic neuron); CHEBI:18243 (dopamine).

Detailed Section Coverage

2. Etiology

  • Primary cause (genetic): Hemizygous recurrent deletion at 22q11.2, most often the ~3 Mb LCR22A–D region (~106 genes); TBX1 haploinsufficiency is the dominant driver of physical phenotypes.
  • Genetic risk factors: The deletion itself is causal and highly penetrant for having the syndrome, though individual features are variably expressed. Modifier genes shape severity: rare damaging variants in chromatin regulators (KMT2D, KMT2C, EP400, NSD1, CHD7, EZH2, etc.) increase conotruncal CHD risk in ~8.5% of cases (PMID: 37463940); COMT Val158Met and PRODH variants modify cognition/psychosis (PMID: 24853458); genes on the non-deleted homolog can act as protective (e.g., a ZFPM2 variant) or unmask recessive disease (PMID: 25981510; PMID: 40038168).
  • Environmental risk factors: None established as necessary — the syndrome is fundamentally genetic. NAHR at the LCR22 repeats occurs sporadically; advanced parental age is not a robust risk factor for this recurrent CNV. Prenatal alcohol exposure and 22q11.2 CNVs may co-occur incidentally in neurodevelopmental cohorts (PMID: 42545840), but no causal environmental trigger is defined.
  • Protective factors: A ZFPM2 variant downstream of TBX1 was proposed as protective against Tetralogy of Fallot in one proband (PMID: 25981510); COMT-Met alleles are relatively protective for cognition.
  • Gene–environment interactions: Not well characterized; the phenotype is largely genetically determined with modifier-gene rather than environmental modulation.

3. Phenotypes

Phenotype Type Frequency Onset HPO term
Conotruncal congenital heart disease (TOF, truncus arteriosus, IAA, VSD) Physical malformation 40–50% Congenital HP:0001636 / HP:0001671
Velopharyngeal insufficiency / cleft palate Physical/functional ~65–70% (palatal) Congenital/childhood HP:0000220 / HP:0000175
T-cell immunodeficiency / recurrent infection Laboratory/clinical ~75% (mostly mild) Neonatal/infancy HP:0005387 / HP:0002719
Hypocalcemia / hypoparathyroidism Laboratory ~50–65% (often neonatal, may recur) Neonatal HP:0002917 / HP:0000829
Intellectual disability / learning disability Behavioral/cognitive Majority; borderline-mild Childhood HP:0001249
Schizophrenia / psychosis Behavioral 20–30% lifetime Adolescence/adulthood HP:0100753
Autism spectrum / ADHD Behavioral Common Childhood HP:0000717 / HP:0007018
Parkinsonism / early-onset PD Clinical sign 1.8% overall; 14% if ≥50 y Adult (median 45 y) HP:0001300
Characteristic craniofacial dysmorphism Physical Common Congenital HP:0001999
Chronic otitis media / hearing loss / airway anomalies Clinical High ENT burden Childhood HP:0000388 / HP:0000365

Expressivity is highly variable even within families; severity ranges from mild to life-threatening. Quality-of-life impact is substantial and lifelong, spanning cardiac, immune, endocrine, cognitive, psychiatric, speech, and ENT domains, requiring multidisciplinary care and structured pediatric-to-adult transition (PMID: 40223294; PMID: 41800660).

4. Genetic / Molecular Information

  • Causal locus/genes: 22q11.2 deletion; TBX1 (HGNC:11592; OMIM 602054) principal driver. Other dosage-sensitive genes: COMT (HGNC:2228), DGCR8 (microprocessor/miRNA biogenesis), CRKL, PRODH, SEPTIN5, RTN4R, ZDHHC8*.
  • Variant class: Structural — recurrent copy-number deletion (LCR22A–D ~3 Mb; LCR22A–B ~1.5 Mb; nested/atypical deletions occur). Not a point mutation; functional consequence is loss of function via haploinsufficiency.
  • Allele frequency: As a recurrent pathogenic CNV, birth prevalence ~1/4,000; depleted in healthy adult population databases (gnomAD-SV) consistent with strong selection.
  • Origin: Predominantly germline de novo (~90%); ~10% inherited (autosomal dominant).
  • Modifier genes: Chromatin regulators (KMT2D etc.), COMT/PRODH, and non-deleted-homolog variants (Findings 5, 6, 11).
  • Chromosomal abnormality: Interstitial microdeletion of 22q11.21; visible by FISH/microarray, not by standard karyotype in most cases.
  • Related dosage disorder: 22q11.21 dosage has been linked to Alzheimer risk in large exome analyses, narrowing to a SCARF2-KLHL22-MED15 region (PMID: 42648288) — illustrating the locus's broad neurologic relevance.

5. Environmental Information

No infectious agent or environmental toxin causes 22q11.2DS; it is a constitutional genetic disorder. Secondary/opportunistic infections (viral, especially EBV; recurrent respiratory pathogens) arise as consequences of T-cell immunodeficiency rather than causes of the syndrome (PMID: 41730804; PMID: 41942950). Lifestyle factors do not contribute to etiology.

6. Mechanism / Pathophysiology — Ordered Causal Chain

1. Recurrent NAHR between LCR22A–D low-copy repeats
      → results in a de novo ~3 Mb hemizygous 22q11.2 deletion (~106 genes)      [PMID 32117416, 14708107]
2. Deletion → haploinsufficiency of dosage-sensitive genes, chiefly TBX1        [PMID 23799583]
3. Reduced TBX1 dosage in pharyngeal ecto/endo/mesoderm
      → dysregulated FGF, retinoic-acid, BMP, and WNT/β-catenin signaling        [PMID 23799583]
4. Aberrant signaling to the rostral neural crest (non-cell-autonomous)
      → defective pharyngeal-arch and neural-crest development                    [PMID 23799583, 40038168]
      ├── BRANCH A → 4th-arch artery / outflow-tract defects
      │        → conotruncal CHD (TOF, truncus, IAA-B)                            [PMID 40038168, 29663641]
      │        → leading cause of pediatric mortality
      ├── BRANCH B → 3rd/4th pouch (thymus) hypoplasia
      │        → impaired T-cell development, restricted TCR repertoire, Treg defect
      │        → immunodeficiency, autoimmunity, atopy, EBV complications         [PMID 41730804]
      ├── BRANCH C → parathyroid (3rd/4th pouch) + thyroid dysgenesis
      │        → hypoparathyroidism → hypocalcemia (seizures/tetany)              [PMID 40038168]
      ├── BRANCH D → palatal / velopharyngeal + craniofacial maldevelopment
      │        → cleft palate, VPI, dysmorphism, ENT disease                      [PMID 40038168, 35645294]
      └── BRANCH E (neuro) → COMT/DGCR8/PRODH dosage + interneuron vulnerability
       → ~50% ↓ COMT activity → altered prefrontal dopamine              [PMID 23992923]
       → VIP+ CGE interneuron bias; reduced DA innervation of PFC
       → intellectual disability, 20–30% schizophrenia, early-onset PD    [PMID 40236134, 39918054, 37238632]
5. Genetic modifiers (chromatin regulators e.g. KMT2D; COMT Val158Met;
   non-deleted-homolog variants) tune severity/penetrance of each branch         [PMID 37463940, 42635044, 24853458]

Upstream vs downstream: The deletion and TBX1 haploinsufficiency are the most upstream events; pharyngeal/neural-crest signaling failure is the key developmental node from which the organ-specific branches diverge. The neuropsychiatric branch is partly independent, driven by dosage of COMT/DGCR8/PRODH and cortical interneuron vulnerability rather than by TBX1 alone — consistent with evidence that the physical phenotype is largely TBX1-attributable while the brain phenotype is multigenic (PMID: 34552467). Changes in brain metabolism from deleted metabolic genes may further contribute to variable brain phenotypes (PMID: 39567195).

  • Cell types (CL): migratory cranial neural crest cell (CL:0000333), T cell (CL:0000084), regulatory T cell (CL:0000815), VIP GABAergic interneuron (CL:4023070), dopaminergic neuron (CL:0000700), cardiac progenitor cell.
  • Biological processes (GO): neural crest cell development (GO:0014032); outflow tract morphogenesis (GO:0003151); thymus development (GO:0048538); parathyroid gland development (GO:0060017); dopamine catabolic process (GO:0042420); chromatin remodeling (GO:0006338).

7. Anatomical Structures Affected

  • Cardiovascular: heart outflow tract, aortic arch / 4th arch arteries (UBERON:0004145), great vessels.
  • Immune/endocrine: thymus (UBERON:0002370), parathyroid glands (UBERON:0001132), thyroid (UBERON:0002046).
  • Craniofacial/upper aerodigestive: palate (UBERON:0001716), velopharynx, middle/inner ear, larynx/airway; characteristic facies.
  • Nervous system: cerebral cortex (prefrontal/dorsal PFC), cerebellum (paraflocculus/flocculus), widespread reductions in brain volume and cortical surface area with increased cortical thickness (PMID: 41358290).
  • Subcellular/molecular compartments: nucleus (transcription-factor and chromatin dysfunction), synapse (dopaminergic/cerebellar synaptic plasticity), mitochondria/metabolism.
  • Lateralization: cardiac and aortic-arch anomalies are frequently right-sided/laterality defects; craniofacial features are typically bilateral.

8. Temporal Development

  • Onset: Congenital (developmental malformations present at birth); immunodeficiency and hypocalcemia manifest neonatally; psychiatric features emerge in adolescence/adulthood; parkinsonism in mid-adulthood (median 45 y).
  • Course: Chronic, lifelong. Partial-DiGeorge immune function tends to improve with age; hypocalcemia can be episodic/recurrent (latent hypoparathyroidism unmasked by stress). Psychiatric and neurodegenerative risks are progressive across the lifespan.
  • Critical periods: Embryonic pharyngeal-arch development (weeks 4–8) for structural defects; adolescence for psychosis risk (surveillance window); age ≥40 for parkinsonism surveillance.

9. Inheritance and Population

  • Prevalence: ~1 in 4,000 live births (~25/100,000); most common microdeletion syndrome. Likely under-ascertained in adults.
  • Inheritance: Autosomal dominant; ~90% de novo, ~10% inherited; ~50% transmission risk from an affected parent.
  • Penetrance/expressivity: Essentially complete penetrance for having some phenotype but highly variable expressivity; no single feature is obligate.
  • Anticipation: Not a repeat-expansion disorder; no true anticipation, though ascertainment bias can mimic it.
  • Germline mosaicism: Rare; recurrence risk to unaffected parents is low.
  • Founder effect / consanguinity: Not applicable — recurrent de novo CNV mediated by ubiquitous LCR22 architecture, not population-specific founder alleles; occurs across all ethnic groups.
  • Sex ratio: Approximately equal (autosomal).

10. Diagnostics

  • First-line molecular diagnosis: Chromosomal microarray (CMA) — highest resolution for deletion size; FISH (TUPLE1/N25 probes) and MLPA are widely used and can detect the recurrent deletion. Standard karyotype is usually normal.
  • Prenatal: cfDNA screening feasible; high PPV with fetal-fraction amplification (PPV 100% in one study, PMID: 38622914); multiplex dPCR cffDNA 73.3%/96.5% sens/spec (PMID: 37684689); confirmatory diagnostic testing (CVS/amniocentesis with CMA/FISH) required. Routine population microdeletion cfDNA screening is not recommended (PMID: 42597105).
  • Ancillary labs/imaging: Serum calcium/PTH; immune panel (T-cell subsets, TREC on newborn screening for SCID/athymia detection); echocardiography; renal ultrasound; brain MRI for research/neurologic indications; panoramic radiograph trabecular analysis as a research bone-health biomarker (PMID: 42277781); salivary α-synuclein as a candidate parkinsonism biomarker (PMID: 38661486).
  • Differential diagnosis: CHARGE syndrome, other conotruncal-anomaly/DiGeorge-spectrum causes (e.g., TBX1 point mutations, chromosome 10p13 deletion), Smith-Magenis syndrome, and other neurodevelopmental CNV syndromes.

11. Outcome / Prognosis

  • Mortality: Congenital heart disease is the leading cause of death in children (PMID: 29663641); complete athymia is life-threatening without transplant.
  • Life expectancy: Reduced but improving; a growing adult population faces acquired cardiovascular disease, psychiatric illness, and neurodegeneration (PMID: 40223294).
  • Morbidity/function: Substantial — cognitive, psychiatric, speech, ENT, immune, and endocrine burdens impair daily functioning; negative psychiatric symptoms link to poorer global and social functioning (PMID: 42585902).
  • Prognostic factors: Severity of CHD; presence of complete athymia; COMT genotype and modifier burden for neurocognition; smaller cerebellar volume relative to syndrome peers predicts lower language scores (PMID: 41358290).

12. Treatment

No cure exists; management is organ-directed and multidisciplinary, per 22q11.2 Society consensus guidelines for children (PMID: 36729053) and adults (PMID: 36729052).

Domain Intervention NCIT-type term
Cardiac Surgical repair of conotruncal defects Cardiac surgery
Endocrine Calcium + active vitamin D (calcitriol); teriparatide for refractory hypocalcemia (PMID: 40866089) Calcium/vitamin D supplementation
Immune Infection prophylaxis, irradiated/CMV-safe blood, live-vaccine caution; cultured thymus tissue implantation for complete athymia; allogeneic HCT alternative (PMID: 41902846; PMID: 39303894) Thymus transplantation
Psychiatric Antipsychotics, standard psychiatric care; caution given COMT dosage Antipsychotic therapy
ENT/speech Palatoplasty, VPI surgery, otologic/airway management, speech therapy (PMID: 41800660) Speech therapy / palatoplasty
Supportive Developmental, educational, and rehabilitative services Rehabilitation therapy

Immunological management is standardized in dedicated guidelines (PMID: 36648576). Pharmacogenomic caution around COMT-metabolized drugs is biologically plausible but not yet guideline-mandated. No approved gene/RNA therapy exists; mouse studies have shown pharmacological rescue of single-gene cortical phenotypes as proof of concept (PMID: 34552467).

13. Prevention

  • Primary prevention: Not possible (constitutional de novo genetic event). Genetic counseling for affected adults (50% transmission risk); reproductive options include preimplantation genetic testing (PGT) and prenatal diagnosis.
  • Secondary prevention: Newborn SCID/TREC screening detects athymia; early echocardiography and calcium monitoring enable timely intervention.
  • Tertiary prevention: Structured lifelong surveillance per consensus guidelines to prevent complications (cardiac, endocrine, immune, psychiatric); proposed motor evaluation from age 40 for parkinsonism.
  • Counseling: Genetic counseling is central (recurrence risk, transmission, variable expressivity).

14. Other Species / Natural Disease

  • Taxonomy/orthologs: Tbx1 is conserved (mouse Tbx1, NCBI Gene 21380; human TBX1 NCBI Gene 6899). No naturally occurring 22q11.2DS-equivalent contiguous deletion is described in companion animals; the disorder is modeled experimentally rather than occurring naturally. Evolutionary conservation of the TBX1 pharyngeal program underpins cross-species model validity.

15. Model Organisms

  • Mouse (primary model): Tbx1 heterozygous and Df(16)A / Del(3.0Mb) deletion mice recapitulate craniofacial anomalies, thymus/parathyroid hypoplasia, aortic-arch/conotruncal anomalies, cerebellar paraflocculus/flocculus dysplasia with motor-learning deficits, and reduced prefrontal dopaminergic innervation (PMID: 39638997; PMID: 37238632). Kmt2d;Tbx1 compound models demonstrate modifier gene action (PMID: 42635044).
  • Model types available: knockout, conditional/lineage-specific, and deletion (Df) mice.
  • Strengths: Faithfully reproduce physical malformations and specific neurobehavioral endophenotypes; enable dissection of dosage and modifier effects, and pharmacological rescue proof-of-concept (PMID: 34552467).
  • Limitations: The multigenic human brain phenotype (schizophrenia, complex cognition) is only partially captured; species differences in gene content of the syntenic region and in cortical interneuron biology limit full recapitulation.

Mechanistic Model / Interpretation

The unifying interpretation is that a single upstream lesion — the 22q11.2 deletion — produces a fan of downstream phenotypes through two partly separable routes. The TBX1-dependent route explains the "physical" DiGeorge/VCFS features: reduced TBX1 dosage perturbs FGF/RA/BMP/WNT signaling in the pharyngeal apparatus and its cross-talk with neural crest, and the affected pharyngeal pouches/arches map cleanly onto the affected organs (outflow tract, thymus, parathyroid, palate, ear/airway). The TBX1-independent, multigenic route explains the "brain" phenotypes: dosage of COMT, DGCR8, PRODH and others, together with intrinsic vulnerability of VIP+ CGE-derived interneurons and reduced prefrontal dopaminergic innervation, drives intellectual disability, the 20–30% schizophrenia risk, and early-onset parkinsonism. Overlaid on both routes is a modifier layer — chromatin regulators (KMT2D and network), COMT Val158Met, and variants unmasked on the intact homolog — that converts uniform haploinsufficiency into the syndrome's hallmark variable expressivity. This two-route-plus-modifier architecture reconciles why physical features are largely TBX1-attributable and highly recurrent across models, while neuropsychiatric outcomes are heterogeneous and only partially modeled in mice.

Evidence Base

PMID Contribution Evidence type
23799583 TBX1 as principal driver; pharyngeal/neural-crest signaling Human/model review
32117416 Deletion size (~3 Mb), ~106 genes Review
35645294 Prevalence ~1/4000; deletion sizes; craniofacial genetics Review
40038168 Neural crest → CHD/palate; hypocalcemia/thyroid; recessive unmasking Review
42585902 20–30% schizophrenia risk; negative symptoms Human cohort
40236134 VIP+ CGE interneuron vulnerability Genomic/cellular
42020136 4.3% of TOF carry deletion; adult under-recognition Human cohort
23992923 ~50% ↓ COMT mRNA/protein/activity; psychosis haplotypes Human/molecular
24853458 COMT Val158Met modifies IQ/EF (n=92) Human cohort
37463940 37 chromatin regulators modify CHD (8.5%) Human WGS
42635044 Kmt2d modifies Tbx1 haploinsufficiency Mouse model
29663641 CHD as leading pediatric mortality Review
39638997 Tbx1 cerebellar/motor phenotype Mouse model
14708107 ~90% de novo; independent de novo events Human case
38622914 cfDNA fetal-fraction amplification PPV 100% Human screening
42597105 SMFM cfDNA guidance Guideline
41730804 Thymic dysfunction → immunodeficiency/autoimmunity/atopy Review
41902846 Thymus implantation for athymia Human cohort
39918054 PD prevalence; onset median 45 y (n=856) Human cohort
37238632 Reduced PFC dopaminergic innervation Mouse model

Limitations and Knowledge Gaps

  1. No primary data analysis was performed — this report synthesizes literature and curated database identifiers; frequency figures are approximate and drawn from heterogeneous cohorts.
  2. Ontology IDs (MONDO, OMIM, HPO, GO, CL, UBERON, CHEBI, NCIT) were assigned from domain knowledge, not programmatically verified against current ontology releases; they should be cross-checked before database ingestion.
  3. Frequency/penetrance estimates vary by ascertainment (cardiac clinics vs psychiatric vs population), and adult under-recognition biases prevalence downward.
  4. Neuropsychiatric mechanism remains incompletely resolved — the relative contributions of COMT, DGCR8, PRODH, interneuron biology, and metabolic changes are not fully quantified, and human mechanistic evidence is largely correlational.
  5. Biomarkers (salivary α-synuclein, mandibular trabecular FD) are exploratory, based on small samples (n≈10–11 per group) and require validation.
  6. Treatment evidence base is limited — consensus guidelines are largely expert-opinion given the rarity and heterogeneity of the syndrome; no disease-modifying therapy exists.

Proposed Follow-up Experiments / Actions

  1. Verify all ontology term IDs against current MONDO/HPO/GO/CL/UBERON/NCIT releases before knowledge-base ingestion.
  2. Assemble a per-phenotype frequency table with confidence intervals from the largest available registries (22q11.2 Society, ENIGMA-22q, International 22q11.2 Brain Behavior Consortium) rather than narrative-review estimates.
  3. Systematically catalog modifier variants (chromatin regulators, COMT/PRODH, non-deleted-homolog variants) with effect sizes for genotype–phenotype annotation.
  4. Validate candidate biomarkers — salivary α-synuclein for parkinsonism and imaging-derived cerebellar/cortical deviation scores for cognitive prognosis — in larger prospective cohorts.
  5. Curate the mouse-model phenotype-recapitulation matrix (Tbx1, Df(16)A, Del(3.0Mb), Kmt2d compounds) mapping each mouse phenotype to its human HPO counterpart with recapitulation confidence.
  6. Track emerging trials (ClinicalTrials.gov) for thymus tissue implantation, psychiatric interventions, and any gene/RNA-directed approaches, capturing NCT identifiers.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 39
Resolved 39
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 39
On topic 28
Off topic 0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 44
Resolved 38
Unresolved (possible confabulation) 0
Obsolete 1
Unverifiable 5
Terms whose name was checked 27
Terms named correctly 15
Terms named as a different term 6
Terms whose name is worth a second look 6

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • HP:0100753 (2 mentions) - the report calls it "schizophrenia", "Adolescence/adulthood"; HP calls it Schizophrenia
  • UBERON:0002370 (2 mentions) - the report calls it "thymus", "Immune/endocrine: thymus"; UBERON calls it thymus**
  • HP:0001300 (2 mentions) - the report calls it "parkinsonism", "Adult (median 45 y)"; HP calls it Parkinsonism
  • HP:0001249 (1 mention) - the report calls it "Childhood"; HP calls it Intellectual disability
  • HP:0001999 (1 mention) - the report calls it "Congenital"; HP calls it Abnormal facial shape
  • UBERON:0001716 (1 mention) - the report calls it "Craniofacial/upper aerodigestive: palate"; UBERON calls it secondary palate**

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

  • CL:4023070 (obsolete caudal ganglionic eminence derived GABAergic cortical interneuron) (2 mentions) - replaced by CL:4023064

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

  • MONDO:0008644 (2 mentions) - the report calls it "22q11.2 deletion syndrome"; MONDO calls it velocardiofacial syndrome, and lists "deletion 22q11.2 syndrome" among its other names
  • CL:0000333 (2 mentions) - the report calls it "migratory cranial neural crest cell"; CL calls it migratory neural crest cell
  • CL:0000617 (1 mention) - the report calls it "GABAergic interneuron"; CL calls it GABAergic neuron
  • CL:4023070 (2 mentions) - the report calls it "VIP GABAergic cortical interneuron"; CL calls it obsolete caudal ganglionic eminence derived GABAergic cortical interneuron, and lists "CGE cortical interneuron" among its other names
  • HP:0005359 (1 mention) - the report calls it "thymic hypoplasia"; HP calls it Aplasia of the thymus, and lists "Athymia" among its other names
  • HP:0002917 (2 mentions) - the report calls it "hypocalcemia"; HP calls it Hypomagnesemia

Terms named inconsistently

The report gives these identifiers more than one name of its own:

  • HP:0100753 - called "schizophrenia", "Adolescence/adulthood"
  • UBERON:0002370 - called "thymus", "Immune/endocrine:** thymus"
  • HP:0001300 - called "parkinsonism", "Adult (median 45 y)"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.

Perplexity ▸
Executive Summary
sonar-deep-research 54 citations 2026-02-03T19:03:06.369871

Executive Summary

22q11.2 Deletion Syndrome (22q11.2DS), historically recognized as DiGeorge syndrome and velocardiofacial syndrome, represents one of the most common human chromosomal microdeletions, occurring in approximately 1 in 4,000 live births[1][2][3]. The syndrome results from a hemizygous microdeletion spanning 1.5 to 3.0 megabases on chromosome 22, encompassing more than 30 protein-coding genes and multiple non-coding regulatory elements[1][2][3]. This chromosomal lesion disrupts the coordinated development of structures derived from the pharyngeal apparatus and neural crest tissues, leading to a highly heterogeneous constellation of clinical manifestations affecting multiple organ systems including the heart, immune system, endocrine glands, skeleton, and central nervous system[1][2][3]. The pathophysiology of 22q11.2DS reflects not a single gene defect but rather the cumulative haploinsufficiency of multiple genes acting on common cellular mechanisms during critical developmental windows, with primary causality attributed to the TBX1 gene and modifying contributions from genes such as COMT, PRODH, DGCR8, and CLDN5[2][3][4]. Recent molecular research has identified disruptions in brain metabolism, mitochondrial function, microRNA biogenesis, and blood-brain barrier integrity as central mechanisms underlying the neuropsychiatric vulnerability observed in 22q11.2DS patients, particularly the markedly elevated risk for schizophrenia spectrum disorders[5][6][7][8]. This comprehensive report synthesizes current understanding of 22q11.2DS pathophysiology by integrating molecular, cellular, developmental, and systems-level mechanisms that collectively explain the diverse and variable clinical phenotypes characterizing this complex genetic disorder.

Chromosomal Architecture and Genetic Basis of 22q11.2 Deletion Syndrome

Structural Organization of the Deleted Region

The 22q11.2 region exhibits a unique genomic architecture defined by the presence of four major low-copy-number repeats (LCRs) designated LCR22A, LCR22B, LCR22C, and LCR22D[2][3]. These repetitive elements, ranging in size from approximately 200 to 300 kilobases, flank distinct genomic intervals and predispose the region to nonallelic homologous recombination, the primary mechanism by which 22q11.2 deletions arise[3][8]. The most common deletion encompasses the approximately 3-megabase interval flanked by LCR22A and LCR22D, affecting approximately 85 percent of individuals with the syndrome[3][8]. This typical "proximal" deletion is hemizygous in nature, meaning affected individuals retain only a single copy of genes within this region rather than the normal pair of homologous chromosomes[1][2][3]. Approximately 10 percent of cases present with smaller nested deletions between LCR22A and LCR22B, termed the 1.5-megabase minimal critical region, while distal deletions involving the LCR22B-D or LCR22C-D intervals account for a smaller proportion of cases[3][8]. The complex LCR architecture of chromosome 22q11.2 appears to function as a chromatin assembly hub with epigenetic regulatory properties, with emerging evidence suggesting that these repetitive elements regulate expression of more than 300 genes located at distinct chromosomal locations beyond the deleted region itself[39]. This long-range regulatory capacity may explain some of the remarkable phenotypic variability observed even among individuals carrying identical deletion breakpoints.

The 22q11.2 region contains more than 45 protein-coding genes, though only approximately 30 to 40 of these undergo complete hemizygous loss in typical proximal deletions[1][2][3]. The deleted region also encompasses seven microRNAs, 38 non-coding RNAs, and 53 pseudogenes[14], representing a complex assemblage of regulatory elements whose disruption contributes to the multisystem pathology of the syndrome[2]. Key protein-coding genes within the minimal critical deleted region include TBX1, COMT, PRODH, DGCR8, CRKL, CLDN5, HIRA, CDC45, ARVCF, and others[1][2][14]. These genes exhibit distinct patterns of tissue-specific and developmental stage-specific expression, suggesting that different genes contribute to different phenotypic features through both overlapping and distinct cellular mechanisms[11][14]. The deletion extends beyond the minimal critical region in many patients, encompassing additional genes such as SMARCB1, which when deleted carries increased risk for malignant rhabdoid tumors[6][14].

TBX1 as the Central Candidate Gene

Among the genes within the deleted 22q11.2 region, T-box transcription factor 1 (TBX1) has emerged as the primary candidate responsible for most of the characteristic clinical features of 22q11.2DS, particularly the cardiac, thymic, parathyroid, and craniofacial abnormalities[2][41]. TBX1 encodes a T-box family transcription factor that plays essential roles during early embryogenesis in regulating the development of structures derived from the pharyngeal apparatus[2][3][41]. During the critical developmental window of embryonic days 9.5 to 11.5 in mice (corresponding approximately to weeks 7 to 8 of human gestation), TBX1 is expressed at high levels in the pharyngeal mesoderm, ectoderm, and endoderm, as well as in the surrounding head mesenchyme[2][3][41]. This spatiotemporal expression pattern precisely overlaps with the developmental processes that generate the cardiac outflow tract, aortic arch arteries, thymus, parathyroid glands, and craniofacial structures[2][3][41]. Heterozygous loss-of-function mutations affecting TBX1 specifically have been identified in rare cases of DiGeorge-like phenotypes, demonstrating that haploinsufficiency of this single gene can recapitulate many features of the full syndrome[2][41]. Complete loss of TBX1 function in knockout mouse models results in embryonic lethality with manifestation of the full spectrum of 22q11.2DS features including persistent truncus arteriosus, cleft palate, and complete absence of the thymus and parathyroid glands[2][3].

Conditional mutagenesis studies employing tissue-specific deletion of TBX1 have revealed that this gene operates through non-autonomous mechanisms requiring its expression in multiple tissue types for proper development[2][3]. Deletion of TBX1 specifically in the mesoderm recapitulates cardiac, thymic, and parathyroid defects, while deletion in the pharyngeal surface ectoderm or endoderm produces overlapping but distinct phenotypes[2][3]. These findings demonstrate the complexity of TBX1 function and suggest that the characteristic features of 22q11.2DS arise from disrupted developmental processes requiring TBX1 expression across multiple cell types and tissue layers[2]. At the cellular level, TBX1 haploinsufficiency has been shown to impair the proliferation and premature differentiation of progenitor cells, reduce neural crest cell patterning, and disrupt microvascular development within the developing brain[2][3][8]. Recent metabolomic studies have identified that TBX1 haploinsufficiency causes brain metabolic imbalance, including elevated levels of methylmalonic acid—a highly neurotoxic metabolite—and disruption of glutamine-glutamate and fatty acid metabolism[7][26]. Notably, vitamin B12 supplementation has demonstrated the ability to rescue certain brain and behavioral anomalies in TBX1 mutant mice, suggesting that targeting the metabolic consequences of TBX1 haploinsufficiency may offer therapeutic potential[7].

Developmental Pathophysiology: Disruption of Pharyngeal Arch Development

Neural Crest Cell Migration and Differentiation Defects

The pathophysiology of 22q11.2DS fundamentally reflects disrupted development of structures derived from the pharyngeal apparatus, which receives cellular contributions from three embryonic germ layers—the endoderm, mesoderm, and ectoderm—as well as from neural crest cells that delaminate from the closing neural tube[3][8][19]. The neural crest cells that contribute to the pharyngeal region originate from the cranial neural folds at the level of the hindbrain and migrate ventrally into the pharyngeal arches where they differentiate into diverse cell types including skeletal elements, smooth muscle, connective tissue, and cells contributing to heart development[3][19]. During this critical developmental period, numerous gene products including TBX1 orchestrate the migration, survival, proliferation, and differentiation of neural crest cells through complex signaling interactions[3][19]. Disruption of neural crest cell development in 22q11.2DS arises not primarily from direct loss of TBX1 function within the neural crest cells themselves—indeed, TBX1 is not expressed in neural crest cells—but rather from impaired development of the pharyngeal epithelium and mesenchyme that normally provide supportive signals for neural crest cell patterning and migration[2][3][8].

The paradoxical non-cell-autonomous mechanism by which 22q11.2DS disrupts neural crest development highlights the complex tissue interactions required for proper pharyngeal arch development[2][3][8]. Specifically, neural crest cell patterning is affected in conditional mutants with TBX1 deletion in both the pharyngeal surface ectoderm and the second heart field, despite the absence of TBX1 expression within the neural crest population itself[2][3]. This implies that proper differentiation and signaling output from ectodermal and mesenchymal tissues requires TBX1 function to establish the correct molecular environment for neural crest cell guidance[2][3]. The affected cellular processes include alterations in the expression of guidance cues such as morphogens and transcription factors within the pharyngeal tissues that normally direct neural crest cell migration, survival, and phenotypic specification[2][3][19]. Additionally, the epithelial-to-mesenchymal transition, a process requiring coordinated changes in cell adhesion and cytoskeletal organization, appears to be disrupted in the context of TBX1 haploinsufficiency, potentially affecting both the transition of pharyngeal endoderm into mesenchymal tissue and the behavior of migrating neural crest cells[3].

Pharyngeal Arch Derivatives and Multisystem Involvement

The tissue disruptions consequent to abnormal neural crest development and impaired TBX1 signaling in 22q11.2DS directly affect development of the following pharyngeal arch derivatives[2][3][19]. The third pharyngeal pouch gives rise to the thymus gland and inferior parathyroid glands through interactions between pharyngeal endoderm and neural crest-derived mesenchyme[3][9][12]. Normal development of these structures depends critically on proper mesenchymal cell development and the establishment of appropriate tissue interactions, processes disrupted by haploinsufficiency of genes including TBX1[3][9][12]. The fourth pharyngeal arch contributes to the cardiac outflow tract through both neural crest cell populations and second heart field mesoderm[3][19]. The cardiac neural crest specifically contributes to septation and remodeling of the outflow tract, development of the aortic arch arteries, and formation of valve mesenchyme[2][3][19]. Disruption of this process through multiple mechanisms—including impaired migration, survival, proliferation, or proper differentiation of neural crest cells—results in the conotruncal cardiac defects characteristic of 22q11.2DS[2][3][19].

The craniofacial structures of the first and second pharyngeal arches derive from both neural crest cells and pharyngeal mesoderm, with skeletal elements arising from these tissues under the control of multiple transcription factors including TBX1[2][3][38]. The palatal abnormalities observed in 22q11.2DS, including cleft palate and velopharyngeal insufficiency, reflect disrupted palatogenesis resulting from impaired mesodermal development and mesenchymal-epithelial interactions[2][3][19]. Similarly, the distinctive craniofacial features including micrognathia, abnormal ear morphology, and characteristic facial dysmorphism reflect alterations in neural crest-derived skeletal development and tissue remodeling[2][3][38]. The pharyngeal mesoderm also gives rise to muscles of the head and pharynx, and disruption of this tissue's development contributes to abnormalities in muscle development and innervation observed in 22q11.2DS patients[2][3].

Cardiac Pathophysiology: Conotruncal Defects and Neural Crest Cell Dysfunction

Cellular and Molecular Mechanisms of Cardiac Malformations

The cardiac defects observed in 22q11.2DS represent some of the most clinically significant manifestations of the syndrome, occurring in approximately 75 percent of affected individuals[31]. These defects reflect fundamental disruption of two critical developmental processes: neural crest cell contribution to cardiac outflow tract development and second heart field contribution to cardiac morphogenesis[2][3][19]. The cardiac neural crest is a population of cells that delaminate from the caudal midbrain and cranial hindbrain and migrate through the pharyngeal arches to reach the developing heart, where they contribute to formation of the cardiac outflow tract, aortic arch arteries, and portions of the heart's connective tissue[2][3][19]. During the period of active neural crest contribution to the heart, the cells migrate through the pharyngeal tissue, undergo complex interactions with endodermal and mesodermal tissues, and then enter the outflow tract where they participate in outflow tract septation—the process by which a single arterial trunk is divided into separate aortic and pulmonary arteries[2][3][19].

Multiple molecular mechanisms contribute to impaired cardiac neural crest cell development in 22q11.2DS[2][3][19]. TBX1 haploinsufficiency disrupts the development of pharyngeal mesenchyme that normally provides supportive signals to migrating neural crest cells[2][3]. Additionally, haploinsufficiency of DGCR8, which encodes a protein essential for microRNA biogenesis, results in neural crest cell-specific cardiovascular defects including persistent truncus arteriosus, interrupted aortic arch, and ventricular septal defects[2][19]. The mechanism involves elevated apoptosis of neural crest cells in the caudal pharyngeal arches immediately prior to their entry into the outflow tract, suggesting that proper miRNA processing is required for neural crest cell survival during this critical developmental window[2][19]. Similarly, disruption of CRKL, an adaptor protein in receptor tyrosine kinase signaling, causes cardiovascular, craniofacial, and glandular defects characteristic of 22q11.2DS by disrupting signal transduction cascades essential for neural crest cell function[2][19].

The second heart field, a population of mesenchymal progenitor cells located in the pharyngeal mesoderm, contributes to the myocardium of the right ventricle and outflow tract through a process of sequential addition of cells to the growing heart tube[2][3][19]. Proper remodeling of the outflow tract requires reciprocal interactions between the neural crest and second heart field, processes dependent on TBX1 and other 22q11.2-encoded proteins[2][3]. TBX1 haploinsufficiency disrupts this interaction, leading to misspecification of the outflow tract along its proximal-distal axis and resulting in ectopic expression of transforming growth factor-β2 and inappropriate mesenchymal transformation of the endocardium[2][3][19]. The excess transforming growth factor-β signaling appears to disrupt the ability of neural crest cells to properly septate the outflow tract and establish normal cardiac architecture[2][3][19].

Specific Cardiac Defects and Their Molecular Bases

The specific cardiac defects associated with 22q11.2DS reflect these developmental disruptions and include several distinct phenotypes[1][2][3][21][24]. Interrupted aortic arch type B, the most specific cardiovascular defect associated with 22q11.2DS, occurs in approximately 50 percent of patients with conotruncal defects and likely results from aplasia of the left fourth pharyngeal artery—a structure that would normally form the ascending aorta[2][3][21]. Tetralogy of Fallot, comprising a ventricular septal defect, right ventricular hypertrophy, pulmonary stenosis, and right-to-left shunt, occurs in approximately 16 percent of patients with conotruncal defects and reflects defective development of the pulmonary infundibulum and improper septation of the outflow tract[2][3][21]. Truncus arteriosus, in which a single arterial trunk arises from the heart rather than separate aortic and pulmonary arteries, occurs in approximately 34 percent of patients with conotruncal defects and represents failure of the neural crest cells to properly septate the outflow[2][3][21]. Ventricular septal defects, holes in the ventricular septum allowing abnormal shunting of blood between right and left ventricles, occur frequently in 22q11.2DS[1][2][3][21]. Right aortic arch, in which the aorta arises from the right side of the heart rather than the left, occurs in approximately 20 percent of individuals with 22q11.2DS and may or may not cause significant hemodynamic compromise[2][41].

These cardiac defects directly result in pathophysiological consequences including reduced oxygen delivery to peripheral tissues due to right-to-left shunting of deoxygenated blood, increased workload on the right ventricle leading to potential right heart failure, and in severe cases, cyanosis (bluish discoloration of the skin and lips due to insufficient oxygenation)[1][2][3]. Infants with severe conotruncal defects typically require surgical correction early in life to maintain adequate systemic circulation[1][2][3][24]. The embryological events leading to these defects occur during approximately weeks 4 to 8 of human gestation, representing a critical window of vulnerability to disruption by 22q11.2 deletion[2][3].

Immunological Pathophysiology: Thymic Hypoplasia and Altered T-Cell Development

Thymic Developmental Defects and Mesenchymal Cell Dysfunction

Thymic hypoplasia or aplasia represents one of the most characteristic and clinically significant features of 22q11.2DS, occurring in 60 to 70 percent of affected individuals[2][9]. The thymus gland, located beneath the breastbone in the anterior chest, serves as the primary lymphoid organ in which T lymphocytes undergo development, selection, and maturation—processes essential for adaptive immune function[2][9][12]. The thymic anlage and inferior parathyroid glands both develop within the third pharyngeal pouch during weeks 7 to 8 of human gestation, derived from complex interactions between pharyngeal endoderm and neural crest-derived mesenchyme[3][9][12]. The developmental defects in thymic tissue begin at this early stage of thymic organogenesis and reflect primarily defective development of the thymic stromal cell population rather than defects in T-cell lymphopoiesis per se[2][9][12].

Recent single-cell RNA sequencing of both murine and human thymuses from 22q11.2DS patients has revealed that the thymic hypoplasia reflects altered development of thymic mesenchymal cells, with disrupted biological pathways involving extracellular matrix assembly and structure, collagen production, fibril organization, and vascular development[9][39]. Specifically, TBX1 is not expressed directly in the thymic epithelial cells or thymocytes but rather in the mesenchymal cells surrounding the third pharyngeal pouch[2][12]. Reduced TBX1 function impairs development of neural crest-derived mesenchymal cells that normally support thymic stromal cell specification and organization[2][9][12]. This demonstrates again the non-cell-autonomous mechanism by which 22q11.2 deletion disrupts development—mesenchymal defects indirectly compromise thymic epithelial cell development and ultimately the proper environment for T-cell maturation[2][9][12]. The reduced thymic size directly limits the output of newly developed T lymphocytes (thymic export), leading to peripheral T-cell lymphopenia—a reduction in circulating T-cell numbers below normal age-matched levels[2][9].

Complete DiGeorge syndrome, characterized by complete absence of thymic tissue and profound T-cell lymphopenia requiring thymic transplantation, affects fewer than 1 percent of individuals with 22q11.2DS[2][9][12]. The vast majority of patients exhibit partial DiGeorge syndrome with variable degrees of thymic hypoplasia and T-cell lymphopenia, which often improves with age through a process termed spontaneous immune reconstitution[2][9]. In these patients, residual thymic tissue, although reduced in size, remains capable of generating T lymphocytes, and the peripheral T-cell pool can expand through homeostatic proliferation of existing T cells, gradually restoring immune competence over years to decades[2][9].

Altered T-Cell Homeostasis and Functional Consequences

The reduced thymic output in 22q11.2DS leads to remarkable adaptive changes in peripheral T-cell populations that have important consequences for immune function and disease susceptibility[2][9]. Thymic hypoplasia leads to homeostatic proliferation of existing T cells as the immune system attempts to maintain peripheral T-cell numbers required for immune protection[2][9]. This compensatory mechanism results in several characteristic alterations to T-cell populations including a restricted T-cell receptor repertoire, altered CD4:CD8 ratios with relative increases in CD8+ T cells, skewing toward a Th2-dominant immune phenotype, and reduced numbers of naive T cells combined with increased proportions of memory T cells[2][9][20]. The altered T-cell homeostasis contributes to both increased susceptibility to infections and paradoxically elevated risk of autoimmune disorders—a striking feature of 22q11.2DS that initially seems contradictory but reflects fundamental defects in central tolerance mechanisms[2][9][20].

The central tolerance process, which occurs in the thymic medulla, involves presentation of self-antigens to developing thymocytes by specialized thymic epithelial cells and dendritic cells, resulting in deletion of autoreactive T cells (negative selection)[2][12]. The defective thymic selection processes in 22q11.2DS, resulting from reduced medullary tissue volume and impaired thymic epithelial cell function, allow autoreactive T cells to escape into the peripheral circulation[2][20]. Additionally, reduced thymic epithelial cell output of regulatory T cells—immunosuppressive T cells that maintain peripheral tolerance—may contribute to the increased autoimmunity[2][9][20]. The result is an immune system characterized by impaired protection against infections due to low T-cell numbers and altered T-cell function, combined with increased risk of autoimmune manifestations including autoimmune thyroiditis (occurring in 10-15 percent of patients), immune cytopenias, autoimmune enteropathy, hepatitis, and nephrotic syndrome[2][9].

B-Cell and Mast Cell Dysfunction

Beyond T-cell abnormalities, 22q11.2DS affects multiple other immune cell populations[2][9][39]. B lymphocytes, which produce antibodies as part of humoral immune responses, show altered development and function in 22q11.2DS[2][9]. Recent RNA sequencing studies of peripheral blood B cells from 22q11.2DS patients reveal altered gene expression patterns likely resulting from epigenetic changes in genes both within and outside the 22q11.2 region[39]. Haploinsufficiency of miR-185, a microRNA encoded within the deleted region, leads to increased Bruton's tyrosine kinase (BTK) expression in B cells, resulting in elevated autoantibody production[2][12][39]. Mast cells, tissue-resident immune cells involved in allergic and inflammatory responses, also display altered transcriptional programs in 22q11.2DS[39]. Broader systemic changes including increased vascular permeability and a disrupted blood-brain barrier further compromise immune function and contribute to the elevated risk of allergic and neuroinflammatory complications observed in these patients[2][39][44].

Endocrine Pathophysiology: Parathyroid and Thyroid Dysfunction

Parathyroid Gland Hypoplasia and Hypocalcemia

Hypocalcemia—a reduction in serum calcium levels—represents one of the most characteristic and potentially life-threatening complications of 22q11.2DS, reflecting profound dysfunction of the parathyroid glands[1][2][20][23]. The four parathyroid glands, small endocrine organs located behind the thyroid in the neck, regulate serum calcium and phosphorus levels through secretion of parathyroid hormone (PTH), a hormone that acts to increase serum calcium by promoting renal calcium reabsorption, enhancing renal production of active vitamin D, and stimulating osteoclastic bone resorption[2][20][23]. In 22q11.2DS, the parathyroid glands develop from the third pharyngeal pouch in association with thymic tissue, derived from interactions between pharyngeal endoderm and neural crest-derived mesenchyme[3][20][23]. TBX1 haploinsufficiency impairs this developmental process, frequently resulting in hypoplastic parathyroid glands that are smaller than normal and produce insufficient PTH[2][3][20][23].

Hypocalcemia in 22q11.2DS typically becomes manifest in the neonatal period or early infancy, though the severity and timing of presentation vary significantly among affected individuals[1][2][20]. The primary mechanism involves hypoparathyroidism—deficient parathyroid hormone production and secretion—leading to inadequate renal calcium reabsorption and impaired vitamin D metabolism[2][20][23]. However, recent clinical studies have revealed that hypoparathyroidism in 22q11.2DS is not absolute but rather represents impaired PTH reserve and relative parathyroid insufficiency, with variable and often inadequate PTH responses to hypocalcemic stimuli[20][23]. Additionally, hypothyroidism—reduced thyroid hormone production—appears to contribute to hypocalcemia in 22q11.2DS, likely through effects on vitamin D metabolism and renal handling of calcium[20][23]. Hypomagnesemia—deficiency of serum magnesium—also frequently accompanies hypocalcemia in these patients and may further suppress PTH secretion and cause end-organ PTH resistance, creating a synergistic effect that deepens hypocalcemia[20][23].

The clinical manifestations of hypocalcemia reflect the critical role of calcium in neuromuscular function and include tetany (involuntary muscle contractions), paresthesias (abnormal tingling sensations), carpopedal spasm (tightening of hands and feet), and seizures—particularly in infants[1][2][20]. Severe or prolonged hypocalcemia can be life-threatening due to cardiac arrhythmias resulting from altered cardiac electrophysiology[2][20]. The lifetime prevalence of hypocalcemia in adults with 22q11.2DS is high, with studies documenting that most patients experience at least one episode of documented hypocalcemia during their lifetime[20][23]. Management typically involves calcium supplementation and active vitamin D therapy, though some patients eventually achieve normalization of calcium levels, presumably due to compensatory improvement in parathyroid hormone production over time[1][2][20].

Thyroid Autoimmunity and Neoplastic Risk

Beyond the parathyroid dysfunction, patients with 22q11.2DS exhibit significantly elevated rates of thyroid autoimmunity and thyroid malignancy compared to the general population[32][35]. Autoimmune thyroid disease occurs in approximately 21.9 percent of 22q11.2DS patients before age 18, with Hashimoto's thyroiditis (autoimmune hypothyroidism) representing the majority of cases followed by Graves' disease (autoimmune hyperthyroidism)[32]. The increased risk of thyroid autoimmunity in 22q11.2DS reflects the broader pattern of autoimmune disease susceptibility in this population resulting from impaired central tolerance and altered T-regulatory cell function[2][32]. Defective thymic selection allowing autoreactive T cells specific for thyroid peroxidase and thyroglobulin autoantigens to escape into the peripheral circulation, combined with reduced numbers of regulatory T cells, creates a permissive environment for development of autoimmune thyroiditis[2][9][32].

Additionally, 22q11.2DS patients carrying deletions that include the SMARCB1 gene face increased risk of malignant rhabdoid tumors[6][14], and emerging evidence suggests elevated risk of thyroid neoplasms in the context of TBX1 haploinsufficiency and thyroid autoimmunity[32]. The mechanistic link between thyroid autoimmunity and thyroid cancer development likely involves chronic inflammatory signaling, altered expression of developmental regulators affecting thyroid cell fate, and potentially increased cell proliferation and transformation in response to sustained tissue inflammation[32]. Close surveillance of thyroid status through periodic ultrasonography and measurement of thyroid function and autoantibodies is therefore recommended for 22q11.2DS patients[32].

Neuropsychiatric Pathophysiology: Brain Development and Psychiatric Disease Risk

Cortical Development and Neurogenesis Disruption

Beyond the cardiac and immunological manifestations that initially brought attention to DiGeorge syndrome, accumulating evidence reveals that 22q11.2DS profoundly affects brain development and function, establishing a markedly elevated risk for psychiatric illness including schizophrenia, autism spectrum disorders, attention-deficit/hyperactivity disorder, anxiety disorders, and depression[2][3][5][10][11][25][27]. The pathophysiological basis of these neuropsychiatric manifestations reflects disruptions of multiple developmental processes in the brain including neurogenesis, neural migration, synaptogenesis, and subsequent circuit maturation[2][3][5][10]. Diminished dosage of the genes deleted in 22q11.2DS specifically compromises neurogenesis and subsequent differentiation in the cerebral cortex[10][49]. Studies of mouse models have demonstrated that the deletion disrupts proliferation of basal progenitors—a population of intermediate neural progenitor cells that give rise to cortical projection neurons—with relative sparing of apical progenitors[10][49]. This selective disruption of basal progenitor proliferation results in altered frequency and laminar distribution of cortical neurons, particularly affecting layer 2/3 projection neurons that are critical for intra-cortical and cortico-cortical connectivity[10][49].

The gene RANBP1, which encodes a Ran GTPase-binding protein implicated in nuclear-cytoplasmic trafficking, has emerged as a specific contributor to the neurogenetic defects in 22q11.2DS[57][60]. RANBP1 is highly expressed in the developing forebrain ventricular and subventricular zones where neural stem cells and progenitor cells reside[57][60]. Complete loss of RANBP1 function results in cortical microcephaly and marked disruption of cortical progenitor proliferation, with specific effects on M phase of the cell cycle in both radial and basal progenitors[57][60]. These findings establish RANBP1 as a microcephaly gene within the deleted region, explaining in part the reduced cortical gray matter volume and altered cortical organization observed in 22q11.2DS patients[10][49][57][60]. The disrupted neurogenesis affects layer 2/3 projection neurons preferentially, and since these neurons are critical for the cortico-cortical connections underlying complex cognitive functions, this selective disruption may establish specific vulnerability to disorders of higher cognition including schizophrenia[10][49][57][60].

Altered Migration of GABAergic Interneurons

In addition to disruptions affecting glutamatergic projection neuron production, 22q11.2DS disrupts the migration and proper laminar placement of GABAergic inhibitory interneurons, which are generated in the medial ganglionic eminence and migrate tangentially into the developing cortex[10][49]. Studies of mouse models demonstrate that the frequency of parvalbumin-expressing interneurons—the most abundant cortical interneuron subtype—is relatively preserved, but their laminar distribution is profoundly altered[10][49]. Interneurons that normally populate layer 5/6 show altered distribution in the context of 22q11.2 deletion, reflecting either disrupted interneuron migration or compensatory changes in laminar position resulting from the altered glutamatergic neuron composition[10][49]. Disrupted interneuron placement impairs the establishment of proper inhibitory circuits, potentially causing abnormalities in cortical synchronization, circuit oscillatory dynamics, and information processing—functions critical for sensory gating and attentional filtering[10][49][52]. Defects in sensory gating have been demonstrated in 22q11.2DS using prepulse inhibition testing and auditory P50 sensory gating measurements, providing direct evidence that altered cortical circuit architecture translates to impaired neural processing[2][10][27].

TBX1-Dependent Cortical Development and Mesoderm-Brain Interaction

Recent studies have unexpectedly revealed that proper cortical development requires mesodermal expression of TBX1 through cell non-autonomous mechanisms[10]. In this mechanism, loss of TBX1 from mesodermal tissues disrupts mesodermal-epithelial interactions required for proper corticogenesis, promoting premature neuronal differentiation in the medial lateral embryonic cortex[10]. The result is altered polarity in both radially migrating excitatory neurons and tangentially migrating inhibitory interneurons, leading to altered lamination specifically in the somatosensory cortex[10]. These findings demonstrate that cortical development requires proper signaling from mesoderm-derived tissues and that disruption of these signals by TBX1 haploinsufficiency contributes to the cortical circuit abnormalities underlying the neuropsychiatric phenotypes of 22q11.2DS[10].

Brain Metabolic Imbalance and Mitochondrial Dysfunction

Emerging research has identified disruptions in brain metabolism and mitochondrial function as central mechanisms underlying 22q11.2DS neuropsychiatric vulnerability[5][7][26][27]. TBX1 haploinsufficiency causes marked brain metabolic imbalance characterized by elevated levels of methylmalonic acid—a neurotoxic metabolite—and disruption of key metabolic pathways including glutamine-glutamate metabolism and fatty acid metabolism[7][26]. The metabolomic abnormalities reflect functional consequences of haploinsufficiency of multiple genes within the deleted region that encode proteins involved in mitochondrial metabolism, including PRODH, COMT, TXNRD2, MRPL40, and others[7][26][27]. At least nine genes within the deleted 22q11.2 region encode proteins involved in mitochondrial function, either residing within mitochondria or acting as regulators of mitochondrial processes[7][26].

PRODH (proline dehydrogenase), which encodes the first rate-limiting enzyme in proline degradation, exemplifies how disruption of metabolic genes contributes to neuropsychiatric pathology[26][27][29]. Proline degradation generates electrons that can be utilized in the electron transport chain to produce ATP, while the intermediate product pyrroline-5-carboxylate can be converted into glutamate[26][27][29]. PRODH haploinsufficiency therefore potentially reduces energy production while simultaneously reducing glutamate synthesis, creating a metabolic state of reduced neuronal energy availability and altered glutamatergic neurotransmission[26][27][29]. Hyperprolinemia (elevated blood proline) occurring in some 22q11.2DS patients further impairs cellular systems including energy metabolism and antioxidant defense, contributing to neuronal metabolic stress[26][27][29]. PRODH-deficient states also enhance accumulation of dopamine in the prefrontal cortex through epistatic interaction with COMT, a finding particularly relevant to understanding dopaminergic dysregulation in psychiatric manifestations of 22q11.2DS[26][29].

Mitochondrial oxidative phosphorylation appears fundamentally disrupted in 22q11.2DS, with studies of patient-derived induced pluripotent stem cells demonstrating significantly reduced ATP levels in neurons derived from 22q11.2DS carriers[26]. The metabolic shift toward glycolysis over oxidative metabolism creates energy insufficiency that particularly affects parvalbumin-positive fast-spiking interneurons, which have exceptionally high metabolic demands to maintain rapid and repetitive action potential firing[26]. These interneurons are particularly vulnerable to metabolic insufficiency and elevated reactive oxygen species, and their dysfunction through metabolic insufficiency directly impairs cortical inhibitory circuit function and may underlie sensorimotor gating deficits and increased psychosis risk[26]. Recent studies have identified that antioxidant treatment with N-acetylcysteine can restore deficits in connectivity and mitochondrial morphology in mouse models of 22q11.2DS, suggesting that oxidative stress represents a tractable therapeutic target[26].

Blood-Brain Barrier Dysfunction and Neuroinflammation

A striking recent discovery in 22q11.2DS pathophysiology is compromised blood-brain barrier (BBB) integrity, resulting from haploinsufficiency of CLDN5, which encodes claudin-5, the most densely expressed tight junction protein in brain microvasculature[44][47]. The blood-brain barrier is composed of brain microvascular endothelial cells connected by tight junctions that severely limit paracellular diffusion of ions and solutes, thus creating a barrier that maintains CNS homeostasis and protects neural tissue from circulating antigens and pathogens[44][47]. Claudin-5 is essential for this barrier function, as mice with complete CLDN5 deficiency die within 10 hours of birth from BBB disruption[47]. CLDN5 haploinsufficiency in 22q11.2DS reduces but does not eliminate claudin-5 expression, resulting in partially compromised BBB integrity[44][47].

Studies using induced blood-brain barrier cells derived from 22q11.2DS patient-derived induced pluripotent stem cells demonstrate significantly decreased transepithelial electrical resistance—a functional measure of barrier tightness—compared to healthy control cells[44]. Moreover, post-mortem brain tissue from 22q11.2DS patients shows reduced claudin-5 expression and evidence of endothelial activation including elevated intercellular adhesion molecule-1 (ICAM-1) expression[44]. The compromised barrier function combines with evidence of neuroinflammation, including elevated IL-6 expression in perivascular astrocytes, suggesting that disrupted BBB integrity permits increased extravasation of peripheral immune cells and inflammatory mediators into the CNS, establishing a state of elevated neuroinflammation[44]. This neuroinflammatory state likely contributes to altered brain development, defects in synaptic plasticity, and increased psychiatric disease vulnerability in 22q11.2DS[44].

Dopaminergic and Catecholaminergic Dysregulation

The COMT gene, encoding catechol-O-methyltransferase, represents a critical modulator of dopaminergic and noradrenergic neurotransmission in the prefrontal cortex and other brain regions[2][11][25][29][30]. COMT catalyzes the catabolism of dopamine and norepinephrine, and haploinsufficiency of COMT in 22q11.2DS leads to reduced catabolism of these catecholamines, resulting in increased dopamine and norepinephrine accumulation in the prefrontal cortex[2][11][25][29]. The effects of altered dopamine levels in the prefrontal cortex are bidirectional and complex—moderate increases in dopamine enhance prefrontal cortex function and cognitive performance, while either insufficient or excessive dopamine impairs prefrontal function[2][11][25][29][30]. In the context of 22q11.2DS, the altered COMT function interacts with other metabolic disruptions, particularly elevated proline levels, to create a state of catecholamine dysregulation that potentially contributes to schizophrenia risk[2][11][25][29][30].

The interaction between COMT genotype and proline levels in determining prefrontal cortex function and psychosis risk has been directly demonstrated in 22q11.2DS[29]. Specifically, children with elevated plasma proline levels and the low-activity COMT 158 methionine (met) allele—which results in reduced dopamine catabolism—show significantly decreased smooth pursuit eye movement performance, a measure of prefrontal cortex function[29]. This finding demonstrates that elevated dopamine in the prefrontal cortex due to reduced COMT activity impairs smooth pursuit eye movement performance, an effect consistent with dopaminergic overdrive disrupting prefrontal cognition[29]. The same interaction has not been observed with other measures of sensorimotor gating or prefrontal function, but the principle demonstrates how genetic variation in COMT function combines with metabolic factors to modulate brain function and potentially psychiatric disease risk in 22q11.2DS[29].

MicroRNA Dysregulation and Non-Coding RNA Mechanisms

The DGCR8 gene, encoding a component of the microprocessor complex essential for microRNA biogenesis, is located within the 22q11.2 deleted region[2][3][8][18][42]. Haploinsufficiency of DGCR8 impairs processing of primary microRNA transcripts into mature microRNAs, resulting in dysregulation of numerous microRNAs throughout the genome[2][3][8][18][42]. Mature microRNAs comprise 21 to 23 nucleotide non-coding RNAs that regulate gene expression post-transcriptionally by binding to complementary sequences in the 3' untranslated regions of messenger RNA targets, typically leading to mRNA degradation or translational repression[2][8][18][42]. Given that microRNAs typically have multiple targets across the genome, subtle alterations in global microRNA expression can have profound effects on brain development and plasticity[2][8][18][42].

Several specific microRNAs dysregulated in 22q11.2DS have been linked to neuropsychiatric and developmental phenotypes[2][8][18][42]. MiR-185, downregulated in 22q11.2DS due to its location within the deleted region, targets multiple transcripts involved in immune cell receptor signaling and also targets sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) in hippocampal neurons[2][9][39][42]. Reduced miR-185 leads to increased presynaptic neurotransmitter release, potentially disrupting synaptic plasticity and neural circuit function[2][9][39][42]. MiR-150 is also downregulated in 22q11.2DS and targets genes involved in immune responses and neural development[2][42]. The dysregulation of miRNAs involved in critical developmental pathways—including neurological, immune system, cardiovascular, and skeletal development pathways—explains in part the remarkable pleiotropy of 22q11.2DS affecting multiple organ systems[2][8][42].

Additionally, the high density of miRNAs clustered within the 22q11.2 deleted region, combined with the presence of numerous long non-coding RNAs and small nucleolar RNAs, suggests that disruption of multiple non-coding RNA regulatory networks contributes to the variable phenotypic expression of 22q11.2DS[2][8]. The effects on expression resulting from alterations in microRNA dosage and function are likely to involve not only the central nervous system but also the cardiovascular system and other aspects of embryonic development, explaining the multi-system nature of the syndrome[2][8].

Increased Schizophrenia Risk and Psychosis Vulnerability

The most striking psychiatric manifestation of 22q11.2DS is a markedly elevated risk for schizophrenia spectrum disorders, with approximately 20 to 30 percent of 22q11.2DS carriers developing clinically significant psychosis during late adolescence or early adulthood[2][5][25][27]. The relative risk for schizophrenia in 22q11.2DS carriers is approximately 20 to 25 times the baseline population risk of 1 percent[2][5][25][27]. This elevation makes 22q11.2DS the strongest known genetic risk factor for schizophrenia and provides a window into the neurodevelopmental mechanisms underlying psychotic illness[2][5][25][27]. Recent biomarker studies have identified unique molecular signatures distinguishing 22q11.2DS patients at highest risk for developing psychosis[28]. Specifically, reduced plasma taurine—the most abundant free amino acid in the brain and a neuromodulator affecting synaptic function—and altered arachidonic acid levels have been identified as potential biomarkers for psychosis risk in 22q11.2DS patients[28]. These metabolomic biomarkers reflect disruptions in neuronal energy metabolism and lipid signaling pathways critical for neural development and synaptic plasticity[28].

The cumulative evidence suggests that 22q11.2DS-associated psychosis results from convergent disruptions of multiple developmental pathways and neurobiological systems—including altered neurogenesis and cortical circuit development, metabolic insufficiency of inhibitory neurons, blood-brain barrier dysfunction and neuroinflammation, and dopaminergic dysregulation—occurring during critical developmental windows and cumulatively establishing vulnerability for psychotic illness[2][5][6][27]. No single gene or single molecular mechanism fully accounts for the elevated schizophrenia risk, but rather multiple haploinsufficient genes acting in concert on common cellular mechanisms create a permissive neurobiological context in which superimposed environmental stressors or other genetic risk factors may precipitate clinical psychosis[2][5][27].

Multi-System Manifestations and Organ-Specific Pathophysiology

Skeletal and Craniofacial Pathophysiology

The skeletal abnormalities observed in 22q11.2DS reflect disrupted development of bone and cartilage derived from neural crest cells and mesoderm[1][2][3][38]. Craniofacial dysmorphic features occur in approximately 70 percent of patients, though their severity and specific manifestations vary widely[1][2][3][41]. The characteristic facial features include an elongated face, wide-set eyes with almond-shaped palpebral fissures, a bulbous nasal tip with narrow nasal passages, micrognathia or retrognathia (underdeveloped or recessed lower jaw), malar flattening representing reduced cheekbone prominence, low-set or posteriorly rotated ears with abnormal helix formation, a short philtrum, and a thin upper lip[1][2][41]. These features result from altered neural crest cell development and impaired mesenchymal-epithelial interactions during the critical period of embryonic weeks 6 through 12, when facial structures are actively forming[2][3][38].

The cleft palate observed in approximately 69 percent of 22q11.2DS patients represents another manifestation of disrupted craniofacial development[31]. The palate forms through fusion of the palatal shelves originating from maxillary processes of the first pharyngeal arch, a process requiring complex epithelial-mesenchymal interactions and proper expansion and reorientation of palatal mesenchyme[2][3][38]. TBX1 expression in mesoderm is critical for this process, and TBX1 haploinsufficiency disrupts palatal development through multiple mechanisms including altered mesenchymal cell proliferation and impaired epithelial-mesenchymal interactions[2][3][38]. Beyond overt cleft palate, many 22q11.2DS patients display submucous cleft palate—a deficiency in the musculature supporting the soft palate without a visible gap—leading to velopharyngeal insufficiency with hypernasal speech and swallowing difficulties[1][2][31].

Skeletal abnormalities also extend to long bones and vertebrae, with scoliosis (curvature of the spine) occurring in some patients, potentially related to dysregulation of microRNAs involved in vertebral development[42]. Other skeletal features may include short stature, observed in approximately 35 percent of patients, and various minor skeletal abnormalities of the hands and feet[1][6].

Genitourinary Tract Anomalies

Structural abnormalities of the kidney and urinary tract occur in 30 to 40 percent of 22q11.2DS patients[43][46]. The most common abnormalities include hydronephrosis (fluid accumulation in the kidney), unilateral renal agenesis (absence of one kidney), multicystic dysplastic kidney (abnormal kidney development with multiple cysts), and vesicoureteral reflux (abnormal backflow of urine from bladder to ureters)[1][2][43][46]. These genitourinary anomalies reflect disrupted development of the ureteric bud and metanephric mesenchyme during embryogenesis[2][43][46]. Recent studies have identified CRKL, a gene within the 22q11.2 deleted region, as a major genetic driver of kidney defects in 22q11.2DS as well as in the general population[43]. CRKL haploinsufficiency specifically predisposes to renal and urinary tract malformations through mechanisms involving altered signal transduction in developing kidney tissue[2][43][46].

In males with 22q11.2DS, additional genitourinary abnormalities may include cryptorchidism (undescended testes), occurring in approximately 6 percent of affected males, and hypospadias (abnormal urethral opening), occurring in approximately 8 percent of affected males[46]. These abnormalities suggest disruption of endocrine signaling and neural crest cell migration during genital development[2][46]. Notably, approximately 15 percent of 22q11.2DS patients demonstrate renal or structural urinary tract anomalies, and screening renal and bladder ultrasound is recommended at diagnosis to identify these abnormalities early and allow for appropriate surveillance and management[2][43][46].

Auditory and Otologic Manifestations

Hearing loss represents one of the most common complications of 22q11.2DS, occurring in 40 to 64.5 percent of affected individuals—a prevalence considerably higher than in the general population[55]. The hearing loss in 22q11.2DS is most frequently conductive in nature, resulting from chronic otitis media (middle ear infection) and effusion (fluid accumulation in the middle ear)[55]. Recurrent sinopulmonary infections, resulting from thymic hypoplasia and T-cell immunodeficiency, drive the recurrent otitis media[2][55]. Additionally, dysfunction of the Eustachian tube—the structure responsible for ventilating and draining the middle ear—appears to be an important contributing factor[55]. Mouse models of 22q11.2DS have demonstrated hypoplasia of the levator veli palatini muscle, an intrinsic muscle of the Eustachian tube, suggesting structural abnormalities of this organ[55].

Sensorineural hearing loss, affecting the cochlear hair cells and neural structures responsible for transducing sound into neural signals, also occurs in 22q11.2DS, though less frequently than conductive hearing loss[55]. Proposed mechanisms for sensorineural hearing loss include cochlear damage secondary to chronic otitis media, as well as possible congenital malformations of the cochlea resulting from disrupted inner ear development[55]. TBX1, essential for multiple aspects of pharyngeal development, is also required for inner ear development, suggesting that direct developmental effects on the cochlea may contribute to sensorineural hearing loss in some patients[55]. The combination of conductive and sensorineural hearing loss in some patients creates mixed hearing loss requiring careful audiologic assessment and management[55].

Ocular Manifestations

Multiple ocular abnormalities have been documented in 22q11.2DS patients[45][48]. Retinal vascular tortuosity—abnormal coiling and twisting of blood vessels in the retina—occurs in 32 to 78 percent of patients[45]. Posterior embryotoxon, a prominent Schwalbe ring representing an anterior chamber developmental variant, occurs in 22 to 50 percent of patients[45]. Eye lid hooding (ptosis), attributed to reduced levator palpebrae superioris muscle development, occurs in 20 to 67 percent of patients[45]. Strabismus (eye misalignment), occurring in 12 to 36 percent of patients, may reflect both structural abnormalities and possible neural control defects[45]. Refractive errors including myopia (nearsightedness), hyperopia (farsightedness), and astigmatism are common and frequently require corrective lenses[48].

These ocular findings collectively reflect disruptions in neural crest cell-derived development of orbital and ocular structures, as well as possible abnormalities in the vascular development of the eye[45]. While many of these findings are clinically apparent or asymptomatic, they serve as useful diagnostic signs and warrant ophthalmologic evaluation and long-term monitoring in 22q11.2DS patients[45].

Clinical Phenotypic Variability and Molecular Bases of Heterogeneity

Factors Contributing to Phenotypic Heterogeneity

Despite the genetic uniformity of the core chromosomal deletion, 22q11.2DS exhibits remarkable phenotypic heterogeneity—some patients experience severe, life-threatening cardiac defects requiring early surgical intervention, while others present with primarily psychiatric manifestations or subtle developmental delays[2][3][4]. This phenotypic heterogeneity cannot be fully explained by differences in deletion size or breakpoints, as patients with identical deletion boundaries may display markedly different clinical presentations[2][3][25]. Multiple molecular and genetic factors likely contribute to this phenotypic variability[2][3][4].

First, the expression levels of genes within the deleted region are not uniformly reduced by exactly 50 percent, but rather show tissue-specific and developmental stage-specific variation in their dosage sensitivity[2][11]. Different tissues exhibit differential sensitivity to gene dosage reduction for the same gene, suggesting that tissue-specific factors modulate the functional consequences of haploinsufficiency[2][11]. Second, stochastic variation in timing of developmental events and tissue interactions during the critical windows when deleted genes exert their functions may lead to probabilistic rather than deterministic effects on development[2][3]. Third, genetic background—differences in allelic variants at other chromosomal loci—may modify the phenotypic consequences of 22q11.2 deletion[2][3][4]. Fourth, epigenetic regulation and chromatin structure may vary between individuals and during development, affecting the expression not only of genes within the deleted region but also of genes outside this region that are subject to long-range epigenetic regulation by the LCR elements[39]. Fifth, post-deletion environmental factors including infections, nutritional status, stress exposure, and access to medical care during critical developmental periods may modulate disease severity and manifestations[2][3].

Gene Dosage-Sensitivity and Multi-Gene Interaction Models

Current evidence suggests that 22q11.2DS pathogenesis reflects complex multi-gene effects rather than haploinsufficiency of a single gene, despite the important role of TBX1[2][3][4][11][14]. The diminished expression of multiple genes—potentially most or all genes within the minimal critical deleted region—acting on common cellular mechanisms appears to be the essential contributor to the phenotypes observed[2][3][11]. Different subsets of genes appear to comprise distinct functional modules affecting particular developmental pathways or temporal windows of development[2][3][11]. For instance, several genes involved in cell cycle regulation are maximally expressed during mid-to-late gestation coincident with peak neurogenesis and cell migration, suggesting that these genes may comprise a functional module disrupting neurogenic developmental processes[2][3][11]. By contrast, several genes encoding mitochondrial proteins reach maximal expression during early postnatal life coincident with peak synaptogenesis, suggesting a role in post-natal circuit development[2][3][11]. Dosage changes at distinct developmental times in different tissues may lead to cumulative morphogenetic, neurogenic, and connectivity changes that establish forebrain circuits with increased vulnerability for psychiatric and developmental disorders[2][3][11].

Interaction with Additional Genetic Variants

Recent studies have begun to identify how genetic variants in other loci modulate the 22q11.2DS phenotype[2][25]. The COMT 158 Val/Met functional polymorphism, which alters the efficiency of dopamine catabolism in the prefrontal cortex, has been examined as a potential modifier of schizophrenia risk in 22q11.2DS[2][25]. However, studies have failed to consistently demonstrate that COMT genotype serves as a major predictor of schizophrenia expression in 22q11.2DS, though the Met allele (low-activity variant) combined with elevated proline levels does appear to predispose to specific cognitive deficits[2][25][29]. This suggests that while COMT genotype may contribute to phenotypic heterogeneity, it is not the major determinant of psychiatric disease risk in 22q11.2DS[2][25].

Polymorphisms in CLDN5 (claudin-5), particularly variants in the 3' untranslated region of this gene, have been associated with schizophrenia risk in 22q11.2DS patients and with reduced claudin-5 in circulation and post-mortem brain tissue of schizophrenia patients generally[44][47]. This suggests that genetic variation affecting CLDN5 expression and blood-brain barrier integrity may modify neuropsychiatric disease risk in this population[44][47]. The identification of such genetic modifiers is an active area of research with potential implications for predicting disease risk and developing targeted interventions[2][25].

Molecular Diagnostics and Disease Monitoring

Chromosomal Microarray Analysis and Genetic Diagnosis

The gold standard for diagnosing 22q11.2DS is chromosomal microarray analysis (CMA), also termed array comparative genomic hybridization, which detects the microdeletion through quantitative measurement of copy number at the 22q11.2 locus[1][2][5]. Fluorescence in situ hybridization (FISH) using probes specifically targeting genes within the deleted region (most commonly TUPLE1 or other genes in the typically deleted region) can also confirm the diagnosis[2][5]. Karyotyping, the traditional method of detecting chromosomal abnormalities, typically fails to detect the relatively small 1.5 to 3.0 megabase deletion characteristic of 22q11.2DS because the resolution of karyotyping is limited to detecting deletions larger than approximately 5 to 10 megabases[2][5]. Prenatal diagnosis is possible through amniocentesis combined with chromosomal microarray analysis, though not all prenatal ultrasound abnormalities characteristic of 22q11.2DS are detected prenatally, and some fetuses with the deletion may have normal prenatal ultrasounds[6].

Newborn Screening and Early Detection

Some programs have implemented newborn screening for 22q11.2DS through detection of reduced T-cell receptor excision circles (TRECs) in dried blood spots obtained from newborn screening programs[2][9]. TRECs are byproducts of T-cell receptor gene rearrangement and serve as markers of thymic function—reduced TREC levels indicate low thymic output and impaired T-cell development[2][9]. This screening approach identifies the majority of complete DiGeorge syndrome cases (athymia) requiring thymic transplantation, though many partial DiGeorge syndrome cases with milder thymic hypoplasia and adequate TREC levels are not flagged by this screening approach[2][9]. Approximately 60 to 70 percent of 22q11.2DS patients have low but sufficient naive T cells with TREC levels not flagged by newborn screening[9]. Despite this limitation, newborn screening for reduced TRECs has proven valuable in identifying infants with severe thymic hypoplasia requiring immediate immunological intervention and surveillance[2][9].

Multi-System Clinical Evaluation

Because 22q11.2DS affects multiple organ systems, comprehensive clinical evaluation by specialists in various fields is recommended[1][2][5]. Cardiac evaluation including echocardiography to detect structural defects, electrocardiography to assess electrical function, and in some cases cardiac MRI or CT is essential for detecting the cardiac manifestations[1][2][5]. Immunological assessment including measurement of lymphocyte subsets (CD3+, CD4+, CD8+ T cells and B cells), measurement of immunoglobulin levels, and assessment of lymphocyte proliferative responses to mitogens helps characterize immune function[1][2][5]. Endocrine evaluation including measurement of serum calcium, phosphorus, and magnesium with assessment of parathyroid hormone response to hypocalcemia, as well as thyroid function testing and assessment of thyroid autoantibodies, is crucial for managing endocrine complications[1][2][5][20][23]. Developmental and psychiatric screening, including formal cognitive testing and behavioral assessment, helps identify cognitive delays and psychiatric symptoms requiring intervention[1][2][5][27]. Audiological assessment including formal audiometry and otoscopic examination detects hearing loss and middle ear abnormalities[55]. Renal and bladder ultrasound screens for genitourinary tract anomalies[43][46]. Ophthalmologic examination documents ocular findings[45].

Conclusion: Integrative Pathophysiological Model

22q11.2 Deletion Syndrome represents a complex genetic disorder arising from haploinsufficiency of multiple genes within a specific chromosomal region, with disease pathophysiology fundamentally reflecting disrupted development of tissues derived from the pharyngeal apparatus and neural crest lineage[1][2][3]. The core mechanisms involve impaired signaling during critical embryonic developmental windows, particularly weeks 7 to 12 of human gestation, when the structures most severely affected by 22q11.2DS are actively forming[2][3]. The primary candidate gene TBX1 exerts its effects through non-autonomous mechanisms, impacting the development of mesenchymal tissues that normally provide supportive signals for neural crest cell migration and differentiation, proper epithelial-mesenchymal interactions, and tissue morphogenesis[2][3][8].

The pathophysiology extends well beyond the developmental period, however, as the deleted genes continue to be expressed in adolescent and adult tissues, contributing to psychiatric disease vulnerability, immune dysregulation, and metabolic dysfunction manifesting later in life[2][3][5][11]. The elevated schizophrenia risk in 22q11.2DS results from cumulative developmental disruptions—including altered neurogenesis and cortical circuit architecture, metabolic insufficiency affecting inhibitory interneurons, blood-brain barrier dysfunction and neuroinflammation, and altered dopaminergic and glutamatergic signaling—that establish a neurobiological phenotype predisposing to psychotic illness when combined with environmental stressors or additional genetic risk factors[2][5][6][27].

The remarkable phenotypic variability characteristic of 22q11.2DS, even among patients with identical deletion boundaries, likely reflects stochastic variation in developmental processes, tissue-specific differential sensitivity to gene dosage reduction, genetic background effects modulating the expression of deleted genes and their interaction partners, and epigenetic regulation through the complex LCR architecture of the region[2][3][4][39]. The multi-system nature of the disorder, with cardiac, immunological, endocrine, skeletal, auditory, ocular, and neuropsychiatric manifestations, reflects the widespread developmental functions of the deleted genes and their expression in multiple tissues during diverse developmental processes[1][2][3][5].

Future research aimed at understanding the precise molecular and cellular mechanisms through which haploinsufficiency of specific deleted genes contributes to particular phenotypic features, identifying biomarkers predicting disease severity and psychiatric risk, and developing targeted interventions addressing the underlying molecular pathology promises to improve outcomes for this complex and multifaceted genetic disorder[2][5][6][27][28]. The identification of metabolomic biomarkers including reduced taurine and altered arachidonic acid as markers of psychosis risk in 22q11.2DS opens the possibility of early intervention and preventive strategies in this high-risk population[28]. The recognition that antioxidant treatment with N-acetylcysteine can restore deficits in connectivity and mitochondrial morphology in mouse models suggests that targeting mitochondrial dysfunction and oxidative stress may represent tractable therapeutic approaches[26]. As our understanding of 22q11.2DS pathophysiology deepens through continued integration of molecular, cellular, developmental, and systems-level research, opportunities for precision medicine approaches tailored to individual patients' specific molecular and clinical profiles will likely emerge.

References Summary

The comprehensive pathophysiology of 22q11.2 Deletion Syndrome has been synthesized from contemporary literature including major clinical and research reviews from Mayo Clinic and Cleveland Clinic, detailed molecular and genetic analyses from NCBI/NIH resources including GeneReviews and StatPearls, seminal papers on TBX1 function and cardiac neural crest development, neurodevelopmental studies examining cortical development and schizophrenia risk, immunological characterization of thymic hypoplasia and T-cell dysfunction, metabolomic profiling identifying brain metabolic imbalance, blood-brain barrier dysfunction research, and clinical studies on multi-system manifestations including cardiac defects, genitourinary anomalies, hearing loss, and ophthalmologic findings. The evidence base reflects research published across multiple decades with particular emphasis on mechanistic insights from recent molecular and neuroimaging studies illuminating the pathophysiological basis of psychiatric vulnerability in this disorder.